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GENERAL INTRODUCTION AND 





Worldwide in 2007, cancer led to the death of 7.9 million people which comprises 
around 13% of all deaths.1 An increase in the number of cancer-related deaths is 
expected with an estimated 9 million in 2015. The main types of cancer leading to 
overall cancer mortality are solid tumors arising from lung, stomach, colorectum, 
liver, esophagus, breast, cervix and prostate.2 Screening programmes might result 
in increased incidence rates of early stage cancer, but treatment of cancers such 
as colorectal, breast and cervical cancer in an early stage have a high cure rate. 
In this thesis, we will focus on gastric and colorectal cancer with the emphasis on 
the latter. We assessed whether cancer patients with minimal metastatic disease 
at the time of surgery who are at risk for disease recurrence, can be identified by 
detection of occult tumor cells in lymph nodes or bone marrow or by analyzing 
the primary tumor for angiogenic and lymphangiogenic markers. Patients groups 
that were investigated were gastric and colorectal cancer patients who underwent 
curative resection and had tumor-negative lymph nodes after conventional 
histopathological examination. In addition, patients with colorectal liver metastases 
who underwent liver resection or isolated liver perfusion after previous treatment 
for their primary tumor, were studied for effectivity of treatment.
Gastric cancer
The incidence of gastric cancer, which is one of the most common cancers in the 
world, varies greatly across different geographic locations being higher in Japan 
and some parts of South America (> 40 per 100,000) and lower in Western Europe 
and the United States (< 15 per 100,000).3 Environmental exposure rather than 
genetic factors play a role in the predisposition to gastric cancer.4 Risk factors 
known for gastric cancer are diets rich in salt, smoked or poorly preserved foods, 
nitrates and high complex-carbohydrates, diets low in fats, proteins, vegetables 
and fruits and poor drinking water, smoking, prior gastric surgery, Helicobacter 
pylori infection, gastric atrophy, gastritis and adenomatous polyps.4;5
Ninety-five percent of all gastric cancers are adenocarcinomas of which 8% to 
10% have an inherited familial component.4 Gastric cancer occasionally develops 
in families with germline mutations in p53 (Li-Fraumeni syndrome) or BRCA2 and 
can also develop as part of the hereditary nonpolyposis colon cancer syndrome, as 
well as part of gastrointestinal polyposis syndromes, including familial adenomatous 
polyposis and Peutz-Jeghers syndrome.4 In 1% to 3% of gastric cancers, germline 
mutations in the gene encoding the cell adhesion protein E-cadherin leads to an 
autosomal-dominant predisposition to gastric carcinoma, referred to as hereditary 
diffuse gastric cancer showing a penetrance of approximately 70%. Therefore, for 
these people, prophylactic gastrectomy is mandated.6 For individuals with high 
risk factors as mentioned previously, the American Society for Gastrointestinal 
Endoscopy recommends endoscopic surveillance for every 1 to 2 years.4 In 
Western countries, there are no formal screening programmes for gastric cancer, 
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in contrast to high-incidence regions such Japan and China, where mass screening 
is cost-effective and has led to a decrease in mortality rates. 
Surgery is the cornerstone in gastric cancer treatment and success depends on the 
size, location and abilitity to reach margins free of gross and microscopic disease. 
Extended D2 lymphadenectomy is the norm in Japan but not in Western countries 
as large randomized controlled trials have failed to show that the extended D2 
lymphadenectomy improves survival when compared with D1 dissection.7;8 Since 
improved survival after postoperative chemoradiotherapy (stage IB or higher)9 or 
perioperative chemotherapy (stage II or higher)10 has been shown by a limited 
number of studies, they are administered to patients only within a clinical trial. 
Colorectal cancer
In 2007, approximately 1.2 million new cases of colorectal cancer (CRC) and 
630,000 deaths due to this disease are expected worldwide.2 The incidence of CRC 
is higher in developed countries, making it the second most common cancer in 
this part of the world with an estimated 341,000 deaths in 2007.2;11 
The risk for developing CRC increases with age as a result of accumulation of (epi)
genetic mutations, with more than 90% of new cases being diagnosed in patients 
older than 50 years. Observational studies show that tobacco avoidance, physical 
activity, weight control and dietary interventions with increase in fibre, fruits and 
vegetables and reductions in fat and alcohol can reduce the risk for CRC.12;13 
Inflammatory bowel diseases, ulcerative colitis and Crohn’s colitis, are associated 
with an increased risk of CRC.14 
Most cases of CRC occur in sporadic forms (88 to 94%) of which about 20% have 
some component of familial risk (two or more first- or second degree relatives 
with CRC).15 Sporadic CRC that occurs in the absence of family history, is usually 
seen in older patients (60-80 years of age), and generally presents as an isolated 
colon or rectal lesion. Approximately 5 to 10% of all CRC are hereditary. The main 
forms are familial adenomatous polyposis (FAP), MUTYH associated polyposis 
(MAP) and hereditary nonpolyposis colorectal cancer (HNPCC).15;16 
Surgery is the treatment of choice in resectable CRC and adjuvant chemotherapy 
is generally administered to stage III patients with lymph-node involvement, as 
benefits have been shown.17-19 
Treatment of patients with advanced CRC (approximately 20% of CRC patients 
at diagnosis20) and distant disease recurrence (almost half of the patients who 
had previously undergone curative resection21) depends on the location of the 
disease, but surgery is the primary treatment of choice. Surgically treated patients 
with isolated liver or lung metastases can reach a five-year survival of up to 
approximately 60%.22-24 Patients are considered for resection of liver metastases 
depending on the number and location of the lesions, lack of major vascular 
involvement, sufficient functional residual hepatic tissue and absent or limited 
extrahepatic disease with the exception of resectable pulmonary metastases.25;26 
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In addition, multiple studies with multiagent chemotherapy have demonstrated 
that patients with metastatic disease isolated to the liver, which previously 
would be considered unresectable, can occasionally be made resectable after 
administration of chemotherapy.27 Also, improved clinical outcome in metastatic 
CRC is shown after multiagent systemic chemotherapy28-32 with an even better 
survival after addition of bevacizumab, a monoclonal antibody against vascular 
endothelial growth factor.33
Better surgical techniques and advances in preoperative imaging have improved 
patient outcome after resection of liver metastases over the last two decades. 
Several prognostic scoring systems have been proposed to optimally benefit 
from surgical treatment. Nevertheless, numerous patients who have undergone 
surgical resection of localized liver metastases develop disease recurrence. These 
patients might benefit from additional systemic treatment as this has been 
shown to improve progression-free survival over surgery alone.34 Providing only 
patients at risk for disease recurrence with additional systemic treatment, avoids 
unnecessary side-effects. Studies are conducted on identifying patients at risk for 
disease recurrence after resection of liver or lung metastases.
Tumor biology of gastric cancer and colorectal cancer
Both gastric cancer and CRC are multi-pathway and multi-step diseases. They are 
characterized by considerable genetic heterogeneity. Several molecular markers 
within the chain of processes leading to cancer have been investigated, the more 
common of which are shown in Table 1.35-37
Particular genetic alterations can be clustered that group both gastric cancer and 
CRC into discrete subtypes. At least two different pathways are seen in gastric 
cancer leading to the intestinal and diffuse tumor type. The intestinal variant 
is well differentiated with recognizable gland formation, and usually arises in 
the setting of a recognizable precancerous condition such as gastric atrophy 
or intestinal metaplasia.5;37 This diploid variant is related to Helicobacter pylori 
infection and nutritional factors and is often located in the corpus and antrum of the 
stomach. Men are more commonly affected than women, and incidence increases 
with age. Metastatic spread is generally hematogenous to distant organs.37 The 
prevalence of the intestinal type is decreasing whereas the prevalence of the 
diffuse type is rising, particularly in developed countries. The diffuse aneuploid 
form of gastric cancer is poorly differentiated, lacks gland formation, and is 
composed of signet ring cells. It is located more frequently in the upper third 
of the stomach, as well as in the gastroesophageal union and the lower third 
of the oesophagus. The diffuse variant consists of tiny clusters of small uniform 
cells, tends to spread submucosally, has less inflammatory infiltration, and 
metastasizes early. The route of spread is generally by invasion of the stomach 
wall and through lymphatic invasion. The diffuse form also has an association 
with blood type A and familial occurrences, suggesting a genetic etiology. 
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In general, the prognosis is less favorable for patients with diffuse-subtype 
histology.5;37 
There are two major pathways in colorectal carcinogenesis. One is the chromosomal 
instability (CIN) pathway that evolves through the classical adenoma–carcinoma 
sequence with usually aneuploid DNA and mutations in the tumor suppressor genes 
APC and TP53 and the proto-oncogene KRAS.38 The other is a pathway involving 
defective DNA repair proteins, resulting in microsatellite instability (MSI).15 These 
two pathways are not independent and some CRCs show a significant degree 
of overlap between these two mechanisms.39 Also, other routes, including the 
transforming growth factor-b/smad pathway, the serrated pathway, and epigenetic 
pathways, have been reported.40 The CIN tumors are more likely to be located in 
the distal colon and behave more aggressively compared to the MSI subsets. The 
latter tumors are usually proximally located, are more likely to have diploid DNA 
and harbor mutations in the mismatch-repair genes. FAP and most sporadic cases 
originating from adenomas may be considered a paradigm for the CIN pathway, 
whereas HNPCC more clearly represents the MSI subset.15
Prognostic factors
Extensive research has led to a large number of prognostic markers in gastric 
cancer and CRC. Current practice of prognosis is based on the Tumor-Node-
Metastasis (TNM) classification.41;42 Under investigation are the presence of occult 
tumor cells in lymph nodes, blood and bone marrow, the presence of circulating 
DNA and RNA in blood and expression of molecular markers of the primary tumor. 
Table 1. Potential molecular markers for primary gastric and colorectal cancer
Mismatch repair gene mutation (MSH2, MSH6, MLH1, PMS1, PMS2)
Chromosomal instability (DNA ploidy) (APC, MCC, DCC)
Allelic imbalances/loss of heterozygosity (18q-)
Epigenetic changes as hypermethylation
Oncogene expression (ras, myc)
Tumor suppressor gene mutations (bcl-2, p21, p27, p53, APC, MCC, DCC)
Proliferation/apoptosis (bcl-2, bax, Ki-67)
Angiogenesis (vascular endothelial growth factor, D2-40, CD31)
Inflammation (cyclooxygenase 2)
Cell adhesion loss (E-cadherin, b-catenin, CD44)
Overexpression or mutation of cell membrane receptors with tyrosine kinase activity 
(epidermal growth factor receptor, Her2/neu, platelet-derived growth factor receptor, 
c-met)
Markers of immortalisation (telomerase)
APC, adenomatous polyposis coli; CD, cluster of differentiation; DCC, deleted in colon cancer;
DNA, desoxy-ribonucleic acid; MCC, missing in colon cancer; MLH, MutL homolog; MSH, MutS 
homolog; PMS, postmeiotic segregation.
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In Table 1 several potential molecular markers for primary gastric and colorectal 
cancer are shown. Although numerous prognostic molecular markers have been 
reported of which the majority detected by immunohistochemical staining, none 
has found itself into routine application as yet. In this thesis, only molecular 
markers related with angiogenesis and lymphangiogenesis will be discussed. In 
addition, this thesis assesses occult tumor cells in lymph nodes in gastric cancer 
and CRC, occult tumor cells in sentinel lymph nodes in CRC and disseminated 
tumor cells in bone marrow from patients with colorectal liver metastases.
Current practice of prognosis in gastric and colorectal cancer
The prognosis of patients with gastric cancer and CRC is related to the degree of 
penetration of the tumor through the stomach or bowel wall, the nodal status and 
the presence of distant metastases. These three characteristics form the basis for 
the TNM staging system which is the most well-established prognostic factors in 
gastric cancer and CRC and currently the main method for staging.41;42 The TNM 
classification for gastric cancer and CRC is shown in Table 2 and 3, respectively. 
Approximately 40% of gastric cancer patients have stage I (21%) or II (20%) 
disease at the time of diagnosis.43 One-third have stage III disease, and a quarter 
has stage IV disease. Five-year survival is approximately 78% for stage IA, 58% 
for stage IB, 34% for stage II, 20% for stage IIIA, 8% for stage IIIB and 5 to 7% 
for stage IV.43;44 
At diagnosis, approximately 40% of CRC patients have TNM stage I and II disease, 
40% have stage III and 20% have stage IV disease.20;41 The five-year survival 
rate decreases from up to 90% for stage I and II CRC to 70% for stage III CRC. 
Stage IV CRC patients have a worse prognosis showing a five-year survival rate 
of around 10%.20
Additional prognostic factors in CRC comprise bowel perforation or obstruction, 
presence of tumor cells in resection margins, number of harvested lymph nodes, 
vessel invasion, tumor grade, tumor budding, tumor border configuration and 
serum carcinoembryonic antigen level.45-47 Generally, only the TNM category is 
being used to decide whether a patient should receive adjuvant therapy although 
in some clinics bowel perforation or obstruction and vessel invasion are also 
decisive in administering adjuvant therapy to the patient. 
After the introduction in 1987, the TNM system has been revised every few years 
to allow the incorporation of new evidence. Unfortunately, this staging system does 
not provide prediction of prognosis for the individual patient, especially for stage 
II and III CRC patients. According to the last sixth TNM staging manual, stage II 
CRC is subdivided into IIA (T3N0M0) and IIB (T4N0M0) and stage III is subdivided 
into IIIA (T1/2N1M0) and IIIB (T3/4N1M0). Worldwide, there is a consensus to 
administer adjuvant chemotherapy to patients with stage III CRC disease whereas 
in most countries stage II CRC patients do not receive adjuvant treatment. 
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Table 2. TNM Classification of gastric cancer41;42
Category Criteria
Primary Tumor (T)
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
Tis Carcinoma in situ: intraepithelial tumor without invasion of the lamina 
propria
T1 Tumor invades lamina propria or submucosa
T2 Tumor invades muscularis propria or subserosa
T2a Tumor invades muscularis propria
T2b Tumor invades subserosa
T3 Tumor penetrates serosa (visceral peritoneum) without invasion of 
adjacent structures
T4 Tumor invades adjacent structures
Regional Lymph Nodes (N)
NX Regional lymph node(s) cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in 1 to 6 regional lymph nodes
N2 Metastasis in 7 to 15 regional lymph nodes
N3 Metastasis in more than 15 regional lymph nodes
Distant Metastasis (M)
MX Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis
Stage grouping
Stage T N M
0 Tis N0 M0
IA T1 N0 M0
IB T1 N1 M0
T2a/b N0 M0
II T1 N2 M0
T2a/b N1 M0
T3 N0 M0
IIIA T2a/b N2 M0
T3 N1 M0
T4 N0 M0
IIIB T3 N2 M0
IV T4 N1-3 M0
T1-3 N3 M0
Any T Any N M1
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However, a study showed stage IIIA colon cancer patients to have a significantly 
better disease-specific five-year survival (83%) than stage IIB colon cancer (72%) 
(P < 0.001).48 This stresses the need for additional prognostic factors to improve 
individual patient treatment. 
Occult tumor cells in lymph nodes
Lymph node metastases are one of the major prognostic factors in solid tumors41;42 
determining whether patients will receive adjuvant therapy in CRC. However, 
conventional examination of lymph nodes involves hematoxylin and eosin staining 
of only one or two 4 to 5 µm sections which is less than 1% of a lymph node 
of 1 cm in diameter.49 Serial sectioning, stepsectioning, immunohistochemical 
staining, polymerase chain reaction (PCR) and reverse transcriptase polymerase 
chain reaction (RT-PCR) will increase the number of tumor-positive lymph nodes, 
especially those with relatively small amount of tumor cells, and thus lead to 
upstaging.50;51 Small groups of metastases detected by detailed examination 
techniques are referred to as occult tumor cells (OTC) which are subdivided into 
micrometastases (MM) and isolated tumor cells (ITC). MM are defined as deposits 
of tumor cells of 2 mm or less but larger than 0.2 mm and ITC either as single 
tumor cells or as clusters of tumor cells of 0.2 mm or less.41;42;52 In the last sixth 
edition of the TNM classification, OTC in lymph nodes were incorporated by stating 
that ITC do not constitute metastases and should be classified as pN0(i+) whereas 
the presence of MM should be staged as node positive pN1(mi).41 This advice was 
not based on clinical evidence though does make biologic sense and fits with the 
lack of clinical significance of OTC according to the majority of reported studies 
in CRC.51 The majority of studies failed to subdivide OTC into MM and ITC. Up till 
now, two published CRC studies showed prognostic relevance of MM and none 
for ITC.53;54 Detailed examination of all regional lymph nodes is expensive and 
time consuming. Since it is of major clinical importance however, sentinel node 
mapping was introduced.55 Sentinel nodes are lymph nodes onto which the tumor 
directly drains and which therefore have the highest chance of harboring tumor 
cells (Figure 1).56;57 By examination of sentinel nodes only, if it reflects the status 
of the whole regional lymph node basin, OTC detection becomes feasible as the 
number of lymph nodes to be examined is greatly reduced.
Tumor cells in blood and bone marrow
Tumor cells in blood are referred to as circulating tumor cells (CTC) and tumor 
cells in bone marrow regard disseminated tumor cells (DTC). Tumor cells in 
bone marrow and blood can be present in low numbers of approximately one 
tumor cell per million hematopoietic cells. Therefore, detection methods need 
to be very sensitive. Enrichment with Ficoll density gradient separation or 
other enrichment techniques followed by immunocytochemistry, RT-PCR or 
magnetic cell sorting are reported.58;59 In breast cancer, DTC have found to 
be independent predictors of disease-free and disease-specific survival.60-62 
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DTC have also been reported as a marker of systemic treatment response.63 CTC 
were shown to be independent predictors of overall survival in metastatic breast 
cancer.64;65 As yet, CTC detection cannot replace DTC detection since several breast 
cancer studies have shown DTC to be superior to CTC detection in prognostic 
relevance.63 
Bone is not a preferential site for metastatic disease in gastric cancer or CRC. 
Even so, dormant tumor cells detected in bone marrow might represent the 
metastatic potential of the primary tumor. One study showed that detection of 
DTC in bone marrow samples could be a marker for assessing the effectiveness of 
neoadjuvant radiochemotherapy in rectal cancer.66 Although, some studies have 
shown prognostic relevance of CTC and DTC, as yet no clarity has been reached 
regarding their prognostic significance mostly because of small patient study 
groups and the lack of standardization in detection methods.67-74
Circulating DNA and RNA in blood
Although higher serum and plasma levels of DNA and RNA have been 
found in various forms of cancer, their presence has also been seen in autoimmune 
diseases, postsurgery, stroke, trauma, sepsis and pregnancy rendering it 
unsuitable for cancer diagnosis.75 Nonetheless, decreasing plasma DNA levels 
Figure 1. Sentinel node mapping in colorectal cancer. After the colon has been carefully 
mobilized (A), one-half to one ml isosulphan blue dye was injected subserosally around the 
tumor (B). Shortly thereafter, a lymphatic channel could be followed to the sentinel node(s) 
(C). Typically, one to four sentinel nodes are mapped during each procedure. The sentinel 
nodes were marked with sutures for pathological examination (D).96
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Table 3. TNM Classification of colorectal cancer41;42
Category Criteria
Primary Tumor (T)
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
Tis Carcinoma in situ: intraepithelial or invasion of lamina propriaa
T1 Tumor invades submucosa
T2 Tumor invades muscularis propria
T3 Tumor invades through the muscularis propria into the subserosa, or 
into nonperitonealized pericolic or perirectal tissues
T4 Tumor directly invades other organs or structures and/or perforates 
visceral peritoneumb
Regional Lymph Nodes (N)c
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in 1 to 3 regional lymph nodes
N2 Metastasis in 4 or more regional lymph nodes
Distant Metastasis (M)
MX Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis
Stage grouping
Stage T N M DUKESd MACd
0 Tis N0 M0
I T1 N0 M0 A A
T2 N0 M0 A B1
IIA T3 N0 M0 B B2
IIB T4 N0 M0 B B3
IIIA T1-T2 N1 M0 C C1
IIIB T3-T4 N1 M0 C C2/C3
IIIC Any T N2 M0 C C1/C2/C3
IV Any T Any N M1 D D
a Tis includes cancer cells confined within the glandular basement membrane (intraepithelial) or lamina 
propria (intramucosal) with no extension through the muscularis mucosae into the submucosa; 
b Direct invasion in T4 includes invasion of other segments of the colorectum by way of the serosa: for 
example, invasion of the sigmoid colon by a carcinoma of the caecum. Tumor that is adherent to other 
organs or structures macroscopically is classified T4. However, if no tumor is present in the adhesion 
microscopically, the classification should be pT3. The V and L substaging should be used to identify the 
presence or absence of vascular or lymphatic invasion; 
c A tumor nodule in the pericolorectal adipose tissue of a primary carcinoma without histologic evidence 
of residual lymph node in the nodule is classified in the pN category as a regional lymph node metastasis 
if the nodule has the form and smooth contour of a lymph node. If the nodule has an irregular contour, 
it should be classified in the T category and also coded as V1 (microscopic venous invasion) or as V2 (if 
it was grossly evident), because there is a strong likelihood that it represents venous invasion; 
d Dukes B is a composite of better (T3N0M0) and worse (T4N0M0) prognostic groups, as is Dukes C 
(Any TN1M0 and Any TN2M0). MAC is the modified Astler-Coller classification.
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have been found in rectal cancer patients with downstaging of disease after 
chemoradiation whereas constantly high or increasing values were seen in patients 
not responding to chemoradiation76, implying detection of nucleic acids valuable 
in monitoring response to cytotoxic therapy or disease progression. Mechanisms 
to explain free nucleic acids in blood might be apoptosis or necrosis of tumor 
cells at the tumor site, lysis or apoptosis of CTC, or an active release from the 
tumor or from lymphocytes. A recent study suggests that RNA is protected 
within a vesicle-like structure implying an active release.77 Future studies have to 
establish a differentation between free nucleic acids coming from cellular death 
mechanisms which indicates a good prognosis and those coming from an active 
release mechanism, probably expressing the activity and proliferative capacity 
of the tumor respresenting a risk factor for poor prognosis. Studies regarding 
detection of circulating nucleic acids in blood show similar variability as studies 
assessing the prognostic significance of tumor cells in lymph nodes, blood and 
bone marrow such as a diverse number of potential markers, use of different 
techniques, studies involving few patients, a lack of consensus on sample type and 
preparation protocols and false-positive results due to contamination or aspecific 
background.78 
Angiogenesis and lymphangiogenesis
Both angiogenesis and lymphangiogenesis are required for growth of the primary 
tumor and metastases and play a pivotal role in metastatic spread. The absence 
of a continuous basement membrane makes the lymphatics a primary route for 
dissemination of many solid tumors.79;80 Also, tumor cells experience less stress 
and mechanical deformation in lymphatic vessels as lymphatic capillaries are five 
to eight times wider than blood capillaries and have far lower flow velocities.79 
In tumors, however, blood vessels have shown to be highly abnormal, with 
immature, disorganized wall structure, detached endothelial cells and an abnormal 
or missing basement membrane which probably aids in tumor cell metastasis.81-83 
These features of lymphatic and blood vessels support the passive intravasation 
hypothesis suggesting that cells growing in a confined space push against each 
other, producing stress that can collapse vessels and, potentially force cells to 
breach fragile vessels (Figure 2).83 The opposing theory on active intravasation 
(Figure 2) is based on the finding that highly metastatic cells can change alignment 
and migrate toward blood vessels with the aid of adhesion mechanisms, whereas 
less metastatic cells cannot.83 An adhesion molecule that might be involved in this 
process, is sialyl Lewis X (sLeX), a blood group-related antigen.84 In addition to 
these theories, two models of metastatic spread have been suggested.85 In the 
first model (Figure 3), tumor cells disseminate from the primary tumor through 
lymphatic or blood vessels during the early stage of tumor growth. Disseminated 
tumor cells proliferate and form solid metastases in lymph nodes, whereas tumor 
cells that spread to distant sites, through the blood, die or remain dormant. 
At later stages, tumor cells disseminate from the established lymph node 
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metastases through the blood circulation to distant sites, where they are able to 
form solid metastases. As a result, metastasis to other organs is dependent on 
the presence of lymph node metastases. This correlation has been shown for head 
and neck cancer.86 In the second model (Figure 3), cells frequently disseminate, 
through blood vessels, from the primary tumor to distant sites, where they 
progress to overt metastases without previous passage through lymph nodes. In 
patients with breast cancer, this hematogenous dissemination seems to be a very 
early event in tumor progression. 
Blood microvessel density has been assessed by antibodies directed against 
several endothelial markers, including CD31 (PECAM-1), CD34 and factor VIII 
(von Willebrand factor) leading to variable results regarding its prognostic value.87 
In recent years, antibodies specifically directed against lymphatic endothelial 
cells have been found such as Prox188, LYVE-189, anti-podoplanin90 and D2-40.91 
One of the most important growth factors regulating tumor angiogenesis is 
vascular endothelial growth factor (VEGF) which consists of five ligands: VEGF-A, 
VEGF-B, VEGF-C, VEGF-D and placenta growth factor and three receptors: 
VEGFR-1, VEGFR-2 and VEGFR-3.92-94 VEGF-A is a known ligand for VEGFR-1 and 
VEGFR-2 which are mainly expressed in blood vascular endothelium. VEGF-C and 
Figure 2. Active and passive mechanisms in initial steps of metastasis. Left: reports 
that tumor cells accumulate mutations, upregulate migration machinery, and align and 
migrate up nutrient or chemokine gradients, are in support of active metastasis. Fibroblasts, 
macrophages, and other stromal cells are also likely to cooperate with cancer cells to actively 
help with the initial stage of metastasis. Right: There is evidence that tumor cells including 
dead or apoptic cells are shed into the vasculature, which implies a passive mechanism. 
It is possible that uncontrolled focal growth crushes or impinges upon fragile tumor blood 
vessels, leading to passive shedding. Similarly, tumor cells may be shed into lymphatic 
vessels.83 ECM, extracellular matrix.
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Figure 3. Two models of metastatic spread. Before reaching their final metastatic 
site, tumor cells must cross several basement membranes: first when progressing from 
carcinoma in situ to invasive carcinoma, then during intravasation and extravasation (upper 
left) and finally when invading other tissues.97 Tumor cell dissemination from the primary 
site can occur via lymphatic routes (red arrows) and by hematogenous routes (blue 
arrows). Secondary hematogenous dissemination also occurs from overt metastases to 
other distant sites (black arrows). In the lymphatic route (red arrows), disseminated 
tumor cells proliferate in the lymph nodes to form solid metastases. At later stages, tumor 
cells disseminate from the established lymph node metastases to distant sites by entering 
the thoracic duct and the right lymphatic duct, each draining into its ipsilateral subclavian 
vein. It is possible that this ability was gained during the progression of these cells in the 
lymph-node environment. As a result, tumor metastasis is dependent on the presence of 
lymph-node metastases.85 In the hematogenous route (blue arrows), tumor cells primarily 
travel through blood vessels to form distant metastases. Two separate models of metastatic 
spread is suggested since for instance breast cancer patients can develop metastases at 
distant organs, whereas the lymph nodes remain tumor free. Again, in head and neck cancer, 
distant metastases is dependent on the presence of lymph node metastases.85 Besides 
outgrowth into clinically evident metastases, tumor cells that arrested in lymph nodes or 
that intra- or extravascularly lodged into organ parenchym for instance bone marrow, can 
also enter apoptosis or remain dormant either as single cells or as a small group of tumor 
cells that underwent a proliferative expansion and cannot recruit a vascular bed98 (lower 
right). 
VEGF-D are ligands for VEGFR-3, mostly expressed in lymphatic endothelium. 
In this thesis, the clinical relevance of microvessel density detected by CD31 and 
D2-40 and of VEGF-C, VEGF-D and sLeX tumor expression in CRC was evaluated.
Chapter 122
Automated microscopy
Detection of immunochemically stained tumor cells in multiple levels of lymph 
nodes, in bone marrow and in blood is laborious and time-consuming. The use of 
automated microscopy by which tumor cells can be detected on basis of different 
color, can overcome these disadvantages. In addition, automated analysis showed 
a higher detection rate of ITC in sentinel lymph nodes from breast cancer patients 
of up to 12.5% compared to conventional microscopy.95 In this thesis, automated 
microscopy has been used to detect tumor cells in lymph nodes and in bone 
marrow.
Aim and outline of the thesis
After the diagnosis of cancer in a solid organ is established, the main question is 
whether the tumor is localized or whether it has already disseminated to regional 
lymph nodes and/or distant organs. Currently, the basis for therapeutic decisions 
is the anatomically TNM staging system for solid-organ cancers developed by the 
International Union Against Cancer (UICC)41 and the American Joint Committee 
on Cancer (AJCC).42 As discussed above, this staging system does not provide 
accurate prediction of prognosis for the individual patient. Despite improvements in 
surgical techniques, many deaths from cancer result from the progressive growth 
of metastases in patients who had been considered curatively treated. In this 
thesis, we focus on identifying patients at risk for disease recurrence after surgical 
treatment of gastric cancer, colorectal cancer or colorectal liver metastases. 
In chapter 2 is analyzed whether the presence of OTC in originally considered 
tumor-negative lymph nodes from curatively resected gastric cancer patients 
can predict disease recurrence. This is done in a case-control design with a 
selection of patients from the previously published multicenter Dutch D1-D2 
Gastric Cancer trial.7 Moreover, the additional value of automated microscopy is 
evaluated. Chapter 3 presents an overview of studies regarding the detection 
methods and clinical relevance of OTC in lymph nodes in CRC. An approach in 
which immunohistochemical staining and multiple sectioning of lymph nodes in 
CRC is combined and subjected to novel high-throughput automated imaging is 
described in chapter 4. In addition, the results are compared with RT-PCR data 
from a previously published study.50 Chapter 5 reports on results of a case-
control study with CRC patients assessing whether detailed examination of lymph 
nodes by multilevel sectioning and immunohistochemical staining can predict 
disease recurrence.
Sentinel node mapping has been introduced in CRC to improve staging by facilitating 
OTC assessment in lymph nodes that are most likely to contain tumor cells. In 
chapter 6, studies on the feasibility and reliability of sentinel node mapping in 
CRC are reviewed with the emphasis on differences in the techniques used.
Although usually no clinically evident bone metastases are developed in CRC, 
DTC are found in bone marrow and we suspect that the presence of tumor cells 
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in bone marrow might represent the aggressive nature of the tumor and could 
therefore be used to predict disease recurrence. This is evaluated in chapter 7 
by assessing whether the presence of DTC in bone marrow from patients who 
undergo locoregional treatment of colorectal liver metastases is associated with 
a worse outcome of disease. The presence of DTC in bone marrow is analyzed by 
using quantitative RT-PCR and immunocytochemistry.
As discussed, it is generally accepted that tumor cells can spread through local 
invasion and hematogenous or lymphatic routes. To finally reach lymph nodes or 
other tissue compartments in the body, the tumor cells have to overcome many 
bounderies with the aid of various proteins. In chapter 8 several markers related 
to tumor cell spread through blood and lymphatic vessels are studied for their 
prognostic significance. Specifically, we examine whether disease recurrence in 
lymph node-negative CRC patients can be predicted by assessing their primary 
tumors for the expression of the angiogenic and lymphangiogenic factors sLeX, 
VEGF-C, and VEGF-D, for blood and lymphatic microvessel density and for the 
presence of blood and lymphatic vessel invasion. 
Finally, the conclusions of above mentioned studies and future perspectives 
regarding these studies are discussed in chapter 9. A summary of this thesis 
translated in Dutch is presented in chapter 10.
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ABSTRACT
Background: The current method for staging in gastric cancer is not sufficient 
as even after a complete primary tumor resection, patients with node-negative 
gastric cancer suffer from disease recurrence. In this study, the relation between 
disease recurrence and the presence of occult tumor cells (OTC) in lymph nodes 
from gastric cancer patients was evaluated. 
Patients and methods: In a case-control design, lymph nodes from 40 cases 
(disease recurrence) and 41 controls (no disease recurrence for at least 5 years) 
with gastric cancer were examined for the presence of OTC, that comprised 
micrometastases (MM; > 0.2 mm and < 2.0 mm) and isolated tumor cells 
(ITC; < 0.2 mm). The original hematoxylin and eosin (HE) stained sections 
of all lymph nodes from cases and controls were previously considered as 
tumor-negative by a pathologist. Fresh HE stained sections were screened by 
conventional microscopy. Histological sections stained by immunohistochemistry 
(IHC) with anticytokeratin antibodies CAM5.2 were screened by conventional 
and automated microscopy. 
Results: Tumor cells were detected in lymph nodes from 40 of 81 (49%) patients. 
There was no significant difference in the presence of OTC, MM or ITC between 
the case and control groups (P = 0.658; P = 0.691; P = 0.887, respectively). 
However, significantly more cases presented with 20% or more OTC-positive 
lymph nodes (P = 0.015). A multivariate logistic regression analysis showed 
that examination of less than 5 lymph nodes (OR 13.8, 95% CI 1.6-120.6, P = 
0.018) was the only significant independent risk factor for disease recurrence, 
especially for locoregional disease recurrence (OR 20.4, 95% CI 2.2-190.8, P = 
0.008). A similar analysis for distant disease recurrence showed a percentage of 
20% or more OTC-positive lymph nodes to be the only significant independent 
risk factor (OR 15.6, 95% CI 1.6-151.4, P = 0.018). The sensitivity of IHC 
evaluated by microscopy to identify cases with 20% or more OTC-positive lymph 
nodes increased from 8% for conventional microscopy to 22% for automated 
microscopy (McNemar’s test, P = 0.063). 
Conclusions: The mere presence of OTC-positive lymph nodes in gastric cancer 
patients did not predict disease recurrence. However, the number of examined 
lymph nodes and the percentage of OTC-positive lymph nodes were independent 
risk factors for locoregional disease recurrence and distant disease recurrence, 
respectively. Automated microscopy was essential in identifying patients with 
20% or more OTC-positive lymph nodes. Therefore a maximum number of 
lymph nodes should be removed and meticulously examined for OTC to identify 
high-risk patients. These patients should be considered for additional treatment.
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INTRODUCTION
The prognosis of patients with resectable gastric cancer is mainly predicted by 
tumor involvement of the lymph nodes1-3 and depth of primary tumor invasion 
into the gastric wall.4 The current method for staging, however, is not sufficient as 
even after a complete primary tumor resection up to 30% of patients with node-
negative gastric cancer suffer from disease recurrence.5 These recurrences might 
be explained by inadequate lymph node staging due to missing of occult tumor 
cells (OTC). OTC comprises of micrometastases (MM) and isolated tumor cells 
(ITC). MM are defined as deposits of tumor cells of 2 mm or less but larger than 
0.2 mm and ITC as single tumor cells or clusters of tumor cells of 0.2 mm or less.6-8
OTC is usually not detected with conventional pathological examination applying 
the hematoxylin and eosin (HE) staining method. The likelihood of detecting 
OTC is higher when focused examination techniques such as serial sectioning, 
immunohistochemistry (IHC) or reverse-transcriptase polymerase chain reaction 
are used. By detecting OTC, patients at high risk for recurrent disease may be 
identified. These patients might be considered for postoperative adjuvant therapy.9 
The aim of this study was to analyze whether the presence of OTC in originally 
considered tumor-negative lymph nodes from curatively resected gastric cancer 
patients can predict disease recurrence. Moreover, the additional value of 
automated microscopy was evaluated.
PATIENTS AND METHODS
Patient source and selection
Between August 1989 and July 1993, a total of 1078 patients were randomized in 
the multicenter Dutch D1-D2 Gastric Cancer trial. This trial was organized by the 
Dutch Gastric Cancer Group and compared a D2 (extended) to a D1 (conventional) 
lymph node dissection. Details of the trial protocol, D1/D2 dissection, the protocol 
for sampling and evaluation of resection margins and the protocol regarding the 
handling of the lymph nodes have been reported previously.10-13 Large lymph 
nodes were cut grossly at 2- to 3-mm intervals and totally embedded in paraffin. 
Follow-up was continued until January 2003 resulting in a median follow-up of 11 
years with a range of 9 to 13 years.
Among 1078 patients randomly assigned in the trial, 711 patients had undergone 
a resection with curative intent with a D1 (n = 380) or D2 (n = 331) lymph node 
dissection. Of these 711 patients with a curative resection, 304 patients had an R0 
resection (i.e. macroscopically and microscopically negative resection margins) 
and lymph nodes considered tumor-negative by the original pathologist. For the 
present study, cases and controls were selected from this group. 
All patients who suffered from locoregional or distant recurrence (n = 43) were 
considered cases. Lymph node tissue blocks from 3 cases were not available 
or not suitable for investigation, leaving 40 cases that were included into the 
study. Fourteen cases suffered from locoregional disease recurrence, 14 patients 
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Figure 1-4. Occult tumor cells in lymph nodes from gastric cancer patients. 
Micrometastases (> 0.2 mm and < 2 mm) at original magnifications of x100 (1a) and x400 
(1b). Isolated tumor cells (tumor cell clusters < 0.2 mm) at original magnifications of x100 
(2a) and x400 (2b). Isolated tumor cells (single cells) at original magnifications of x100 
(3a) and x400 (3b). Isolated tumor cells only seen on the hematoxylin and eosin stained 
section at original magnifications of x100 (4a) and x400 (4b).
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from locoregional and distant recurrence and 12 patients suffered from distant 
recurrence. For each case, at least one control was selected from the patient 
group who did not suffer from disease recurrence for a minimum of 5 years 
(n = 261). Controls (n = 41) were matched for depth of tumor invasion and age. 
Immunohistochemistry
Three consecutive 4 µm tissue sections were cut from each paraffin block, 
prepared on aminopropylethoxysilane coated slides, and dried overnight at 37°C. 
One section was stained with the HE method and two sections were used for IHC. 
One of these sections was stained with the antibody CAM5.2 (Becton Dickinson, 
CA), a murine monoclonal antibody specific for cytokeratin 7 (weak) and 8. The 
other section was used as a negative control stained with the primary antibody 
omitted. As positive control a known CAM5.2 positive primairy tumor was used. 
As negative control tumor sections were incubated with phosphate-buffered saline 
(PBS) instead of CAM5.2. The sections were deparaffinized in xylol. Endogenous 
peroxidase was blocked in 0.3% hydrogen peroxide methanol at room temperature 
for 20 minutes. Subsequently the sections were rehydrated. After washing in PBS, 
antigen retrieval treatment was done by incubating the sections in a 0.1% trypsin 
calciumchloride (0.1%) solution during 20 minutes at 37oC. Hereafter, the slides 
were rinsed twice in PBS. The primary antibody was applied at a 1:320 dilution in 
PBS with 1% bovine serum albumine. The sections were incubated overnight at 
room temperature. The detection of cytokeratin was achieved by incubating the 
sections for 30 minutes with the biotinylated rabbit-anti-mouse conjugate (Dako, 
Glostrup, Denmark, 1:200), followed by three PBS washes and incubation for 
30 minutes with the streptavidin-biotin-peroxidase conjugate (DAKO, Glostrup, 
Denmark, 1:100). After three washes in PBS visualization of cytokeratin was 
achieved by a 10 minutes incubation with 3,3’-diaminobenzidinetetrachloride 
substrate in a buffered 0.05 M Tris/HCl (pH 7.6) solution containing 0.002% 
hydrogen peroxide. Cytokeratin-positive cells stained brown. Counterstaining 
was done with Mayer’s Hematoxylin. For microscopic analysis the sections were 
dehydrated in graded ethanol followed by xylol and mounted in pertex.
Screening of the slides
The sections stained by the HE and the IHC method (negative control and 
CAM5.2) were screened by a pathologist using conventional light microscopy at a 
magnification of 100 times. The sections stained by the IHC method using CAM5.2 
were also screened with automated microscopy using the ARIOL system® (Applied 
Imaging Corporation, San Jose, CA). The ARIOL system consisted of a slidefeeder 
and a microscope linked to a computer with software for detecting cells with a 
different color within an evenly stained background. The X, Y and Z coordinates 
and images of the selected objects were stored for relocation of the slides under 
the microscope. The slidefeeder could contain 50 slides that were screened within 
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24 hours. Objects found by this system were reviewed by the operator of the ARIOL 
system, a technician specialized in cytology. The pathologist reviewed all tumor 
cells detected by the ARIOL system that were previously missed with conventional 
microscopy. Nonspecifically stained cells such as macrophages, dendritic cells 
or white blood cells were excluded. OTC comprised micrometastases (MM) and 
isolated tumor cells (ITC). MM were defined as deposits of tumor cells of 2 mm or 
less but larger than 0.2 mm and ITC as single tumor cells or clusters of tumor cells 
of 0.2 mm or less. Macrometastases were larger than 2 mm.
Statistical analysis
Statistical analysis was carried out using SPSS software, version 11.5 (SPSS Inc, 
Chicago, IL). Numerical data are presented as mean + standard deviation. The 
clinicopathologic features of cases and controls were compared either by a chi-
square test or a student T-test. Univariate and multivariate odds ratio’s (OR), 
95% confidence intervals (95% CI) and p-values (P) were calculated by applying 
logistic regression analysis. Differences between screening results by automated 
microscopy and conventional microscopy were analyzed by using the McNemar 
test. A p-value of less than 0.05 was considered an indication of statistical 
significance. Factors with a (overall) p-value less than 0.10 in the univariate 
analysis were entered into the multivariate logistic regression model.
RESULTS
Clinical relevance of occult tumor cells
In total, 1396 lymph nodes of 81 patients were studied (median, 15; range, 1 to 
92 lymph nodes). The characteristics of these patients are shown in Table 1. The 
percentage of lymph nodes that were found to be tumor-positive and of patients 
having tumor-positive lymph nodes are shown in Table 2. The results with the 
HE method, IHC evaluated by conventional microscopy and IHC evaluated by 
automated microscopy are shown separately. Not all lymph nodes were analyzed 
with all three methods as deducible from the total number of analyzed lymph 
nodes shown in the table. The combined results, i.e. results from HE staining and 
IHC staining evaluated both by conventional and automated microscopy, were 
used for the analysis. The negative control sections did not contain aspecifically 
stained cells. Tumor cells were detected in lymph nodes from 40 of 81 (49%) 
patients by screening of HE and IHC sections (Figure 1-4). Two cases (5%) and 
one control (2%) had lymph nodes with macrometastases. These patients were 
excluded from further analysis leaving a total of 38 cases and 40 controls (Table 
3). Nineteen cases (50%) and 18 controls (45%) had OTC-positive lymph nodes, 
which numbers did not differ statistically between both these groups (P = 0.658)
There was also no significant difference in the presence of MM or ITC between the 
case and control group (21% vs 18%, P = 0.691; 29% vs 28%, P = 0.887). 
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Characteristics n % n % n % Pa
Sexe
Female 32 40 14 35 18 44 NS
Male 49 61 26 65 23 56
Age (years)b 63 + 11.5 63.9 + 11.5 62.1 + 11.5 NSc
Staged
IA 16 20 7 18 9 22 NS
IB 50 62 26 65 24 59
II 14 17 7 18 7 17
IIIA 1 1 0 0 1 2
Location
C (Upper third) 14 18 7 18 7 17 NS
M (Middle third) 28 35 12 31 16 39
A (Lower third) 38 48 20 51 18 44
WHO classification
Papillary 10 12 5 13 5 12 NS
Tubular 34 42 14 35 20 49
Mucinous 6 7 3 8 3 7
Signet ring cell 28 35 17 43 11 27
Undifferentiated 3 4 1 3 2 5
Laurén classification
Intestinal 50 62 21 53 29 71 NS
Diffuse 24 30 16 40 8 20
Mixed 7 9 3 8 4 10
Differentiation
Good 5 6 4 10 1 2 .012
Moderate 33 41 10 25 23 56
Poor 43 53 26 65 17 42
Size (cm)
< 2 6 8 4 10 2 5 NS
2 – 3 34 43 15 39 19 48
> 3 39 49 20 51 19 48
Unknown 2 - 1 - 1 -
a Chi-square test of cases vs controls, unless mentioned otherwise; b Presented as mean + standard 
deviation; c Student T-test; d According to the 5th edition of the TNM classification.19
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However, the mean percentage of OTC-positive lymph nodes was significantly 
higher in the case group compared with the control group (13.4 + 22.0 vs 5.0 + 
7.0; P = 0.024). Nine of 38 cases and one of 40 controls were found to have 20% 
or more OTC-positive lymph nodes (24% vs 3%, P = 0.015), indicating that a 
high number of positive lymph nodes is predictive for disease recurrence. A single 
variable regression analysis showed that a percentage of 20% or more OTC-
positive lymph nodes was a significant predictor for disease recurrence (Table 3).
In total, three patients had OTC in lymph nodes outside the first level lymph nodes 
only (i.e. skip metastases). The level of lymph nodes was categorized according 
to the 4th edition of the TNM classification14 and the General Rules for the Gastric 
Cancer Study in Surgery and Pathology by the Japanese Research Society for the 
Study of Gastric Cancer.15 Two of these patients were in the case group and one 
patient was in the control group. 
There was a correlation between patients with less than 5 lymph nodes 
examined and disease recurrence (Chi-square test, Table 1; P = 0.001). Patient 
characteristics that in two types of statistical analysis significantly correlated with 
disease recurrence were tumor differentiation and the number of examined lymph 
nodes (Chi-square test, Table 1 and single variable regression analysis, Table 4). 
The difference between the case and control group in having less than 5 lymph 
nodes examined and in 20% or more OTC-positive lymph nodes was found to be in 
the D1 dissection group and not in the D2 dissection group (Chi-square; P < 0.001 
vs P = 0.586 and P = 0.008 vs P = 0.793, respectively). Therefore, patients with 
less than 5 lymph nodes examined or 20% or more OTC-positive lymph nodes did 
not have a worse prognosis if they had undergone a D2 dissection. 
In a multivariate logistic regression analysis, the variables tumor differentiation, 







Characteristics n % n % n % Pa
Resection type
D1 54 67 26 65 28 68 NS
D2 27 33 14 35 13 32
Resection type
Total 25 31 12 30 13 32 NS
Partial 56 69 28 70 28 68
Number of lymph nodes
> 5 68 84 28 70 40 98 .001
< 5 13 16 12 30 1 2
a Chi-square test of cases vs controls, unless mentioned otherwise.
- continued
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A. Lymph node status n % n % n % n %
Presence of tumor cells 43 3.1 70 5.1 108 7.9 119 8.5
Macrometastases 6 0.4 6 0.4 6 0.4 6 0.4
MM 18 1.3 25 1.8 34 2.5 38 2.4
ITC 19 1.4 39 2.8 68 5.0 75 5.4
Negative 1337 96.9 1311 94.9 1258 92.1 1277 91.5
(n=81) (n=80) (n=80) (n=81)
B. Patient status n % n % n % n %
Presence of tumor cells 19 24 26 33 35 44 40 49
Macrometastases 3 4 3 4 3 4 3 4
MM 8 10 12 15 13 16 15 19
ITC 8 10 11 14 19 24 22 27
Negative 62 77 54 68 45 56 41 51
HE, hematoxylin and eosin staining; IHC, immunohistochemistry; MM, micrometastases; ITC, isolated 
tumor cells; a Seven lymph nodes from three patients were found tumor-positive by HE staining only 
and scored negative on the IHC slides because these sections did not contain tumor cells anymore; 
b Four lymph nodes from two positive patients were recorded as negative in IHC evaluated by automated 
microscopy screening because the objects found by the system were considered as doubtful.
number of examined lymph nodes, and percentage of patients with 20% or more 
OTC-positive lymph nodes were entered. The examination of less than 5 lymph 
nodes (OR 13.8, 95% CI 1.6-120.6, P = 0.018) was the only independent risk 
factor for disease recurrence. Having a percentage of 20% or more positive 
lymph nodes was no independent risk factor (OR 9.0, 95% CI 1.0-81.2, P = 
0.051), although there is a trend of being a risk factor as the P value was close to 
significance. Distant disease recurrence and locoregional disease recurrence were 
separately analyzed because of a possible difference in the metastasizing pattern. 
There was no correlation between the number of examined lymph nodes and 
distant metastases (P = 0.374) but the number of examined lymph nodes did 
correlate with locoregional relapse (P = 0.002). Furthermore, the presence of 
20% or more OTC-positive lymph nodes was associated with distant metastases 
(P = 0.001) but not with locoregional recurrence (P = 0.778). 
The majority of patients (8 of 9) from the case group with 20% or more OTC-positive 
lymph nodes suffered from distant disease recurrence. A multivariate logistic 
regression analysis for distant disease recurrence showed the only independent 
risk factor to be having a percentage of 20% or more positive lymph nodes (OR 
15.6, 95% CI 1.6-151.4, P = 0.018) and a similar analysis for locoregional disease 
recurrence showed the examination of less than 5 lymph nodes (OR 20.4, 95% CI 
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2.2-190.8, P = 0.008) to be the only independent risk factor.
A sensitivity and specificity calculation for disease recurrence within a period of 5 
years for less than 5 examined lymph nodes or having 20% or more OTC-positive 
lymph nodes revealed a sensitivity of 29% and specificity of 98% (n = 78), and 
a sensitivity of 21% and specificity of 93% (n = 78), respectively. The combined 
condition of less than 5 examined lymph nodes or having 20% or more OTC-
positive lymph nodes led to a sensitivity of 45% and a specificity of 95% (n = 78). 
Three of 11 patients from the case group with less than 5 lymph nodes examined 
had stage IA gastric cancer, 7 had stage IB and 1 had stage II gastric cancer. 
Two of 9 cases with 20% or more OTC-positive lymph nodes had stage IA gastric 
cancer, 4 had stage IB and 3 had stage II gastric cancer. All stage IA patients from 
the case group with less than 5 lymph nodes examined or with 20% or more OTC-
positive lymph nodes (n = 3) had undergone a D1 resection.
Screening of the slides
IHC staining evaluated by conventional microscopy was compared with HE 
staining and IHC staining evaluated by automated microscopy was compared 
with IHC staining evaluated by conventional microscopy. Six lymph nodes from 3 
patients containing macrometastases were identified by all 3 screening methods. 
Table 3. Clinical relevance of occult tumor cells in lymph nodes from patients with gastric 








n % n % n % Pa OR 95% CI P
Presence of OTC 37 47 19 50 18 45 .658 1.2 (0.5-3.0) .659
Presence of MM 15 19 8 21 7 18 .691 1.3 (0.4-3.9) .691
Presence of ITC 22 28 11 29 11 28 .887 1.1 (0.4-2.9) .887
OTC-positive lymph 
nodes (mean)b
1.3 + 2.1 1.5 + 2.3 1.1+ 1.8 .465c 1.1 (0.9-1.3) .462
OTC-positive lymph 
nodes (mean %)b
9.1 + 16.6 13.4 + 22 5 + 7 .024c 1.04 (1.0-1.1) .043
OTC-positive lymph nodes
(categorized %)
0% 41 53 19 50 22 55 .015 1
> 0% and < 20% 27 35 10 26 17 43 0.5 (0.2-1.3) .136
> 20% 10 13 9 24 1 3 12.1 (1.5-101) .021
OTC in 2 or 
more lymph nodes
19 24 11 29 8 20 .357 1.6 (0.6-4.6) .360
MM in 2 or
more lymph nodes
9 12 6 16 3 8 .252 2.3 (0.5-10) .262
OTC, occult tumor cells; MM, micrometastases; ITC, isolated tumor cells; OR, odds ratio; CI, confidence 
interval;a Chi-square test of cases vs controls, unless mentioned otherwise; b Presented as mean + 
standard deviation; c Student T-test.
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These patients were included in this assessment because by excluding these 
patients, 3 lymph nodes with MM would also have been excluded. From 1 patient 
only 1 lymph node was available which was stained by the HE method only. 
Table 4. Single variable regression analysis of disease recurrence (n=78)
Univariate analysis
Characteristics OR 95% CI P
Sexe
Female 1
Male 1.3 (0.5-3.1) .610
Age (years) 1.0 (1.0-1.1) .438
Stagea .962b
IA 1
IB 1.4 (0.4-4.6) .591
II 1.3 (0.3-5.9) .705
IIIA NA
Location .732b
C (Upper third) 1
M (Middle third) 0.6 (0.2-2.3) .483
A (Lower third) 1.2 (0.3-4.0) .796
WHO classification .681b
Papillary 1
Tubular 0.7 (0.2-2.8) .602
Mucinous 1.0 (0.1-7.6) 1.000
Signet ring cell 1.5 (0.3-6.3) .614
Undifferentiated 0.5 (0.0-7.5) .615
Laurén classification .178b
Intestinal 1
Diffuse 2.6 (0.9-7.4) .067
Mixed 1.1 (0.2-5.2) .952
Differentiation .036b
Good 1
Moderate 0.2 (0.0-1.6) .121
Poor 0.5 (0.0-5.1) .551
Size (cm) .775b
< 2 1
2 - 3 0.8 (0.3-2.0) .622
> 3 1.1 (0.5-2.7) .825
OR, odds ratio; CI, confidence interval; NA, not assessable; a According to the 5th edition of the TNM 
classification19; b Overall P value.
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A total of 1365 lymph nodes from 80 patients were examined by both HE staining 
and IHC evaluated by conventional microscopy. 
The number of positive lymph nodes increased from 43 (3%) found by HE staining 
to 77 (6%) found by IHC evaluated by conventional microscopy. The number of 
patients with positive lymph nodes increased from 19 (24%) when identified by HE 
staining to 29 (36%) by IHC evaluated by conventional microscopy. Seven lymph 
nodes (0.5%) from 3 of the 29 tumor-positive patients were found tumor-positive 
by HE staining only and scored negative on the IHC slides because these sections 
did not contain tumor cells anymore (Figure 4). IHC slides of 1366 lymph nodes 
from 80 patients were examined by both conventional microscopy and automated 
microscopy. When comparing IHC evaluated by conventional microscopy to 
IHC evaluated by automated microscopy, the number of positive lymph nodes 
increased from 70 (5%) to 112 (8%) out of 1366 and the number of patients with 
positive lymph nodes increased from 26 (33%) to 37 (46%). Four positive lymph 
nodes from 2 of the 37 OTC-positive patients were recorded as negative in IHC 
evaluated by automated microscopy screening because the objects found by the 
system were considered as doubtful by the pathologist. The ARIOL system did 
not miss any tumor cells in lymph nodes. In Table 5, the additional value of IHC 
and automated microscopy in detecting patients with 20% or more positive lymph 
nodes, is shown. By using IHC evaluated by conventional microscopy 1 patient in 
the control group was identified with 20% or more positive lymph nodes. However, 
with IHC combined with automated microscopy, 5 of 8 patients in the case group 
were additionally identified as having 20% or more positive lymph nodes. 
The sensitivity and specificity of the 3 screening methods are displayed in Table 
6. IHC screened by automated microscopy identified 22% of patients in the case 
group compared with 8% and 11% identified by IHC screened by conventional 
Table 4. Single variable regression analysis of disease recurrence (n=78)
Univariate analysis
Characteristics OR 95% CI P
Resection type
D1 1
D2 1.2 (0.5-3.1) .687
Resection type
Total 1
Partial 1.2 (0.5-3.1) .734
Number of lymph nodes
> 5 1
< 5 15.9 (1.9-130.4) .010
OR, odds ratio; CI, confidence interval.
- continued
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Table 6. The sensitivity and specificity of the screening methods in detecting patients with 
20% or more positive lymph nodes (n=77)





IHC screened by conventional microscopy 8 98
IHC screened by automated microscopy 22a 98
HE, hematoxylin and eosin staining; IHC, immunohistochemistry; a McNemar’s test comparing 
automated to conventional microscopy, P = 0.063.
Table 5. The additional value of IHC to HE staining 
and automated microscopy to conventional screening 
when considering a patient positive with 20% or more 








cases (n=37) negative 33 0
positive 1a 3









cases (n=37) negative 29 5
positive 0 3
controls (n=40) negative 39 0
positive 0 1
IHC, immunohistochemistry; HE, hematoxylin and eosin 
staining; a Lymph nodes were found tumor-positive by HE 
staining only and scored negative on the IHC slides because 
these sections did not contain tumor cells anymore.
microscopy and the HE 
method, respectively. 
When comparing the 
sensitivity of automated 
microscopy to conventional 
microscopy, McNemar’s 
test showed a P value 
of 0.063 suggesting 
additional value of the 
former screening method. 
The specificity of the HE 
method, IHC screened by 
conventional microscopy 
and IHC screened by 
automated microscopy 
was 100%, 98% and 98%, 
respectively.
Original HE slides of 31 
of 43 tumor-positive 
lymph nodes, detected 
with the HE method, 
could be retrieved from 
the involved Pathology 
Departments. Nine original 
HE slides with 12 lymph 
node sections were lost 
because material older than 10 years had already been destroyed. Re-evaluation 
of the original HE slides revealed that in 24 of 31 (77%) positive lymph nodes, 
tumor cells were also present in these original sections. Six of the 31 positive 
lymph nodes contained macrometastases and 25 were OTC-positive. Three 
of 6 lymph nodes with macrometastases in the new HE sections also showed 
macrometastases in the original sections and 21 of 25 lymph nodes with OTC 
were on re-observation of the original HE slides also found to be OTC-positive. 
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Considering the fact that 24 of 31 (77%) of the positive lymph nodes could already 
have been identified in the original HE sections, it can be concluded that tumor 
cells were detected in 7 of 31 (23%) lymph nodes through serial sectioning i.e. 
additional sections for HE staining. 
DISCUSSION
This case-control study showed that simply the presence of OTC, either MM or ITC 
in lymph nodes from patients with gastric cancer is not correlated with disease 
recurrence. The examination of less than 5 lymph nodes was the only independent 
risk factor for disease recurrence. When analyzing the type of disease recurrence 
separately, the number of examined lymph nodes and the presence of 20% or 
more OTC-positive lymph nodes were independent risk factors for locoregional 
disease recurrence and distant disease recurrence, respectively. The number 
of examined lymph nodes has already been reported as a prognostic factor.16-18 
Current guidelines from the American Joint Committee on Cancer Staging 
(AJCC)7;19 recommend examination of a minimum of 15 lymph nodes to justify 
the N0 status. However, Klein Kranenbarg et al.16 previously studied patients 
from the Dutch Gastric Cancer Group Trial (DGCGT) and reported a minimum 
of 5 examined lymph nodes as a reliable number for staging purposes. Liu et 
al.17 reported a considerable survival advantage for patients with stage III gastric 
cancer when more than 15 lymph nodes were removed. Ichikura et al.18 showed 
that N0 patients with more than 9 lymph nodes examined had a significantly 
higher survival rate than N0 patients with 5 to 9 lymph nodes examined and 
patients with N1 or N2 disease19, tended toward lower survival rates when less 
than 30 lymph nodes were examined. Therefore, the number of examined lymph 
nodes is of prognostic significance for patients with N0, N1 and N2 disease. 
Moreover, our study showed that the number of examined lymph nodes and the 
presence of 20% or more OTC-positive lymph nodes were independent risk factors 
for locoregional disease recurrence and distant disease recurrence, respectively. 
This suggests that locoregional disease recurrence probably is the result of lymph 
nodes that were not removed. Conversely, when 20% or more of the lymph nodes 
are OTC-positive, tumor cells may already have travelled to other sites in the body 
eventually leading to distant metastases. The addition of tumor cell detection in 
bone marrow20 and peritoneal washes21-23 could add to identifying patients at risk 
for developing disease recurrence.
We have also found in another study24, in which multiple sections of sentinel nodes 
were examined, that automated microscopy detected more OTC than routine 
pathology. In our current study, without using automated microscopy, we would 
have missed 5 of 9 patients in the case group with 20% or more positive lymph 
nodes. Therefore IHC evaluated by automated microscopy showed additional 
value in identifying high-risk patients. 
Nine25-33 of the 14 previously published studies25-38 on the prognostic relevance of 
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Table 7. Immunohistochemistry studies regarding the clinical relevance of occult tumor 
cells in lymph nodes













Siewert et al.25 1996 AE1/AE3 62 33.8 90c negative
Maehara et 
al.26
1996 CAM5.2 34 12.4 24 negative
Ishida et al.27 1997 CAM5.2 and 
or CEA
21d 22.4 67 negative
Kikuchi et al.34 1999 AE1/AE3 51 27.3 43 none
Cai et al.28 2000 CAM5.2 69 24.6 25 negative
Bozzetti et al.35 2000 a pool of 35βH11, 
34βE12,CAM5.2,
AE1/AE3 and KL1
29 25 28 none
Harrison et 
al.29
2000 CAM5.2 25 9.0 36 negative
Fukagawa 
et al.36
2001 AE1/AE3 107 41.9 36 none
Nakajo et al.30 2001 AE1/AE3 67 26.3 15e negative
Yasuda et al.31 2002 CAM5.2 64 31.9 32 negative
Lee et al.32 2002 AE1/AE3 70 23.7 24 negative
Choi et al.37 2002 anti-CK8 73 25.8 18 none
Ishigami 
et al.33
2003 AE1/AE3 144 23.4 9 negative
Morgagni 
et al.38, f
2003 MNF116 300 18 10 None
HE, hematoxylin and eosin staining; CK, cytokeratin; CEA, carcinoembryonic antigen; a There are 20 
different types of cytokeratins; AE1/AE3 is a mixture of two different clones of  monoclonal antibodies 
(Dako); AE1 recognizes CK10, 13, 14, 15, 16, and 19; AE3 recognizes CK1, 2, 3, 4, 5, 6, 7 and 8; CAM5.2 
recognizes CK7 (weak) and 8 (Becton Dickinson); 35βH11 recognizes CK8 (Dako); 34βE12 recognizes 
CK1, 5, 10 and 14 (Dako); KL1 recognizes CK1, 2, 5, 6, 7, 8, 11, 14, 16, 17 and 18 (Immunotech); 
anti-CK8 recognizes CK8 (Dako); MNF116 recognizes CK5, 6, 8, 17 and probably 19 (Dako); CEA 
recognizes carcinoembryonic antigen (IBL, Fujioka, Japan); b Impact on prognosis includes impact on 
overall survival and/or disease-free and/or disease-specific survival based on logrank, univariate and/
or multivariate analyses with a P value < 0.05; c significant prognostic factor when the threshold of 3 or 
more tumor cells in more than 10% of the examined lymph nodes was exceeded; d Stage II patients;
e Micrometastases were defined as a cluster of tumor cells with a stromal reaction (15%); no effect on 
prognosis was shown by individual tumor cells without a change in the stroma (6%); f This was the only 
study examining 3 levels of each lymph node.
OTC in lymph nodes from gastric cancer patients report a negative impact of the 
presence of OTC in lymph nodes on patient’s prognosis (Table 7). In the study 
by Siewert et al.25 the percentage of OTC-positive lymph nodes was prognostic 
relevant. The study by Nakajo et al.30 showed a prognostic effect of tumor cells 
in lymph nodes with stromal reaction but no effect of tumor cells in lymph nodes 
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without stromal reactions. The other 7 studies reported a prognostic relevance of 
just the presence of OTC in lymph nodes. Our analysis has important additional 
value to these 14 studies. First, we used automated microscopy to detect OTC in 
lymph node sections IHC-stained for tumor cells. Therefore, the chance of finding 
OTC was highly increased at the level of both marking and detecting tumor cells. 
Second, our case-control design is more appropriate because the reported number 
of events i.e. disease recurrences in histologically node-negative patient groups 
is low.28;36;38 This makes it difficult from a statistical point of view, to determine 
the prognostic role of OTC. A case-control study overcomes this problem. Most 
studies shown in Table 7 are retrospective cohort studies with the majority of 
patients undergoing extended lymphadenectomy. Furthermore, the strength of 
our study was its original prospective randomised controlled design which ensured 
identical inclusion and follow-up of cases and controls and identical collection 
and handling of lymph nodes from cases and controls. In view of the fact that 
the prognosis of patients with resectable gastric cancer is mainly predicted by 
the tumor involvement of lymph nodes and the depth of primary tumor invasion 
into the gastric wall, cases and controls were matched for T stage in the present 
study. The fourth advantage of our study is the inclusion of almost an equal 
number of patients with a D1 and D2 dissection type in both the case and control 
group. We did find the difference between the case and control group in number 
of examined lymph nodes and percentage of OTC-positive lymph nodes to be in 
the D1 dissection group and not in the D2 dissection group. Thus, patients with 
less than 5 lymph nodes examined or 20% or more OTC-positive lymph nodes 
did not have a worse prognosis if they had undergone a D2 dissection. Klein 
Kranenbarg et al.16 previously showed that more lymph nodes were examined 
in the D2 dissection group suggesting a better survival in this group. On the 
contrary, the DGCGT10;11 and other studies39;40 reported no difference in survival 
between patients who underwent a D2 dissection and patients who underwent a 
D1 dissection, although the DGCGT did show a survival benefit of patients with 
N2 disease19 who underwent a D2 dissection.11 The 10-year disease recurrence 
rate was 97% for N2 patients who underwent a D1 dissection compared with 69% 
of the patients who underwent a D2 dissection (P = 0.013 by the logrank test) 
suggesting that patients with more than a certain number of positive lymph nodes 
might benefit from D2 dissection. Our results are in contrast with Petrelli’s41 plea in 
his editorial to end the debate whether to perform a D1 or D2 dissection. Indeed, 
the DGCGT showed an increased postoperative morbidity and mortality in patients 
who underwent a D2 dissection (25% vs 43%; P < 0.001 and 4% vs 10%; P = 
0.004, respectively)10 and patients showed no significant survival benefit after a 
follow-up of more than 10 years (30% vs 35%; P = 0.53).11 However, morbidity 
and mortality were mostly caused by performing pancreatectomy and splenectomy. 
Recent studies show that D2 surgery with organ preservation, performed in 
specialized centers, is a safe procedure with limited morbidity and mortality.42-45 
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INTRODUCTION
High-risk node-negative colorectal cancer (CRC) patients may be identifiable 
through the detection of occult tumor cells (OTC) in lymph nodes. OTC comprise 
micrometastases (MM) and isolated tumor cells (ITC). MM are defined as deposits 
of tumor cells of 2 mm or less but larger than 0.2 mm and ITC either as single 
tumor cells or as clusters of tumor cells of 0.2 mm or less.1-3 OTC are usually 
not detected with conventional pathological examination, as only one or two 4 
to 5 µm sections of each lymph node are being examined after staining with the 
hematoxylin and eosin (HE) method. It is calculated that a single 4 µm section 
through the center of a lymph node measuring 1 cm in diameter merely samples 
approximately 0.06 percent of the lymph node4 which is presumed to reflect the 
entire lymph node. Examination techniques focused on detection of OTC include 
serial sectioning, step sectioning, immunohistochemistry (IHC), polymerase chain 
reaction (PCR) and reverse transcriptase polymerase chain reaction (RT-PCR). 
There is a higher chance of detecting OTC with these techniques as a larger part 
of the lymph node is being examined and because of their higher sensitivity for 
detecting tumor cells. 
ABSTRACT
Background: Presently, in Europe the treatment of node-negative colorectal 
cancer (CRC) patients consists of surgical resection of the primary tumor 
without adjuvant systemic therapy. However, up to 30% of these patients will 
develop disease recurrence. These high-risk patients are possibly identified by 
occult tumor cell (OTC) assessment in lymph nodes. In this paper, studies on the 
clinical relevance of OTC in lymph nodes are reviewed.
Methods: A literature search was conducted in the National Library of Medicine 
by using the keywords colonic, rectal, colorectal, neoplasm, adenocarcinoma, 
cancer, lymph node, polymerase chain reaction, mRNA, immunohistochemistry, 
micrometastases and isolated tumor cells. Additional articles were identified by 
cross-referencing from papers retrieved in the initial search. 
Results: The upstaging percentages through OTC assessment and the 
prognostic relevance of OTC in lymph nodes vary among studies, which is 
related to differences in techniques used to detect OTC. 
Conclusions: We conclude that OTC examination techniques should be 
standardized to illuminate whether OTC in lymph nodes can reliably identify 
high-risk node-negative patients.
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The role of OTC detection in CRC is not clear yet although numerous studies on 
this topic have previously been published. This review deals with the detection 
methods and clinical relevance of OTC in lymph nodes in CRC. Emphasis is put on 
differences in examination techniques to detect OTC.
METHODS
A literature search was conducted with PubMed software in the National Library 
of Medicine, containing articles from 1953 until 2004. The following key words 
were used in appropriate combinations: colonic or rectal or colorectal neoplasm, 
adenocarcinoma and cancer, lymph node, polymerase chain reaction, mRNA, 
immunohistochemistry, micrometastases and isolated tumor cells. Papers with 
anal cancer in the title were excluded and the language was restricted to English. 
All hits from this PubMed search were individually checked, and included only if 
they addressed the subject of this review. Additional articles were identified by 
cross-referencing from papers retrieved in the initial search. Overall, only articles 
that included the prognostic relevance of OTC in lymph nodes were included for 
this overview. There was no limit to the number of patients. 
Occult tumor cells in lymph nodes detected with polymerase chain 
reaction
The PCR assay can be used to detect OTC in lymph nodes by amplification of certain 
DNA regions that may contain tumor-specific mutations for instance regions in the 
tumor suppressor genes p53 and K-ras. The K-ras gene can contain mutations at 
codon 12, 13 or 61 and in the p53 gene mutations cluster in exons 5 to 8. 
There are four published studies in which HE-negative lymph nodes were examined 
with the PCR method and the effect of a positive PCR on the prognosis of the 
patients was analyzed.5-8 Hayashi et al.5 screened HE-negative lymph nodes for 
the presence of mutations in the K-ras or p53 genes. Twenty-seven out of 37 
patients with PCR positive lymph nodes suffered from tumor recurrence within 
5 years, whereas none of the 34 patients with OTC-negative lymph nodes had a 
recurrence. Thebo et al.6 used K-ras mutations at codon 12 and 13 to detect OTC. 
No recurrences were reported in the OTC-negative group (n = 4) compared to a 
recurrence rate of 38% in the OTC-positive group (n = 16). Clarke et al.7 examined 
lymph nodes by using K-ras mutations at codon 12. No difference was shown in 
survival between patients with a positive PCR and patients with a negative PCR. 
Four out of 13 OTC-positive patients died of recurrence within 5 years and one out 
of four OTC-negative patients also died of recurrence. Belly et al.8 also used K-ras 
mutations at codon 12 to detect OTC. Of 14 OTC-positive patients, eight died of 
disease within 5 years compared to four out of 24 OTC-negative patients.
A disadvantage of the PCR method is the fact that the p53 and K-ras mutations 
do not occur consistently in CRC. Mutations of the p53 gene and the K-ras gene 
are present in approximately 70%9 and 38%10 in CRC, respectively. Only when 
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the primary tumors harbor mutations, these mutations can be utilized to detect 
OTC in HE-negative lymph nodes. Hayashi et al.5 could not detect mutations in the 
p53 or K-ras gene in 41% of 120 primary tumors leading to the exclusion of many 
patients for OTC detection. An additional problem is the large number of codons or 
even exons in which mutations can be detected, especially in the p53 gene. This 
implies that for detection of all the possible mutations many different PCR primers 
are needed which is not feasible in clinical practice and rather expensive. 
Concluding, three out of four studies showed clinical relevance of OTC detected 
with the PCR method. However, technical factors will prevent the PCR from 
becoming a ubiquitously utilized application for OTC detection. 
Occult tumor cells in lymph nodes detected with reverse transcriptase 
polymerase chain reaction
RT-PCR within the context of OTC assessment in CRC involves amplification of 
specific messenger RNA present in epithelial cells or malignant cells. A study by 
Liefers et al.11 showed that patients with CEA RT-PCR negative lymph nodes had a 
significantly better 5-year disease-free survival than patients with positive lymph 
nodes (91 vs 50%, P = 0.02). Five other RT-PCR studies12-16 also showed that a 
positive RT-PCR result had a negative impact on survival. Three of these 6 studies 
used CEA11;12;15, 2 used CK2014;16 and 1 used GCC13 as a marker. One of these 
studies also used CEA as a marker and showed no difference between patients 
with a positive RT-PCR result and patients with a negative result.13 However, with 
this marker they showed an upstaging percentage of 5 whereas the other three 
CEA studies showed an upstaging range of 30% to 54%. This suggest a limited 
sensitivity of this specific protocol what may explain the lack of influence on 
clinical outcome. The low upstaging percentage of 5% could be due to the use of 
paraffin-embedded lymph nodes.
During the past years a one-tube one-enzyme quantitative real-time RT-PCR has 
been developed by several companies. This method involves a closed system and 
makes use of fluorescence to quantify the PCR product. Real-time RT-PCR is highly 
sensitive, has a lower risk of contamination and is far less laborious compared 
to the conventional RT-PCR. Lassmann et al.17 showed no prognostic value of a 
positive real-time RT-PCR test with the marker CK20. A recent study by Bustin 
et al.18 neither found any correlation between patient’s prognosis and a positive 
real-time RT-PCR test when using the markers CK20, CEA and GCC at 40 PCR 
cycles. The higher sensitivity of the real-time RT-PCR is shown in the upstaging 
percentages with the markers CEA and CK20 of 98% and 75%, respectively. 
The reason why Lassmann et al.17 found a lower upstaging percentage of 35% 
with their real-time CK20 RT-PCR might relate to the use of paraffin material. 
Furthermore, the lower GCC upstaging percentage of 22% in the study by Bustin 
et al.18 compared to the GCC upstaging percentage of 48% in the study by Cagir 
et al.13 could be the result of a higher number of PCR cycles in the latter study i.e. 
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40 cycles versus 70 cycles. A disadvantage of the higher sensitivity of the real-
time RT-PCR is the detection of background gene expression in hematopoietic cells 
or circulating normal epithelial cells, and thus false-positive patients, that might 
explain the higher percentage of upstaging when compared to the earlier studies. 
The rate of false-positive patients can be limited by optimizing the number of PCR 
cycles. Miyake et al.19 reported that under 35 cycles of PCR, lymph nodes from 
patients with benign diseases did not express CEA and CK20, but, when using 40 
cycles, bands for CEA appeared in 7% of normal lymph nodes and bands for CK20 
appeared in 20% of normal lymph nodes. These results indicate that there is only 
a narrow window in which reliable results can be obtained. Similar results were 
reported earlier by Liefers et al.11 who examined HE-negative lymph nodes by 
using a nested RT-PCR. A very faint band was detected in some negative control 
samples when 20 or 25 cycles were used in the second PCR round. Therefore, it 
was decided that 15 cycles should be used in the second PCR round leading to a 
total of 35 cycles in their nested RT-PCR method. 
A pitfall associated with the PCR and RT-PCR method is contamination of lymph 
nodes by cells from the primary tumor or bowel epithelium leading to false-positive 
results. Rosenberg et al.14 examined HE-negative lymph nodes with both RT-PCR 
and IHC. In 13 of 44 RT-PCR positive patients, the positivity was caused by tumor 
cell contamination located exclusively outside the lymph node capsule. Defining 
these 13 patients as RT-PCR negative improved the specificity of the RT-PCR assay 
from 57% to 75%. The overall 5-year survival rates of the IHC-controlled RT-PCR 
positive group were significantly worse than the negative group (P < 0.001), and 
the differences were greater than with RT-PCR alone (P < 0.009). Contamination 
of lymph nodes by cells from the primary tumor or bowel epithelium can be 
limited by removing the lymph nodes before incision of the bowel specimen during 
examination by the pathologist.
From these data it can be concluded that OTC in lymph nodes detected with 
RT-PCR show prognostic value provided that fresh or frozen lymph nodes, the 
markers CEA, CK20 and GCC and the optimal number of PCR cycles are used. 
Occult tumor cells in lymph nodes detected with immunohistochemistry
Although RT-PCR is potentially more sensitive than IHC, the latter method is 
commonly available in daily practice and has the advantage of morphological 
confirmation of detected tumor cells. Conversely, the specificity of IHC seems to 
be lower.15;20 Noura et al.15 studied paraffin-embedded lymph nodes with both CEA 
RT-PCR and IHC by using the anti-pancytokeratin antibody AE1/AE3 and showed 
that the former method had prognostic value, whereas the latter did not. 
Nine21-28 out of 28 studies15;17;21-41 showed a significantly worse clinical outcome in 
patients with lymph nodes containing OTC: five22;23;25-27 out of eight studies using 
CAM5.2 (63%)22;23;25-27;29-31, one21 out of seven using AE1/AE3 (14%)15;21;32-36, one28 
out of two using CEA (50%)28;37, one28 out of two using CK20 (50%)17;28, one24 out 
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of two using MNF116 (50%)24;38, zero out of two using BerEP4 studies28;35, zero 
out of one using CC4921, zero out of one using anti-CK39, zero out of one using 
KL-140, and zero out of one using RSP53 antibodies.40 One study, using a mixture 
of antibodies among which AE1/AE3 and CAM5.2, reported no worse prognosis 
of patients with OTC in lymph nodes.41 Three17;28;30 out of the 28 studies showed 
a trend towards a worse clinical outcome: one30 out of eight studies using the 
antibody CAM5.2 (13%), one17 out of two using CK20 (50%), and one28 of two 
using BerEP4 (50%) antibodies. The other 15 studies showed no prognostic effect 
of OTC-positive lymph nodes. Eight21-28 of 22 studies15;17;21-36;38-41 (36%) using 
antibodies directed against cytokeratin showed a worse prognosis of patients 
with OTC in lymph nodes compared to one28 of six studies21;28;35;37;40 (17%) using 
antibodies directed against other antigens.
In conclusion, only nine out of 28 IHC studies showed a significantly worse clinical 
outcome in patients with lymph nodes containing OTC. In particular studies 
using the antibody CAM5.2, reported OTC-positive lymph nodes to be of clinical 
relevance.
Factors influencing detection of occult tumor cells with 
immunohistochemistry
Xu et al.42 reported undesirable cytokeratin positivity in nonepithelial cells in lymph 
nodes from breast cancer patients. Cytokeratin positivity was found in reticulum 
cells and plasma cells with pan-CK and CAM5.2 but not with AE1/AE3a. Seemingly, 
antibodies raised primarily against CK8 (CAM5.2 and pan-CK) can detect 
background CK8 expression in nonepithelial cells, which cannot be revealed by AE1/
AE3, though it recognizes a broad spectrum of different cytokeratins. Adversely, 
use of a broad spectrum antibody such as AE1/AE3, might not be as sensitive as 
other subset-specific antibodies like CAM5.2 in identifying certain undifferentiated 
carcinomas. This might explain the higher percentage of CAM5.2 studies 
showing clinical relevance compared to AE1/AE3 studies as mentioned above. 
Morphological evaluation is key in distinguishing tumor cells from nonepithelial 
cells. Others methods that can be used to distinguish tumor cells from plasma 
cells, dendritic cells, mesothelial cells and macrophages, include double staining 
with anti-immunoglobulin kappa or lambda light chains, anti-S100, anti-calretinin, 
and anti-CD68 antibodies respectively. Studies comparing antibodies should lead 
to the antibody with the highest sensitivity and specificity in recognizing tumor 
cells in lymph nodes.
Three27;28 out of eight studies27;28;32;35;41 examining more than one level per 
lymph node showed prognostic significance of OTC compared to six21-26 out of 20 
studies15;17;21-26;29-31;33;34;36-40 examining one level. Two22;25 out of six studies15;22;25;39;40 
examining more than one section per level showed prognostic significance of OTC 
a There are 20 different types of cytokeratins; CAM5.2 recognizes CK7 (weak) and 8; AE1/AE3 is a 
mixture of two different clones of monoclonal antibodies; AE1 recognizes CK10, 13, 14, 15, 16, and 19; 
AE3 recognizes CK1, 2, 3, 4, 5, 6, 7 and 8; MNF116 recognizes CK5, 6, 8, 17 and probably 19; anti-CK 
recognizes CK 8, 18 and 19; KL-1 recognizes CK1, 2, 5, 6, 7, 8, 11, 14, 16, 17 and 18.
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compared to seven21;23;24;26-28 out of 22 studies17;21;23;24;26-38;41 examining one section 
per level. Adell et al.39 reported that 95% of CRC patients with OTC were identified 
by examining three levels from three lymph nodes with AE1/AE3. McGuckin et 
al.43 examined lymph nodes from breast cancer patients and showed that the 
majority of lymph node metastases can be detected by examining two levels 300 
µm apart. Fisher et al.33 studied the largest CRC patient group thus far and found 
OTC in lymph nodes in 18.3% of 399 patients but could not confirm any prognostic 
significance of OTC in lymph nodes. This may be related to the examination of 
only one level of each lymph node in combination with the use of the antibody 
AE1/AE3. 
In all of the abovementioned papers, OTC were detected through screening by 
a pathologist using routine light microscopy. This bares the risk of inaccurate 
screening due to factors such as OTC size, interobserver differences and incomplete 
section screening. Automated microscopy may facilitate and render IHC more 
reliable because the aforementioned factors are eliminated.44;45 
As yet, an optimum number of two levels has been reported. It can be suggested 
that in order to assess whether OTC in lymph nodes predicts patient’s prognosis, at 
least two levels of the lymph nodes should be examined using an anti-cytokeratin 
antibody.
Number and size of lymph nodes
In the studies by Sasaki et al.22 and Yasuda et al.25, not only the presence but also 
the number of OTC-positive lymph nodes was considered in relation to decreased 
survival. The former study showed a significantly higher frequency of OTC-positive 
nodes in patients with recurrent disease. The latter study reported OTC in four 
or more lymph nodes to be significantly associated with recurrent disease. Both 
studies showed a significantly higher frequency of OTC in second tier lymph nodes 
of patients with poor prognosis. 
Overall survival of CRC patients without HE detectable nodal metastases, improves 
with increasing number of lymph nodes recovered.46;47 Cserni et al.47 studied data 
from 8574 stage II CRC patients. They could not define a cut-off value for the 
number of lymph nodes needed to be examined for adequate nodal staging. 
According to their statistical analysis the risk of death decreased by 2.1% for 
each negative lymph node. Ruers et al.48 reported the number of nodes that had 
to be examined for reliable staging to be T stage dependent. Fifteen nodes for 
T2 tumors, 10 nodes for T3 tumors and seven nodes for T4 tumors needed to 
be examined. Current guidelines from the American Joint Committee on Cancer 
Staging (AJCC) recommend examination of a minimum of 12 lymph nodes for 
accurate staging.49 However, this is not always feasible. By studying 569 CRC 
specimens, Johnson et al.50 reported that only 22% of the patients underwent an 
adequate lymph node harvest according to the current AJCC recommendation. 
Sometimes only few or no lymph nodes are found, even when surgeons resect a 
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large part of the perimuscular fatty tissue. Involved factors might be preoperative 
radiotherapy in rectal carcinoma, leading to decrease in lymph node size51, or 
the presence of few or very small lymph nodes.52 The former factor was shown 
in the Total Mesorectal Excision trial where the mean number of examined lymph 
nodes was 9.7 in the surgery only group and 7.7 in the radiotherapy group (P < 
0.001).51 Maurel et al.52 reported a significantly higher number of examined lymph 
nodes in patients younger than 75. Fat clearance techniques might facilitate in 
finding small lymph nodes. Haboubi et al.53 showed that by adding fat clearance to 
conventional lymph node harvesting, the mean number of recovered lymph nodes 
increased from 6.7 to 58.2 lymph nodes. However, these relatively inexpensive 
techniques involve the use of xylene and alcohol and, therefore, are considered 
impractical and unsafe. This is the major reason that fat clearance techniques are 
not being used worldwide. It should be noted that even very small lymph nodes 
can contain metastases. Andreola et al.41 reported that 45% of metastatic lymph 
nodes of 49 stage III patients had a diameter smaller than 5 mm, determining 
the stage in 15 (31%) of the patients. Haboubi et al.30 showed that 86% of lymph 
nodes with OTC had a diameter smaller than 5 mm. Ruers et al.48 suggested that 
a standard of how much cm2 of mesocolon should be removed by the surgeon 
and how many lymph nodes should be retrieved by the pathologist per cm2 will 
contribute to quality control in colon cancer.
Summarizing, the number of OTC-positive lymph nodes should also be considered 
in relation to decreased survival. Moreover, the problem of defining an optimal 
number of lymph nodes and finding small lymph nodes might be tackled by 
standardization of how much cm2 of mesocolon should be removed by the surgeon. 
Size and location of occult tumor cells in lymph nodes
Using the actual size of OTC instead of dividing them into categories such as ITC and 
MM might answer the question whether the size of metastases matters.33 As yet it 
is not clear whether MM and ITC have the same influence on the patient’s clinical 
outcome. It is possible that in immunocompetent individuals, OTC are destroyed 
by the immune system before growing into large metastases or that not all OTC 
are viable and therefore do not have the capacity to proliferate. Determining the 
viability of OTC could shed some light on the metastasis potential of these tumor 
cells e.g. by determining the number of apoptotic cells versus vital cells. 
Furthermore, it may be important to consider the intra-nodal location of OTC in 
the analysis. Tumor cells in lymph nodes can be located in subcapsular sinuses, 
also referred to as peripheral sinuses, paracortical sinuses or medullar structures. 
They can also be located intrafollicularly or show a diffuse distribution. It has been 
shown that tumor cells are usually present in the subcapsular sinuses29;32;37;54;55 
but the impact of the location of OTC on patient’s prognosis has not been clearly 
addressed yet. In summary, when considering OTC in lymph nodes in CRC, it might 
be necessary to include the size and intra-nodal location of OTC in the analysis. 
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INTRODUCTION
The presence of lymph node metastasis is one of the most important prognostic 
factors and therapeutic selectors for many types of cancer. Despite the prognostic 
value of lymph node status as assessed by conventional histopathology, a significant 
percentage of patients with node-negative colorectal carcinoma (diagnosed 
as lymph node negative by conventional examination) develop recurrence of 
disease.1-3 Reasons for such exceptions are the biology of the tumor but also the 
limited sensitivity of conventional histopathology to detect rarely occurring occult 
cells in lymph nodes. For practical reasons only a few hematoxylin and eosin (HE) 
stained sections are examined, which limits the sensitivity of the technique to 
detect occult tumor cells. 
ABSTRACT
Background: At present, reverse transcription polymerase chain reaction 
(RT-PCR) against carcinoembryonic antigen mRNA is one of the few research 
tools for the detection of occult cells in histopathologically assessed negative 
lymph nodes from patients with colorectal cancer. The aim of this study was 
to investigate the suitability of supervised low-resolution image analysis of 
immunohistochemically stained sections as alternative. 
Patients and methods: Multiple sections (n = 50) of regional lymph nodes 
from patients with colorectal cancer were immunohistochemically stained 
and analyzed by applying low-resolution image analysis (flatbed scanning) 
for semiautomated detection of cytokeratin (CK)-positive stained cells. The 
sensitivity of this approach was demonstrated for 20 patients with stage II 
colorectal cancer and compared with RT-PCR regarding the detection of clinically 
assessed recurrence of disease within 10 years.
Results: CK+ cells were detected in all of the patients (n = 6; 100%) with 
recurrence, compared with five patients (83%) found positive by carcinoembryonic 
antigen RT-PCR. From patients (n = 14) who did not develop a recurrence, eight 
(57%) had positive lymph nodes. In all patients with recurrence, we visually 
identified at least one group of CK+ cells (>2 cells). 
Conclusions: Automated image analysis is a promising tool for the detection 
of occult cells in histopathologically negative nodes. It is potentially more 
sensitive but less specific for detecting recurrence of disease than conventional 
histopathology or RT-PCR and is particularly useful for the evaluation of sentinel 
nodes. Furthermore, it opens new ways for basic research of occult cells based 
on molecular profiling after laser-microdissection.
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Recently, alternative approaches to detect occult cells in lymph nodes have been 
described. Liefers et al.1 examined lymph nodes from a group of 26 patients 
with stage II colorectal cancer, originally reported as negative by histopathology, 
using RT-PCR against carcinoembryonic antigen (CEA) messenger RNA. In their 
retrospective study, 14 of 26 patients were reported as positive for CEA. The 
5-year recurrence-free survival for the CEA positive patients was 50% and for CEA 
negative patients, 91%. Others found similar results.2;3
A different approach to increase sensitivity is by immunohistochemistry (IHC). 
This method relies on the analysis of IHC stained sections of lymph nodes for the 
detection of immunostained cells. It has been reported for patients with breast 
carcinoma that the application of IHC in combination with the analysis of multiple 
sections results in the detection of up to 35% more positive nodes as compared 
to conventional histopathology.4-12 The clinical value however of this observation 
needs to be confirmed.
The sensitivity of the detection of occult cells has been shown to increase with 
the number of sections per lymph node examined up till a certain number of 
sections,13 but the practical applicability of multiple sectioning is limited by the 
labor intensive nature of preparing a large amount of IHC stained sections. For the 
analysis of sentinel nodes, however, multiple sectioning is highly recommended 
by the Association of Directors of Anatomic and Surgical Pathology (ADASP) and 
considered practically feasible.7
In this article, we describe an approach in which IHC staining and multiple sectioning 
is combined and subjected to novel high-throughput automated imaging. This 
imaging system uses a high performance flatbed scanner (FBSc), which is able 
to digitize, in one A3 format, hundreds of cytological or histological specimens. 
Digitally acquired images of the IHC stained tissue are then automatically analyzed 
for the presence of positive-stained occult cells. Storage of cell coordinates allows 
for direct morphological evaluation using conventional microscopy.
In this study, we have compared visual examination of cytokeratin-immunostained 
serial sections (as gold standard) with automated analysis and with the RT-PCR 
data from the referred Liefers article1 with the emphasis on the sensitivity of the 
method to detect patients with recurrence of disease within a period of 10 years 
after a diagnosis of colorectal cancer tumor-node-metastasis (TNM) stage II.
PATIENTS AND METHODS
Patients
From 20 patients with TNM stage II colorectal cancer, lymph nodes were obtained 
consecutively from curative resections performed at the Department of Surgery of 
the Leiden University Medical Center (LUMC) between January 1990 and February 
1992. From this material, originally studied using RT-PCR by Liefers et al.1, 119 
of 246 lymph nodes were still available. Twenty-one blocks showed poor material 
not suited for analysis (fat tissue, degenerated material, no histological material 
remaining). 
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Preoperative and perioperative examinations of the patients showed no evidence of 
metastatic disease. Follow-up was carried out in accordance with the department’s 
protocol (Department of Surgery, LUMC) and was based on periodic evaluations of 
the patient.1 The follow-up of the patients was at least 10 years and was updated 
by checking the patient files as of 1 February, 2002. 
Sectioning and immunohistochemical staining
In the original study, one-half of the node was fixed in formalin and was embedded 
in paraffin for routine histopathological examination.1 The other half of the resected 
node was used for RNA isolation for the analysis of CEA-specific mRNA using RT-
PCR. For the present study, all of the available lymph nodes were analyzed for 
those patients who were originally PCR-positive for CEA. From the PCR-negative 
group for each patient, six lymph nodes were chosen randomly to match the 
average number of nodes in the positive group. From this material, serial sections 
(10 sections of 5 µm in series at each level) were cut with intervals of 200 µm until 
no material was left in the paraffin block. Sections were stained for cytokeratin 
(CK) using the antibody AE1/AE3.14 The sections were hydrated and subjected 
to sodium citrate (0.01 M, pH 6.0 at 100oC) for 10 min before incubation with 
the mixture of primary biotinylated monoclonal anti-cytokeratin antibodies AE1/
AE3 (Dako, Glostrup, Denmark). Immunostaining was based on the avidin-biotin-
peroxidase technique using 3,3’-diaminobenzidine (DAB) as the endpoint product; 
all of the sections were counterstained with hematoxylin. 
Method of analysis of the slides
All of the IHC slides were first manually examined in a very thorough way. The 
results served as the gold standard for the automated analysis. A node was called 
positive when at least one IHC positive cell was found (excluding white blood cells, 
macrophages e.g. known for nonspecific staining) confirmed by a second person 
(a pathologist). Subsequently sections were recorded using the flatbed scanner. 
Automated analysis was performed on all of the recorded nodes. The location of 
all manually detected CK+ cells was marked on printouts of the recorded images 
and compared with the automated analysis.
Automated analysis 
The system consists of a flatbed Agfa XY-15 scanner interfaced to a 933 MHz 
Power Mac G4 computer via a SCSI-2 interface. The optical resolution was 5000 
dpi in both directions corresponding to a pixel distance of 5 µm image acquisition.
A special mold has been constructed to scan a maximum of 45 microscopic slides 
automatically (Figure 1). Digitization was performed using the ColorExact software 
package from Agfa. In addition to the system software, we designed dedicated 
image analysis software to analyze the bed-scan for the presence of microscopic 
slides within the mold and the lymph node sections on each slide. 
The analysis of the lymph node sections was divided into the following steps: 
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the selection of a lymph node, the detection of candidate occult cells, and the 
measurement of cell features (area, shape, peak intensity, and averaged probe 
color). On the basis of these features, eventual falsely selected objects (i.e. other 
than CK+ cells) were recognized as such. The analysis of a lymph node section 
resulted in a gallery of images of the candidate occult CK+ cells found and an 
overview image of the lymph node with position markers where the events were 
found (Figure 2). On the basis of the gallery, the majority of falsely selected 
objects was easily recognized visually. When needed, the stored cell coordinates 
were used to relocate events by automated microscopy for visual interpretation 
at high spatial resolution (Figure 3). The total time necessary to automatically 
process a lymph node, which involved 80 slides with 5 sections per slide, was 
81 minutes, of which 1 minute was required to make a full bed-scan at lower 
resolution and to determine the coordinates of the image crops for the scanning 
of the individual sections. 
For the optimization of the selection algorithm of the automated analysis program, 
a positive node was analyzed. Parameters were set on the detection of groups 
and single CK+ cells. Recorded images were automatically analyzed, and the 
results were compared with those obtained by conventional microscopy. Using 
optimized selection criteria for automated analysis, we detected 34 (94%) of 36 
visually recognized cells by automated analysis. These algorithms were used for 
the present study.
Figure 1. A3 size mould to hold 15 x 3 = 45 slides on the AGFA XY15 scanner. Each slide 
may contain several tissue sections.
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Statistical analysis
We have reanalyzed the set of patients previously investigated by Liefers et al.1 
because of the availability of the material and the long-term follow-up (10 years). 
Obtained results using our method (IHC-automated analysis) were compared with 
the updated data of the RT-PCR study on the same set of patients. Carefully 
performed manual examination of the same slides served as the gold standard 
for this comparison. First, the automated analysis was compared with the manual 
evaluation. The data were described comparing patients with a recurrence of 
disease versus nonrecurrence, regarding IHC-automated analysis (Table 1) 
and RT-PCR (Table 2). Then, IHC was compared to RT-PCR by calculating the 
sensitivity and specificity (Table 3). Finally, we calculated the optimal distance 
for the sectioning of the paraffin material to detect all of the patients with a 
recurrence of disease (Figure 4).
RESULTS
IHC-automated analysis compared to conventional microscopy
A total of 119 lymph nodes (from 20 patients) were available; 33 were found 
positive and 65, negative, and 21 were not analyzed (see “Patients and Methods”). 
Per lymph node on average, 49 (range, 8-81) histological sections were analyzed. 
Comparing automated analysis with visual analysis using conventional microscopy 
revealed that, from a total of 33 visually evaluated positive nodes, two nodes were 
missed using automated analysis. Both nodes contained only one cell resulting in 
a sensitivity of 94% to detect a positive node. However, both patients had three 
more nodes in which occult cells were detected. Therefore, no positive patients 
were missed by automated analysis. One patient was missed with visual analysis 
but was found positive on visual verification of the candidate cells after automated 
analysis. This case illustrates the imperfectness of conventional screening 
compared with an automated performance of the image analysis procedure.
Table 4 presents the results of the lymph node analysis and the clinical outcome 
of the 20 patients.
IHC-automated analysis compared with RT-PCR
All of the patients (n = 6) who had developed a recurrence of disease were 
detected by IHC-automated analysis (Table 1). From 43 analyzed nodes in this 
patient group, 17 (40%) were found positive for CK-stained cells with on average 
eight cells per positive node. In all of these patients, groups of cells (number cells 
≥2) were visually recognized.
From all other patients (n = 14) who did not develop recurrence of disease, 8 
(57%) were found positive. In 16 (21%) of 77 nodes analyzed in this group, 
CK+ cells were found. Only five patients (36%) had cells located in groups. 
One patient (7 CK+ groups) died within 1 month after operation because 
of a gastric hemorrhage. One patient died from a cause other than disease, 
and three patients showed no evidence of disease 10 years after surgery. 
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In three patients, no groups of cells were detected. 
Using the RT-PCR method, we detected five (83%) patients with recurrence of 
disease. Forty-five nodes were analyzed in this group, of which 12 (27%) were 
found positive for CEA expression. Three patients (21%) with no recurrence of 
disease had positive lymph nodes (Table 2).
Sensitivity and specificity
Realizing that a relatively low number of patient samples has been investigated, 
we, nevertheless, calculated the sensitivity and specificity of both methods.
The sensitivity of IHC-automated analysis to detect CK+ nodes in patients with 
recurrence of disease was 100%; the specificity was 43%. The sensitivity and 
specificity of the RT-PCR method on the same set of patients studied by Liefers et 
al.1 are, respectively, 83% and 79% (Table 3).
Sampling distance of paraffin blocks
By reanalyzing the data, we calculated the effect of the distance of sectioning of 
the paraffin material with respect to successful detection of recurrence of disease. 
Figure 4 shows the effect of varying the distance between sections with respect to 
Table 1. Number of automatically detected cytokeratin-positive (CK+) cells and groups in 
lymph nodes of patients with and without recurrence of disease
Disease status Recurrence (n=6) Non-recurrence (n=14)
Positive patients 6 (100%) 8 (57%)
Positive lymph nodes 17/43 (40%) 16/77 (21%)
Patients with CK+ cells 6 (100%) 8 (57%)
No of CK+ cells 81 40
Patients with CK+ groupsa 6 (100%) 5 (36%)
No of CK+ groupsa 31 12
a “groups” is defined as ≥ 2 CK+ cells.
Table 2. Results of RT-PCR for CEA expression (same patients as shown in Table 4)a
Disease status Recurrence (n=6) Non-recurrence (n=14)
Positive patients 5 (83%) 3 (21%)
Positive lymph nodes 12/45 (27%) 5/109 (5%)
CEA, carcinoembryonic antigen;a Data from Liefers et al.1
Table 3. Calculation of the sensitivity and specificity of IHC-automated analysis and 
RT-PCR with respect to the detection of patients with recurrence of disease
Sensitivity Specificity
IHC-automated analysis




the detection of positive lymph nodes (“positive” was defined here as containing 
at least one CK+ cell). Additionally, the percentage of lymph nodes is shown 
in which at least one group of cells (≥ 2 CK+ cells) was found. The sensitivity 
of both the visual and automated detection decreases from 100% and 93% to, 
respectively, 98% and 85% when one-half of the number of sections is analyzed. 
Figure 2. A. Gallery with images of candidate occult cells detected in a lymph node 
section of a patient with colorectal carcinoma. Selection of candidate cells is based on 
immunoperoxidase (brown) staining for cytokeratin. Counterstaining is performed with 
hematoxylin (blue). B. Overview of the lymph node with markers displaying the location of 
the candidate cells.
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One CK+ lymph node containing one group (2 cells) was missed when only one in 
every two sections was analyzed. When the detection of at least one CK+ group of 
cells was used as the criterion, sensitivity decreased from 100% to 90% and from 
93% to 73% for automated and visual inspection, respectively.
Figure 3. A. Examples of images recorded by the flatbed scanner at 5600 dpi. Sections 
of lymph nodes from patients with colorectal carcinoma. Cells are positively stained for 
cytokeratin and counterstained using hematoxylin. B. Zoom function of recorded image; 
arrow marks single cytokeratin-positive cells (1b, 2b) or a small group of cytokeratin-
positive cells (3b). C. Conventional microscope image of the same cells. Recorded with color 
CCD camera using x16 objective.
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DISCUSSION
This study shows that visual examination of multiple IHC stained sections for the 
presence of occult tumor cells can be automated by low-resolution image analysis. 
As such, this method may serve as a useful alternative for RT-PCR, particularly when 
large numbers of sections are analyzed (at least 50 per node for this study). In all 
of the patients (n = 6) with recurrence of disease, IHC positive cells were detected 
using this method, demonstrating its feasibility for this application. Compared 
with the RT-PCR study previously performed by Liefers et al.1, automated analysis 
of IHC stained sections appeared to be more sensitive in detecting patients with 
recurrence of disease (100% vs 83%). We also found more positive nodes in this 
group (40% vs 27%). However, in 57% of the patients who did not develop a 
recurrence of disease, positive cells were also found, compared with 21% for the 
RT-PCR method. When the cut-off level was increased from one cell to two CK+ 
cells, the specificity increased from 43% to 57%. This makes automated analysis 
more sensitive but less specific than the referred RT-PCR method and, therefore, 
requires additional analysis of the detected positive cells. 
The number of analyzed patient samples, however, is considered too small to 
conclude that the differences are significant and meaningful. Discrepancies with 
the RT-PCR results may be attributable to unavoidable sampling errors. Yasuda et 
al.15 analyzed six serial sections using IHC and detected micrometastases in 92% 
of patients with recurrence but also found a high percentage of positive patients in 
the nonrecurrent group (70%). When more specific markers than pan-cytokeratin 
are available as published by Izbicki et al.16 for esophageal cancer (BerEp4), the 
high rate of false positive findings can possibly be reduced, thereby increasing the 
specificity of the current assay.
Figure 4. Percentage of detected lymph nodes as function of the distance between sequential 
sections for both visual and automated detection based either on cytokeratin-positive cells 
or on positive groups of cells only. A lymph node was classified as positive when at least one 
verified cytokeratin-positive cell (or a group: ≥ 2 cells) was detected.
which at least one group of cells (2 CK cells) was found.
The sensitivity of both the visual and automated detection
decreases from 100 and 93% to, respectively, 98 and 85%
when one-half of the number of sections is analyzed. One
CK lymph node containing one group (2 cells) was missed
when o ly one in every two sections was analyzed. When the
detection of at least one CK positive group of cells was used
as the criterion, sensitivity decreased from 100 to 90% and
from 93 to 73% for automated and visual inspection, respec-
tively.
DISCUSSION
This study shows that visual examination of multiple
immunohistochemically stained sections for the presence of
occult tumor cells can be automated by low-resolution image
analysis. As such, this method may serve as a useful alter-
native for RT-PCR, particularly when large numbers of sec-
tions are analyzed (at least 50 per node for this study). In all
of the patients (n  6) with recurrence of disease, immuno-
histochemically positive cells were detected using this
method, demonstrating its feasibility for this application.
Compared with the RT-PCR study previously performed by
Liefers et al. (1), automated analysis of immunohistochemi-
cally stained sections appeared to be more sensitive in de-
tecting patients with recurrence of disease (100 versus 83%).
We also found more positive nodes in this group (40 versus
27%). However, in 57% of the patients who did not develop
a recurrence of disease, positive cells were also found, com-
pared with 21% for the RT-PCR method. When the cutoff
level was increased from one cell to two CK cells, the
specificity increased from 43% to 57%. This makes auto-
mated analysis more sensitive but less specific than the
referred RT-PCR method and, therefore, requires additional
analysis of the detected positive cells.
The number of analyzed patient samples, however, is
considered too small to conclude that the differences are
significant and meaningful. Discrepancies with the RT-PCR
results may be attributable to unavoidable sampling error .
Yasuda et al. (15) analyzed six serial sections using IHC and
detected micrometastases in 92% of patients with recurrence
but l o found a high percentage of positive patients i the
nonrecurrent group (70%). When more specific markers than
pan-CK are available as published by Izbicki et al. (16) for
esophageal cancer (BerEp4), the high rate of false ositive
findings can possibly be reduced, thereby increasing the
specificity of the current assay.
It is estimated that routine H&E analysis has only a 1%
chance of identifying a focus of cancer cells less than three
cells in diameter (17). This level of sensitivity implies the
finding that about 25% of patients with colorectal cancers
who are node negative by routine H&E examination may
develop distant metastases (1– 4). The istopathological cri-
teria for occult metastases are far from clear. Most of the
studies identifying occult tumor cells have been performed in
breast cancer. For instance, Turner et al. (18) and Kell et al.
(19) report that, for patients with breast cancer with minimal
axillary involvement, the presence of efferent vascular inva-
sion or nodal hilar tissue invasion and the location of a
micrometastasis in sinusoidal rather than parenchymal tissue
may indicate a less favorable prognosis. Others have sug-
gested the inclusion of the size of the metastasis, groups
versus single cells, and the microanatomical location of oc-
cult cells as prognostic features (20). H wever, eval ation of
the potential value of these parameters has not been system-
atically pursued.
Fig. 4 Percentage of detected lymph nodes as function of the distance between sequential sections for both visual and automated detection based
either on CK cells or o positive groups of cells only. A lymph n de was classified as positive when at least o e verifi d CK cell (or a group, 2
cells) was detected.
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It is estimated that routine HE analysis only has a 1% chance of identifying a 
focus of cancer cells less than three cells in diameter.17 This level of sensitivity 
implies the finding that about 25% of patients with colorectal cancers who are 
node negative by routine HE examination may develop distant metastases.1-4 The 
histopathological criteria for occult metastases are far from clear. Most of the 
studies identifying occult tumor cells have been performed in breast cancer. For 
instance, Turner et al.18 and Kell et al.19 report that, for patients with breast cancer 
with minimal axillary involvement, the presence of efferent vascular invasion or 
nodal hilar tissue invasion and the location of a micrometastasis in sinusoidal 
rather than parenchymal tissue may indicate a less favorable prognosis. Others 
have suggested the inclusion of the size of the metastasis, groups versus single 
cells, and the microanatomical location of occult cells as prognostic features.20 
However, evaluation of the potential value of these parameters has not been 
systematically pursued. 
Table 4. Detection of micrometastasis and outcomes of patients with stage II colorectal 
cancer
Lymph nodes Outcome
Patient no Examined Positive Vital status Disease status
1 4 3 Dead Recurrencea
2 10 1 Dead Recurrence
3 2 1 Dead Recurrence
4 3 2 Dead Recurrence
5 17 4 Dead Recurrence
6 7 6 Dead Recurrence
7 3 0 Dead Otherb
8 6 0 Dead Other
9 5 0 Dead Other
10 4 2 Dead Other
11 6 3 Dead Other
12 6 0 Dead Other
13 5 0 Alive NEDc
14 10 4 Alive NED
15 6 0 Alive NED
16 4 1 Alive NED
17 10 2 Alive NED
18 4 2 Alive NED
19 6 1 Alive NED
20 1 0 Alive NED
a Recurrence death from local or distant recurrent disease; b Other death from a cause 
other than cancer; c NED, no evidence of disease.
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Although RT-PCR methods have been investigated to improve sensitivity, specific 
markers still do not exist for many tumors. RT-PCR is proven to be very sensitive 
and able to detect 1 in 10 million cells but is often prone to false positive 
classification because of contamination, and illegitimate low-level expression of 
marker transcripts in normal lymph nodes has also been reported.21 Furthermore, 
PCR has the restriction that detected events cannot be morphologically evaluated 
and confirmed. Microscope-based analysis has the advantage of enabling 
morphological analysis of the detected occult cells by the pathologist. The use of 
monoclonal antibodies to further characterize the detected cells (either by bright-
field or fluorescence microscopy) may be useful.22 It is evident that the number 
of positive nodes will increase on analysis of more sections, and may strongly 
increase.23 Automated analysis as described here may be further improved by 
connection of the scanner to an off-line automated microscope for rapid relocation 
of the detected events and by fine tuning of the cell classification algorithm with 
respect to the accuracy. The analysis is rather time consuming, and speed can be 
increased but is, when focusing on sentinel nodes, not a prerequisite. For use in a 
clinical setting, the sectioning and staining of all resected lymph nodes is too labor 
intensive. However, for the analysis of sentinel nodes, which most of the time 
involves only one to three lymph nodes, serial sectioning is highly recommended 
by the ADASP and is practically feasible.7
The clinical significance of immunohistochemically detected tumor cells present 
in excised lymph nodes in case of colorectal cancer remains unclear. In a recent 
multi-institutional study of 736 patients with breast cancer, the presence of 
immunohistochemically detected occult cells in axillary lymph node metastases 
was found to be significant and, in case of postmenopausal women, was an 
independent predictor of overall survival. For colorectal cancer, this reaffirms the 
need for larger studies with longer follow-up.4
The relatively large data set (4569 sections of 119 nodes of 20 patients) of the 
presented study allowed to examine the effects of the sectioning density on the 
detection of CK+ cells in a particular lymph node. It appeared that the number 
of CK+ cells decreased inversely proportional to the sampling distance (data not 
shown). This relation suggests that the CK+ cells are more or less randomly 
distributed throughout the node. Because the presence of CK+ cells was rather 
low in a number of CK+ lymph nodes, a large proportion of the lymph node has to 
be analyzed to classify the node as positive. As can be seen in Figure 4, one CK+ 
lymph node containing only two CK+ cells (group) was missed (even visually), 
when only one in every two sections was analyzed. When the detection efficiency 
of lymph nodes with at least one CK+ group is considered, one would expect 
that detection of groups, being larger than single cells, would be less dependent 
on the sectioning distance. Figure 4 shows the opposite, however. This can be 
explained by the low frequency of groups present in most of the lymph nodes 
when compared with the number of single CK+ cells and by the fact that most of 
those groups consisted of only 2 to 3 cells.
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To better understand the biology of metastasis, research is needed to further 
characterize the detected cells, which may ultimately lead to an increase in 
specificity and diagnostic accuracy. Such information can be obtained by physical 
isolation of these cells by laser microdissection followed by single-cell RT-PCR and 
analysis of gene composition.24 
Such research has recently been published by Klein et al.25, who found a different 
genetic make-up for single cells versus groups of cells. The clinical importance of 
these findings, however, is not yet known.
This information can be used to produce specific markers for diagnostic assays 
that may ultimately allow the identification of biologically important populations 
of cells that can be directly linked to clinical outcome. 
The present study was performed on a well-documented selection of colorectal 
cancer patients and served as a model. It is obvious that a similar approach is also 
indicated for breast cancer or for melanomas in which lymph node involvement and, 
particularly, the role of the sentinel node is an important focus of research.8;9;26-31
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INTRODUCTION
The presence of lymph node metastases is one of the most important prognostic 
factors in colorectal cancer (CRC) for which adjuvant systemic chemotherapy is 
generally recommended.1-4 Patients with curatively resected stage I and II CRC 
without nodal tumor involvement do not receive adjuvant systemic therapy 
since only small improvements in survival have been shown.4-6 However, ten to 
30 percent of these node-negative patients will develop locoregional recurrence 
or distant metastases.1;7;8 Adjuvant systemic treatment of all node-negative 
CRC patients is not recommended by the ASCO (American Society of Clinical 
Oncology) as it would lead to overtreatment and unnecessary complications.9 
ABSTRACT
Background: Up to 30 percent of stage II patients with curatively resected 
colorectal cancer (CRC) will develop disease recurrence. We evaluated whether 
examination of lymph nodes by multilevel sectioning and immunohistochemical 
staining can improve prognostication. 
Patients and methods: Lymph nodes (n = 780) from 36 CRC patients who had 
developed disease recurrence (cases) and 72 patients who showed no recurrence 
of disease for at least 5 years (controls) were analyzed. Sections of four levels at 
200 µm interval were immunohistochemically stained for cytokeratin expression. 
The first level was analyzed by conventional and automated microscopy and the 
three following levels were analyzed by automated microscopy for the presence 
of tumor cells. 
Results: Overall, cases showed more micrometastases (three patients) 
than controls (one patient). Analysis of a second level led to the additional 
detection of one patient with micrometastases (case) and one patient with 
macrometastasis (case). Examining more levels only led to additional isolated 
tumor cells which were equally divided between cases and controls. Likewise, 
automated microscopy resulted only in detection of additional isolated tumor 
cells when compared to conventional microscopy. In multivariate analysis, 
micrometastases (OR 26.3, 95% CI 1.9-364.8, P = 0.015), T4 stage (OR 4.8, 
95% CI 1.4-16.7, P = 0.013) and number of lymph nodes (OR 0.9, 95% CI 0.8-
1.0, P = 0.028) were independent predictors for disease recurrence. 
Conclusions: Lymph node analysis of two levels and immunohistochemical 
staining add to the detection of macrometastases and micrometastases in 
CRC. Micrometastases were found to be an independent predictor of disease 
recurrence. Isolated tumor cells were of no prognostic significance.
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Identification of node-negative CRC patients with a high risk of disease recurrence 
may lead to a more appropriate selection for adjuvant treatment. 
Conventional histopathology has a limited sensitivity to detect occult tumor cells in 
lymph nodes, described as micrometastases (> 0.2 mm and < 2 mm) and isolated 
tumor cells (< 0.2 mm or single tumor cells).10-12 Alternative approaches to detect 
occult tumor cells in lymph nodes have been reported such as: polymerase chain 
reaction13, reverse transcriptase polymerase chain reaction (RT-PCR)14, multilevel 
sectioning15, immunohistochemical staining16 and automated microscopy.17 
In a study published by Liefers et al.14 was shown that stage II patients with 
carcinoembryonic (CEA) RT-PCR negative lymph nodes have a significantly better 
five-year disease-related survival than patients with CEA RT-PCR positive lymph 
nodes (91 vs 50%, P = 0.02). These results were confirmed by several other 
groups.18-22 The detection of immunohistochemically stained tumor cells has the 
advantage of visual examination of the detected cells using microscopy. Multilevel 
sectioning and immunohistochemistry have been shown to increase the detection 
rate of lymph node metastases in CRC patients.13 Since screening of multiple 
immunohistochemically stained sections is time consuming and difficult to 
reproduce, automated microscopy has been implemented.23;24
In this case-control study, we evaluated whether detailed examination of 
lymph nodes for the presence of occult tumor cells by multilevel sectioning and 
immunohistochemical staining can improve prognostication in CRC.
PATIENTS AND METHODS
Patient selection
Between January 1981 and December 2001, 1044 patients underwent surgery for 
a primary CRC at the Leiden University Medical Center. For the present study, a 
selection was made for patients with negative lymph nodes (N0) and no metastases 
(M0) at the time of surgery (n = 506). Patients who were operated on their first 
CRC in another hospital, or who were diagnosed with another invasive malignancy 
before or within five years after the date of diagnosis of the primary colorectal 
carcinoma, and patients who developed a local recurrence were excluded for the 
present study. The latter group was excluded to rule out the factor of inadequate 
surgery. Cases (n = 40) were defined as patients who had regional or distant 
recurrent disease at least three months after but within five years after the date of 
diagnosis of primary CRC. Regional metastases were considered intra-abdominal 
or intrapelvic metastases in lymph nodes or in connective tissue. Thirty-six cases 
could be included in this study because lymph nodes from four cases could not be 
retrieved from the archive. Controls (n = 189) were patients who did not develop 
locoregional or distant disease within five years after diagnosis of primary CRC. 
For each case two controls were matched for Tumor-Node-Metastasis (TNM) stage, 
date of incidence and date of birth, leading to a total number of 72 controls. The 
median follow-up of the case group was 2.5 years (range 5.3 months – 6.3 years) 
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Figure 1. Lymph node sections stained for cytokeratin by AE1/AE3 antibodies 
resulting in brown cells and counterstained using hematoxylin and eosin. 
Micrometastases (> 0.2 mm and < 2 mm) at original magnification of x125 (A) and x250 
(B); Isolated tumor cells (tumor cell clusters < 0.2 mm) at original magnification of x125 
(C) and x500 (D); Isolated tumor cells (single cells) at original magnification of x250 (E) 
and x1000 (F).
and the median follow-up of the control patient group was 10.8 years (range 
5.1 – 21.4 years). Out of 19 patients with rectal carcinoma, two patients had 
received preoperative radiotherapy and three patients had received postoperative 
radiotherapy. None of the patients had received adjuvant chemotherapy. 
Tissue specimens
After resection the lymph nodes were fixed in formalin, processed through 
Detailed examination of lymph nodes in colorectal cancer 81
graded ethanol, and embedded in paraffin as part of a routine procedure for 
histopathological investigation. From 108 patients, a total of 780 lymph nodes 
was harvested (median 6; range 1 to 26 lymph nodes). The lymph nodes were 
embedded in a total of 225 paraffin blocks. 
Immunohistochemistry
For detection of tumor cells, a cocktail of murine monoclonal antibodies AE1 and 
AE3 (Dako, Denmark), was used. AE1 recognizes cytokeratin 10, 13, 14, 15, 16, 
and 19 and AE3 recognizes cytokeratin 1, 2, 3, 4, 5, 6, 7 and 8. Four micron sections 
were cut at four levels of each paraffin block with intervals of 200 μm. The sections 
were situated on aminopropylethoxysilane coated slides and dried overnight at 
37oC. The sections were subsequently deparaffinized in xylene, rehydrated and 
blocked for endogenous peroxidase in 0.3% hydrogen peroxide/methanol at room 
temperature for 20 minutes. After washing in phosphate buffered saline (PBS), 
antigen retrieval treatment was performed by incubating the sections in a 0.01 M 
sodium citrate solution (pH 6.0) for 10 minutes at 100oC. Then slides were rinsed 
twice in PBS and the primary antibody AE1/AE3 was applied at a 1:200 dilution in 
PBS with 1% bovine serum albumine, respectively. The sections were incubated 
overnight at room temperature, washed with PBS and incubated for 30 minutes with 
Envision- horseradish peroxidase (Dako, Denmark). After three PBS washes and 
one rinse in 0.05 M Tris/HCl (pH 7.6), visualization of cytokeratin was achieved by 
incubation for 10 minutes with 3,3’-diaminobenzidinetetrachloride substrate in a 
buffered 0.05 M Tris/HCl (pH 7.6) solution containing 0.002% hydrogen peroxide. 
Sections were counterstained with Mayer’s Hematoxylin and dehydrated in graded 
ethanol followed by xylene and mounted in glycerol. Cytokeratin-positive cells 
showed a brown staining of the cytoplasm.
Additionally, we intended to analyze the 200 µm tissue of paraffin-embedded 
lymph nodes between the sections used for immunohistochemical staining by 
using RT-PCR. However, this was not feasible since yield and quality of extracted 
RNA was insufficient (data not shown).
Analysis of the slides
All sections were analyzed using the ARIOL system® (Applied Imaging a Genetix 
company). The features of the ARIOL system® have been published previously.25 
Sections of the first level were also analyzed by a pathologist (AML) using 
conventional microscopy at a total magnification of 100 times. Selected candidate 
tumor cells were verified by the operator and also visually confirmed by an 
independent pathologist (HM). Nonspecifically stained cells such as hematopoietic 
cells were visually recognized and excluded from the analysis. Macrometastases 
were defined as groups of cells larger than 2 mm. Deposits of tumor cells of 2 mm 
or less but larger than 0.2 mm were considered as micrometastases and single 




Statistical analysis was carried out using SPSS software, version 12.0.1 (SPSS Inc, 
Chicago, IL). Numerical data are presented as mean + standard deviation or median 
and range in case of skewness. The clinicopathologic features of cases and controls 
were compared either by a Chi-square or Fisher’s exact for categorical variables or 
by a Mann-Whitney or student T-test for numerical variables. Differences between 
screening results by automated microscopy and conventional microscopy were 
analyzed by using the McNemar’s test. Univariate and multivariate odds ratio’s 
(OR), 95% confidence intervals (95% CI) and p-values (P) were calculated by 
applying logistic regression analysis. A p-value of less than 0.05 was considered 
an indication of statistical significance. Variables with a p-value lower than 0.10 
in the univariate analysis were entered in the multivariate analysis. Since the 
number of examined lymph nodes has been shown to be prognostically relevant 
in several studies26, this variable was also entered in the multivariate analysis. 
RESULTS
Clinicopathological features
Clinicopathologic characteristics of the patients are shown in Table 1. No significant 
differences in sex, T stage, tumor size, tumor location, tumor differentiation, 
mucinous tumors, serum CEA level and harvested lymph nodes (Mann-Whitney 
test, median 6 (range 1 to 18) vs median 6 (range 1 to 26), P = 0.096) were 
seen between the case and control group. If T2 and T3 stage were combined, 
more cases than controls were staged as T4 than T2/3 (Fisher’s exact test, 8 of 
36 (22%) vs 6 of 72 (8%), P = 0.066). Except for T stage (T4 vs T2/T3: OR 3.1, 
95% CI 1.0-9.9, P = 0.050), the single variable regression analysis for disease 
recurrence of clinicopathological parameters (Table 1) did not show any other 
significant risk factors. The single variable regression analysis for the number of 
lymph nodes showed the following: OR 0.9, 95% CI 0.9-1.0, P = 0.132.
Multilevel sectioning, immunohistochemical staining and automated 
microscopy
Analysis of the first lymph node level identified micrometastases in three (3%) 
patients (two cases and one control) and isolated tumor cells in 39 (37%) 
patients (13 cases and 26 controls) (Table 2). One micrometastasis found 
in an immunohistochemically stained section was also present on the original 
hematoxylin and eosin (HE) stained slide but was not recognized by the pathologist. 
Macrometastases in three (3%) patients (two cases and one control) that had 
not been recognized as lymph node metastases on the original HE stained slides 
were also seen. They had been described as vascular invasion or tumor deposits 
without lymphoid tissue in the pathology reports. On the immunohistochemically 
stained slides of all levels, lymphoid tissue was present around the tumor cells. 
These macrometastases were excluded from further analysis. 
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Table 1. Patient and primary tumor characteristics (n=108)
Cases (n=36) Controls (n=72)
Characteristics n % n % Pa
Sex
Female 16 44 37 51 .496
Male 20 56 35 49
Age (years)b 67 + 12 67 + 12 .911c
TNM staged
I 2 6 4 6 1.000e
II 34 94 68 94
T stagef
T2 2 6 4 6 .126
T3 26 72 62 86
T4 8 22 6 8
Tumor size (cm) (n=104)b, g 4.9 + 1.9 (n=34) 5.2 + 2.1 (n=70) .539c
Tumor location
Colon (coecum – sigmoid) 30 83 59 82 .858
Rectum (rectosigmoid – 
rectum) 
6 17 13 18
Differentiation
Good 9 25 18 25 .912
Moderate 22 61 46 64
Poor 5 14 8 11
Mucinoush
No 32 89 66 92 .728e
Yes 4 11 6 8
Preoperative serum CEA level 
(n=43)j
< 6 µg/l 5 56 25 74 .417e
> 6 µg/l 4 44 9 26
Number of examined lymph 
nodesb
6.1 + 4.5 7.8 + 5.7 .096k
CEA, carcinoembryonic antigen;a Chi-square test of cases vs controls, unless mentioned otherwise; b 
Presented as mean + standard deviation; c Student T-test; d According to the 6th edition of the TNM 
classification11; e Fisher’s exact test; f If T2 and T3 stage were combined, the P value was 0.043; this 
comparison was therefore used in the logistic regression; g Tumor size could not be found in pathology 
reports from four patients; h A tumor was considered mucinous when more than 50% of its volume 
existed of mucinous component; j Serum CEA had been determined in only 43 of 108 patients as it was 
not a standard procedure; k Mann-Whitney test.
All macrometastases and micrometastases were detected by both conventional and 
automated microscopy. Automated microscopy led to the detection of additional 
isolated tumor cells (McNemar’s test, 39 vs 10 patients, respectively, P < 0.001) 
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Table 2. Detection of tumor cells in paraffin-embedded lymph nodes from colorectal 
cancer patients (n=105) after multilevel sectioninga and immunohistochemical staining 
combined with automated microscopyb
One level Two levels Three levels Four levels
A. Lymph node status 
(n=772)
n % n % n % n %
Macrometastases - - 1 0.1 1 0.1 1 0.1
Micrometastases 6 0.8 8 1.0 8 1.0 8 1.0
Isolated tumor cells 99 12.8 126 16.3 153 19.8 172 22.3
B. Patient status 
(n=105)
n % n % n % n %
Macrometastases - - 1 1.0 1 1.0 1 1.0
Micrometastases 3 2.9 4 3.8 4 3.8 4 3.8
Isolated tumor cells 39 37.1 48 45.7 59 56.2 61 58.1
a Four micron sections were cut at four levels of each paraffin block with intervals of 200 μm; b Patients 
with macrometastases in the first lymph node level that had previously not been recognized as such, 
were excluded.
(Table 3). All but one isolated tumor cell found by conventional microscopy was 
also detected by automated microscopy. The missed isolated tumor cell was 
overlooked during visual inspection of ARIOL system results by the operator.
Analysis of a second level, resulted in additional detection of one patient with 
macrometastasis (a case), one patient with micrometastases (a case) and nine 
patients with isolated tumor cells (two cases and seven controls) (Table 2). These 
patients had no tumor cells detected in the first level nor in the original HE stained 
slide.
When analyzing a third level, eleven patients (three cases and eight controls) 
were additionally identified with isolated tumor cells and assessment of a fourth 
level, identified two patients (two controls) with isolated tumor cells. This led to 
a total number of 61 patients with isolated tumor cells (Table 2). No additional 
macrometastases or micrometastases were found when analyzing a third and 
fourth level. In Figure 1 examples of micrometastases (1A, B) and isolated tumor 
cells (1C-F) are shown.
Concluding, after analysis of two lymph node levels, macrometastases were 
observed in one patient (one case) and micrometastases in four patients (three 
cases and one control). Analysis of two additional lymph node levels solely 
identified the presence of isolated tumor cells. 
Prognostic significance of lymph node metastases
More patients with micrometastases were seen in the case group than in the 
control group (Fisher’s exact test, three of 34 (9%) vs one of 71 (1%), P = 0.099). 
There was no difference in the presence of lymph nodes harboring isolated tumor 
cells, between the case and control group (Chi-square test, 18 of 34 (53%) vs 
43 of 71 (61%), P = 0.459) (Table 4). Separate analysis of patients with colon 
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Table 3. Detection of tumor cells in lymph nodes from colorectal cancer patients after 








A. Lymph node status (n=772) n % n % n %
Macrometastases - - - - - -
Micrometastases 6 0.8 6 0.8 6 0.8
Isolated tumor cells 15 1.9 99 12.8 100b 13.0
B. Patient status (n=105) n % n % n %
Macrometastases - - - -
Micrometastases 3 2.9 3 2.9 3 2.9
Isolated tumor cells 10 9.5 39 37.1 39 37.1
a Patients with macrometastases in the first lymph node level that had previously not been recognized 
as such, were excluded; b One lymph node with isolated tumor cells was missed by ARIOL automated 
microscopy.
carcinoma, rectal carcinoma, right-sided or left-sided carcinoma, did not result 
in significant difference in the presence of isolated tumor cells or percentage 
of lymph nodes harboring isolated tumor cells for the case and control group. 
Neither did excluding patients with T4 tumors or disregarding single tumor cells 
as isolated tumor cells.
From the clinicopathological variables, the T stage and the number of examined 
lymph nodes were entered in the multivariate logistic regression analysis with 
the presence of micrometastases. These results showed that the presence of 
micrometastases (OR 26.3, 95% CI 1.9-364.8, P = 0.015), a T4 stage (OR 4.8, 
95% CI 1.4-16.7, P = 0.013) and the number of harvested lymph nodes (OR 0.9, 
95% CI 0.8-1.0, P = 0.028) were independent predictors for disease recurrence. 
When including the patient with macrometastasis detected after analysis of a 
second level, the OR changed in favour of the presence of macrometastases or 
micrometastases in lymph nodes, showing the presence of macrometastases or 
micrometastases (OR 34.5, 95% CI 2.7-440, P = 0.006), a T4 stage (OR 2.9, 95% 
CI 0.4-23.5, P = 0.040) and the number of examined lymph nodes (OR 0.9, 95% 
CI 0.8-1.0, P = 0.025) to be independent predictors for disease recurrence.
Relation between lymph node metastases and clinicopathological features
There was no correlation observed for the presence of micrometastases in lymph 
nodes and patient’s gender, tumor location, tumor size, T-stage, TNM stage and 
serum CEA level (all P values > 0.05). In rectal carcinoma fewer lymph nodes were 
harvested than in colon carcinoma (Mann-Whitney test, median 3, range 1 to 13 
vs median 7, range 1 to 26, P = 0.037). Also patients with less than 12 harvested 
lymph nodes were significantly older than patients with 12 or more harvested 
lymph nodes (Student T-test, 69 + 10 vs 61 + 15, P = 0.008). No difference was 
seen in the number of lymph nodes harvested for the different T stages. 
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DISCUSSION
In this study, we analyzed paraffin-embedded lymph nodes from patients with CRC 
by using multilevel sectioning combined with immunohistochemical staining and 
demonstrated that the presence of micrometastases was an independent predictor 
for disease recurrence. Analysis of a second lymph node level led to detection 
of additional prognostically relevant macrometastases and micrometastases. 
Examination of more levels and the use of automated microscopy led to detection 
of additional isolated tumor cells which were prognostically not relevant.
We performed this study because the prognostic significance of occult tumor 
cells in lymph nodes in CRC is still a matter of debate. A meta-analysis showed 
that immunohistochemical detection of occult tumor cells combined with serial 
or multilevel sectioning led to upstaging of 32% of previously considered node-
negative patients but the presence of occult tumor cells did not lead to a statistically 
significant adverse clinical outcome.27 The meta-analysis reported an upstaging of 
37% by RT-PCR and in contrast to immunohistochemistry studies, most RT-PCR 
studies found the presence of occult tumor cells in lymph nodes to predict a worse 
clinical outcome (overall three-year survival of 78% vs 97%, P < 0.001).13;14;18-
22;27 However, although several alternative techniques are evaluated for improving 
RNA yield28;29, optimal results with RT-PCR are mainly achieved when using fresh 
frozen tissue.30;31 This is more laborious and lacks morphological assessment. 
Therefore, serial or multilevel sectioning combined with immunohistochemical 
staining is preferred since it can be reliably used on paraffin-embedded tissue and 
the morphology of stained cells can be examined. 
The fact that most immunohistochemistry studies show no difference in 
clinical outcome between patients with lymph nodes containing occult tumor 
cells and patients with tumor-negative lymph nodes, we ascribe to the 
lack of making a distinction between micrometastases and isolated tumor 
cells.13;32-39 The last sixth TNM edition11;12 recommends classifying occult 
tumor cells in lymph nodes into micrometastases and isolated tumor cells. 
Table 4. Clinical relevance of occult tumor cells in lymph nodes from patients with 
colorectal cancer (n=105)a
Cases (n=34) Controls (n=71)
Lymph node status n % n %   Pb
Tumor-positive 22 65 44 62 .786
Macrometastases 1 3 0 0 .324c
Micrometastases 3 9 1 1 .099c
Isolated tumor cells 18 53 43 61 .459
Cases were defined as patients who had regional or distant disease recurrence within five years 
after the date of diagnosis of primary colorectal cancer; Controls were patients who did not develop 
locoregional or distant disease within five years after diagnosis of primary colorectal cancer; a Patients 
with macrometastases in the first lymph node level that had previously not been recognized as such, 
were excluded; b Chi-square test of cases vs controls, unless mentioned otherwise; c Fisher’s exact test.
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According to this TNM edition, isolated tumor cells in lymph nodes which are less 
than 0.2 mm in diameter, are insignificant and should be classified as pN0(i+). 
Lymph-node deposits with a diameter between 0.2 mm and 2 mm should be 
classified as micrometastases (mi) and staged as node positive pN1(mi). Even 
so, this recommendation published in 2002, was not based on evidence but more 
on logical reasoning. In our study isolated tumor cells were found of no clinical 
relevance and do confirm the guidelines of the TNM classification system. Only two 
other research groups31;40 have previously published study results regarding CRC 
patients in which they differentiated between micrometastases and isolated tumor 
cells, emphasizing the importance of our study. Messerini et al.40 examined lymph 
nodes from 395 stage IIA CRC patients by immunohistochemical staining of 12 
serial sections with antibodies directed against cytokeratin 20. Micrometastases 
were detected in lymph nodes from 9.9% of the patients and isolated tumor 
cells were seen in 28.4% of patients. Similar to our findings, they did not find 
prognostic relevance of isolated tumor cells and showed a lower survival rate 
in patients with micrometastases compared to patients with isolated tumor cell-
positive and tumor-negative lymph nodes. We suggest that the lack of prognostic 
significance of isolated tumor cells might be explained by assuming that these 
cells are shed from the primary tumor and transported through lymphatic vessels 
to the lymph nodes, but do not have the potential of independent outgrow, and 
therefore, do not form established metastases. The second research group31 who 
made a distinction between micrometastases and isolated tumor cells in CRC, 
examined two lymph node levels at a 200 µm interval with antibodies AE1/AE3. 
They detected micrometastases in seven of 234 patients (3%) which corresponds 
to the detection rate in our patient group. This group did not evaluate the prognostic 
relevance of micrometastases in CRC leaving only two studies by Messerini et al.40 
and our study who did. 
Although we choose for a case-control design since this was more cost-effective 
than a retrospective cohort study, our study has advantages such as reliable 
follow-up of the patients by our Department of Oncological Documentation and the 
matching of two controls for each case. A limitation of our study which is known 
when evaluating archival material for research purposes, was the infeasibility to 
select for patients with at least 12 lymph nodes examined for accurate staging 
as recommended by the American Joint Committee on Cancer Staging (AJCC)12 
and the International Union against Cancer (UICC-TNM).11 Twenty percent of 
our patient group underwent an adequate lymph node harvest of at least 12 
lymph nodes. Other studies examining large archival material also demonstrated 
this limitation. Only 22% of 569 CRC specimens studied by Johnson et al.41 and 
37% of 116,995 CRC patients in a study by Baxter et al.42 received adequate 
evaluation of 12 or more lymph nodes. Factors that have been reported to 
affect the number of lymph nodes retrieved in CRC specimens were the effect 
of different pathology assistants, older age, rectal cancer and the T stage.42-44 
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We also saw less patients with a harvest of at least 12 lymph nodes in rectal 
carcinoma than in colon carcinoma and patients with at least 12 lymph nodes 
harvested were significantly younger than patients with less than 12 lymph 
nodes harvested. Even so, evidence exists that the number of harvested lymph 
nodes has increased during the last two decades. In our group, an RT-PCR study 
regarding detection of occult tumor cells in lymph nodes from 26 CRC patients 
who were included from January 1990 and February 1992 has been previously 
published.14 In this study, 246 lymph nodes were freshly isolated leading to an 
average of 9.5 compared to an average of 7.2 in our present study in which 
lymph nodes were isolated after fixation in formalin. Experience in our pathology 
laboratory has shown that more lymph nodes are harvested when isolated freshly 
than when harvested after formalin fixation (data not published). Also, in a 
prospective sentinel lymph node study in CRC patients31 between 1996 and 2001, 
more lymph nodes were harvesting in the study group (average 14) than in the 
control group (average 10), suggesting that more lymph nodes are harvesting 
within a trial design. Fat clearance techniques increases the number of harvested 
lymph nodes, especially small lymph nodes less than 5 mm.45;46 However, these 
methods are time consuming, expensive and impractical as they involve noxious 
volatile agents.
Nevertheless, in our study the number of examined lymph nodes was included 
in the multivariate analysis and in line with the literature, we found that a lower 
number of examined lymph nodes was an independent risk factor26 for disease 
recurrence together with T4 stage and the presence of micrometastases. Since 
detailed analysis of lymph nodes using serial or multilevel sectioning and 
immunohistochemistry is costly and time- and labor-consuming, we should take 
into account restriction of lymph node sampling or ultrastaging of sentinel lymph 
node(s) which have the highest risk for harboring metastases. In a recent study 
by Pusztaszeri et al.44, the value of sampling lymph nodes located at distance 
sidelong CRC specimens was assessed. Mesocolic and perirectal fat were divided 
into two fractions: close to (< 5 cm) and distant from (> 5 cm) from the primary 
tumor. They found that in the colon, lymph node location is more important than 
lymph node number because metastatic lymph nodes were present mostly in the 
peritumoral area. This suggested that lymph nodes should be initially recovered 
from the pericolic fat close to the tumor. If there are less than 4 tumor-positive 
lymph nodes and less than 12 tumor-negative lymph nodes examined in total, 
only then additional lymph nodes should be retrieved from the distal fraction for 
potential upstaging. In the rectum, systematic sampling of close and distant lymph 
nodes seemed mandatory because in some cases, metastases were detected only 
in distant lymph nodes, particularly in patients who had undergone neoadjuvant 
radiotherapy.
Additionally, interim results from Bilchik et al.47 assessing sentinel lymph nodes 
for the presence of occult tumor cells, suggests the presence of micrometastases 
in sentinel lymph nodes to increase the risk for disease recurrence. 
Detailed examination of lymph nodes in colorectal cancer 89
Importantly, quantitative restriction of lymph node sampling and sentinel lymph 
node mapping in CRC does not substitute a complete oncologic resection and thus 
far all lymph nodes will continued to be examined with conventional hematoxylin 
and eosin staining. 
In conclusion, there is need for better prognostication in stage II CRC patients 
since disease recurrence will occur in up to 30% of these patients and the 
administration of adjuvant chemotherapy to all node-negative CRC patients is 
controversial. Our study results show that immunohistochemistry combined with 
two level analyses of lymph nodes is helpful in detecting macrometastases and 
micrometastases which showed prognostic relevance. Isolated tumor cells were of 
no prognostic importance. 
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ABSTRACT
Background: Sentinel node mapping (SNM) has been introduced in colorectal 
cancer (CRC) to improve staging by facilitating occult tumor cell (OTC) 
assessment in lymph nodes that are most likely to be tumor-positive. In this 
paper, studies on the feasibility and reliability of SNM in CRC are reviewed.
Methods: A literature search was conducted in the National Library of Medicine 
by using the keywords colonic, rectal, colorectal, neoplasm, adenocarcinoma, 
cancer and sentinel. Additional articles were identified by cross-referencing from 
papers retrieved in the initial search. 
Results: There is a large variation in identification rates and false-negative 
rates mainly due to the learning curve effect, differences in SNM technique and 
tumor T stage.
Conclusions: We conclude that SNM in CRC is technically feasible. 
Standardization of SNM procedures is mandatory to resolve the debate on the 
reliability of sentinel lymph node status for predicting the tumor status of all 
lymph nodes. Only then can adjuvant treatment of patients upstaged by OTC 
detection in sentinel nodes be justified. 
INTRODUCTION
Lymph node metastases are one of the most important predictors of survival in 
patients with resectable colorectal cancer (CRC). In most countries, patients with 
curatively resected CRC without nodal tumor involvement do not receive adjuvant 
systemic therapy, since meaningful survival benefits have not yet been proven.1;2 
However, up to 30% of these patients will develop locoregional recurrence or 
distant metastases.3 A recent study shows that stage II CRC patients who receive 
5-fluorouracil have a significantly lower risk of disease recurrence.4 Nevertheless, 
adjuvant systemic treatment of all node-negative CRC patients would lead to 
overtreatment and unnecessary complications due to adverse effects of adjuvant 
systemic therapy. Providing only the high-risk patients with adjuvant therapy 
prevents this and leads to a better quality of life and an optimized cure rate 
for these patients. The high-risk node-negative CRC patients may be identified 
through the detection of occult tumor cells (OTC) in lymph nodes. OTC comprise 
of micrometastases and isolated tumor cells that are usually not detected with 
conventional hematoxylin and eosin (HE) staining. Micrometastases are defined 
as deposits of tumor cells of 2 mm or less but larger than 0.2 mm and isolated 
tumor cells either as single tumor cells or as clusters of tumor cells of 0.2 mm or 
less.5-7 Focused examination methods such as serial sectioning, step sectioning, 
immunohistochemistry, polymerase chain reaction and reverse transcriptase 
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polymerase chain reaction increase the likelihood of finding OTC. Examining all 
regional lymph nodes with these methods would be preferred, but is expensive 
and time consuming and therefore not feasible in daily practice. 
Sentinel node mapping (SNM), also known as lymphatic mapping, offers a potential 
solution. During an SNM procedure sentinel nodes (SNs), i.e. lymph nodes onto 
which the tumor drains directly, are retrieved.8 These SNs have the highest chance 
of harboring tumor cells.9-12 When SNs are free from tumor, nonsentinel nodes 
(NSNs) are also expected to be tumor-negative. By examination of SNs only, 
which reflect the status of the whole regional lymph node basin, OTC detection 
becomes attainable as the number of lymph nodes to be examined is greatly 
reduced.
The SNM concept originated in 1923 when Braithwaite13;14 evaluated the flow of 
lymphatic vessels near the ileocaecal valve using indigo carmine. He used the 
terms “lymphatic mapping” and “glands sentinel”. The term “sentinel node” was 
initially used in 1960 by Gould et al.15 in their study to detect lymphatic metastases 
in parotid carcinoma. In 1977, Cabanas et al.16 performed lymphangiograms in 
penile carcinoma to search for a specific lymph centre where the lymphatic vessels 
drained to. They referred to this specific lymph centre as the “sentinel lymph node”. 
The SNM procedure was further developed in melanoma by Morton et al.8 and in 
breast cancer by Guiliano et al.17 The aim of SNM in melanoma and breast cancer is 
to limit postoperative morbidity by preventing an unnecessary lymphadenectomy. 
A lymphadenectomy will be performed when the usually perioperatively examined 
SNs harbor tumor cells. In CRC, however, lymph nodes near the tumor are 
routinely resected en bloc with the primary tumor. Lymphadenectomy in CRC is 
a standardized procedure, generally without complications or comorbidity and a 
one-stage surgical procedure is preferred in abdominal surgery. Thus, the main 
advantage of SNM in CRC, is OTC assessment in a limited number of lymph nodes. 
A second important advantage of in vivo SNM in CRC is the detection of aberrant 
lymphatic drainage patterns that may occur in up to 14% of the patients, leading 
to an adjustment of the initial resection plan.18 
There are a growing number of publications on the role of SNM in CRC. This review 
assesses the feasibility and reliability of SNM in CRC. Differences in the SNM 
techniques used are emphasized.
METHODS
A literature search was conducted with PubMed software in the National Library 
of Medicine, containing articles from 1953 until 2004. The following keywords 
were used in appropriate combinations: colonic or rectal or colorectal neoplasm, 
adenocarcinoma or cancer and sentinel. Papers with anal cancer in the title were 
excluded and the language was restricted to English. All hits from this PubMed 
search were individually checked, and included only if they addressed the subject 
of this review. Additional articles were identified by cross-referencing from papers 
retrieved in the initial search. 
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Among the SNM studies considered in this review, several variables were used to 
indicate the feasibility and reliability of this procedure. The identification or success 
rate was calculated as the number of SNM procedures where at least one blue node 
was found, divided by the total number of SNM procedures. True positives (TP) 
were defined as cases where the SNs were positive and the NSNs were positive 
or negative. True negatives (TN) were defined as cases where both the SNs and 
NSNs were negative. False-negative cases (FN) were defined as cases where the 
SNs were negative whereas the NSNs were positive. The FN rate was calculated 
using the formula FN/(FN+TP). Sensitivity was defined as the complement of the 
false-negative rate [TP/(TP+FN)]. Negative predictive value was calculated using 
the formula TN/(TN+FN). The upstaging percentage represented the cases where 
lymph nodes, tumor-negative by conventional HE staining, became tumor-positive 
when additional examination methods were used. The upstaging percentage was 
calculated by dividing the number of HE-negative cases found to be tumor-positive 
with additional examination techniques by the total number of HE-negative cases 
investigated with additional examination techniques.
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In vivo versus ex vivo sentinel node mapping
In contrast to SNM in breast cancer and melanoma, the regional lymphatic vessels 
and lymph nodes in CRC are routinely resected along with the primary tumor. 
Hence, ex vivo injection of a tracer in CRC is possible. During an in vivo SNM 
procedure there is still pressure to push the tracer into lymphatic vessels. When 
performing an ex vivo SNM procedure, the injected site should be gently massaged 
for approximately 2 to 5 minutes to push the tracer into lymphatic vessels.19 A 
disadvantage of the ex vivo procedure is the inability to detect aberrant lymphatic 
drainage patterns. However, during an ex vivo SNM the patient is not at risk 
of allergic reactions or falsely low pulse oximeter readings due to injection of 
isosulphan blue or patent blue dye. Furthermore, ex vivo SNM has the advantage 
of precise injection of dye into the submucosa. In some studies the tracer was 
injected in four quadrants around the tumor.19 However, this method seems to be 
associated with accidental exclusion of draining lymphatic vessels and the tracer 
should therefore be injected circumferentially around the tumor.20
Tracers used for sentinel node mapping
There are several types of tracers21 that can be used when performing an SNM 
procedure; these include blue dye, radioactive or fluorescent tracer. Blue dyes 
that are being used are lymphazurin isosulphan blue, patent blue, methylene 
blue or Evans blue.22 Other dyes that can be used are indigo carmine22 and 
indocyanine green.23 Among radioactive tracers24 there are technetium labelled-
sulphur colloid, antimony, tin colloid, human serum albumin and technetium-
labelled phytate, each with different particle sizes.25;26 In the United States, 
lymphazurin isosulphan blue and technetium sulphur colloid are mostly used.27 
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Patent blue28, technetium sulphur colloid29 and technetium human serum 
albumin30 were used in Europe. The Japanese surgeons prefer the radioactive 
tracer technetium tin colloid for SNM in CRC.31
The size of blue dye particles is smaller than the radioactive colloid particles. 
Therefore, dyes show a shorter transit time through the lymphatic vessels with 
an increasing risk of staining of the second tier lymph nodes. However, blue dye 
is inexpensive and relatively easy to use. Furthermore, no protection measures 
have to be taken and the infiltrated lymphatic vessels and lymph nodes are easily 
visualized without additional equipment. Unfortunately, isosulphan blue and 
patent blue dye have been associated with allergic reactions in 1% to 1.6% of 
patients.32-38 These allergic reactions varied from urticaria and hypotension to life-
threatening anaphylactic shock. Both dyes are also known to lead to falsely low 
pulse oximeter readings during the course of surgery.32;39-42 Thus far, methylene 
blue and fluorescent tracer have not been used in CRC. The former, however, was 
associated with skin lesions at the injection site in breast cancer patients when 
using combined deep parenchymal and intradermal injections.43 
In 1910;12;28;44-59 of the 25 studies published on SNM in CRC (Table 1), blue dye was 
used as a tracer, usually injected in vivo. Four studies reported SNM using both 
blue dye and radioactive tracer27;30;60;61 and in two studies only radioactive tracer 
was used.29;31 The volume of blue dye used ranged from 0.5 to 2 ml except in three 
studies46;55;61 where up to 5 ml blue dye was used. The moment of injection was 
usually in vivo and the site of injection was mostly subserosally and sometimes 
submucosally during an endoscopy or ex vivo procedure. In all but one study53 
using blue dye, the identification time between injection of the tracer and labelling 
of SNs ranged from 1 to 60 minutes. In the study by Gandy et al.53, however, the 
resected specimens were fixed in formalin for 48 hours followed by the search for 
blue nodes. After identification, blue nodes were processed separately because 
blue dye is removed during routine histological processing. The studies using 
radioactive tracers injected preoperatively or perioperatively to detect SNs showed 
an identification time ranging from 26 minutes to 20 hours. Different types of 
radioactive tracer were used in these studies. The first use of a radioactive tracer 
in SNM in CRC was reported in 2000 by Kitagawa et al.62 When using a radioactive 
tracer additional equipment such as a gamma probe is required to detect the 
radioactivity level of the lymph nodes. No reports linking radioactive tracers to 
allergic reaction or interference with patient monitoring have been published. 
Merrie et al.60 used patent blue dye combined with the radioactive tracer technetium 
colloidal antimony sulphide in 21 SNM procedures. Eighty-one percent of the hot 
nodes were identified by blue dye and 51% of the blue nodes were identified by the 
radioactive tracer. The lower number of blue nodes that were also radioactive was 
explained by the rapid passage of blue dye through the lymph nodes to the following 
nodes. For the hot nodes that did not show blue dye it was proposed that the blue 
dye had passed through the node without leaving a stain, or that these nodes were 
more immunologically active, resulting in greater uptake of the radioactive tracer. 
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The average number of blue nodes was 6.2 and the average number of hot nodes 
was 3.9. 
Saha et al.27 showed that a combination of isosulphan blue dye and the radioactive 
tracer technetium sulphur colloid (TSC) may improve the identification and 
accuracy rate of SNM in CRC. The SNM with blue dye was successful in 100% 
of 57 patients versus 89% when using the radioactive tracer. Blue dye detected 
152 SNs, the radioactive tracer detected 100 SNs, and both modalities detected 
96. Of the SNs detected by blue dye only, 10.7% had nodal metastases, whereas 
19.8% of SNs detected by both modalities had nodal metastases (P = 0.028). 
This suggests that using both type of tracers leads to a higher accuracy rate of 
the SNM. However, Patten et al.61, who used the same combination of isosulphan 
blue dye and TSC, showed no increase in sensitivity of detection of tumor-positive 
SNs compared to the use of blue dye alone. Additionally, Saha et al.27 reported a 
lower average number of SNs (2.7 vs 3.5 SNs) and a lower FN rate (16% vs 50%) 
compared to Patten et al.61 These studies show discrepancies in the additional 
value of a radioactive tracer. 
As yet there is no consensus on the best tracer or combination of tracers to be 
used.
Identification rates
The identification rate of the 25 studies ranged from 58% to 100% with an 
average rate of 89% (Table 1). Factors that might have contributed to the failed 
SNM procedures were incomplete circumferential injection around the tumor28 
or insufficient volumes of tracer for large tumors55 and inclusion of advanced 
tumors.29 Also a learning curve has been confirmed by studies reporting an 
identification rate of almost 100% if the first SNM procedures were not included in 
the analysis.10;52 In conclusion, SNM in CRC is technically feasible.
False-negative rates
The FN rate ranged from 0% to 63% with an average of 33% (Table 1). Use of 
both blue dye and radioactive tracer led to an average FN rate of 28% with a range 
of 0 to 50%. The two studies using only radioactive tracer showed FN rates of 
18% and 56%. High FN rates might be explained by extensive nodal replacement 
and large tumors. These factors can cause occluded lymphatic vessels leading to 
lymph drainage through an alternative route.28;61 Another contributing factor to 
FN cases might be a long identification time between the injection of the tracer 
and the identification of SNs. On the other hand, one would expect that limitation 
of the time between injection of the tracer and resection of the bowel specimen 
should suffice because of pressure loss preventing the dye from travelling further. 
However, blue dye travels fast and might have already left the real SNs by the 
time that the specimen has been resected and the pathologist looks for blue 
nodes. This phenomenon might also explain the wide range of detected SNs in 
some studies (Table 1). 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Ten of the 25 studies reported a FN rate of 20% or less (Table 1). Four of these 
10 studies were the only studies that considered the first four blue nodes, usually 
marked in vivo, to be the real SNs.10;27;52;58 Bendavid et al.51 considered the four to 
five blue nodes closest to the tumor as SNs. Waters et al.45 and Demirbas et al.56 
reported average numbers of SNs of 1 and 3, respectively. The study by Kitagawa 
et al.31 showed a range of SNs from 0 to 8. Gandy et al.53 considered all blue nodes 
as SNs and reported an average number of 7.1 SNs. The majority of the 15 SNM 
studies reporting a FN rate higher than 20%, considered all blue or radioactive 
nodes as SNs leading to wider ranges of SNs. Up to 21 SNs were found as shown 
in Table 1.12 To consider the first blue nodes as the real SNs has limitations. A 
subject for debate is the fact that blue nodes are usually found by inspection.52;58 
However, it is assumed that SNs are often locoregional nodes, which are usually 
located near the serosa within the mesocolic fatty tissue. This suggests that with 
the aforementioned way of selecting blue nodes, there is a chance of missing 
real SNs, and selecting second tier lymph nodes. Therefore, it might be expected 
that immediate examination of the entire mesocolon by inspection, palpation and 
incisions and considering the first to fourth blue nodes closest to the tumor, might 
be more reliable.20 
Studies in CRC show higher FN rates than studies in melanoma and breast cancer, 
when considering HE staining results. Three SNM studies in melanoma show 
FN rates of 0%, 5% and 8%.8;63-65 All 20 SNM studies in breast cancer recently 
reviewed by Kelly et al.66 showed an average FN rate of 8% (range 0% to 19%). 
The difference in FN rate between SNM in CRC and SNM in melanoma or breast 
cancer might be due to the larger tumors found in the colon and the rectum and 
also to the dissimilarity in lymphatic drainage pattern. Furthermore, in melanoma 
and breast cancer, enlarged suspected lymph nodes that have not taken up dye 
are easier to find by inspection and palpation of the lymph nodes. 
In summary, we conclude that there is a large variation in FN rates usually 
ascribed to the differences in SNM technique and tumor T stage. Most studies 
show that SNM in CRC is usually unreliable in patients with lymph nodes containing 
macrometastases detected with HE staining. All studies regarding the first four 
blue nodes as the real SNs showed low FN rates.
Sentinel node mapping in rectal cancer 
In vivo SNM in rectal cancer with blue dye is technically difficult because 
of the anatomic location of the rectum deep within the narrow pelvis. A clear 
view of the tumor site is therefore not always feasible. Additionally manual 
injection of the tracer into the perimuscular fatty tissue is troublesome and real-
time observation of the fast transit of blue dye into SNs is almost impossible. 
However, submucosal injection of blue dye during an ex vivo SNM procedure 
followed by immediate incisions in the perimuscular fatty tissue to find the 
blue nodes is possible.12 Another way is lymphoscintigraphy by preoperative or 
perioperative submucosal injection of radioactive tracer through endoscopy.29;31 
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When using a radioactive tracer, there is no need for real-time observation due to 
the longer transit time and the detection of hot nodes through a probe. 
Kitagawa et al.31 included patients with sigmoid colon or rectal cancer and Bembenek 
et al.29 included only rectal cancer patients. Both used a radioactive tracer that 
was injected submucosally during preoperative endoscopy. The identification rates 
of these studies were similar, but the FN rates differed. The first study reported 
an identification rate of 91% and a FN rate of 18% and the latter reported an 
identification rate of 96% and a FN rate of 56%. Ninety percent of the patients of 
the study by Bembenek et al.29 had locally advanced cancer (endosonographically 
uT3/4) of whom 86% had undergone neoadjuvant radiochemotherapy. Kitagawa 
et al.31 included clinically localized sigmoid colon and rectal cancer patients. Fifty-
two percent of these patients were diagnosed with T1 or T2 tumor stage. All four 
FN cases in this study were seen in patients with T3 tumors. The difference in 
patient tumor stage may explain the difference in FN rates between these two 
studies. 
Lymphoscintigraphy might be more applicable in cases of rectal cancer because of 
the ability to detect aberrant lymph drainage patterns to extramesorectal lymph 
nodes, which might be considered an indication for lateral lymphadenectomy. 
Some researchers claim that lateral lymphadenectomy is unnecessary because 
even if there are radioactive extramesorectal lymph nodes, these are usually 
tumor-free.67 Nevertheless, Cutini et al.68 reported that one of two patients in 
their study with radioactive extramesorectal lymph nodes had metastases in these 
nodes. Kitagawa et al.31 showed direct lymph drainage to lateral lymph nodes in 
10% of their rectal cancer patients. These numbers confirm the clinical importance 
of lymphoscintigraphy in rectal cancer patients.
Sentinel node mapping during a laparoscopic procedure versus open 
surgery 
Without elaborating on SNM during laparoscopic colon resection (LCR), we would 
like to remark briefly that there is evidence that SNM during LCR is technically 
feasible and yields similar identification and accuracy rates as SNM during open 
colon resection.69;70 SNM during a LCR can be useful for patients with small early-
stage tumors.
Occult tumor cell detection in sentinel nodes
It should be kept in mind that the SNM procedure in CRC is an aid to OTC 
detection in lymph nodes. Therefore, it is necessary to study the reliability of 
SNM mapping in HE node-negative patients. Smith et al.71 reported a power 
calculation determining the number of HE node-negative patients required to 
prove that SNM upstages patients by selective identification of nodes rather than 
by chance. When assuming that the proportion of HE node-negative patients 
that are truly node-positive is 30%, a total of at least 34 HE node-negative 
patients would be required in order to upstage all 30% of these patients. 
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If the percentage of patients that were truly node-positive is 20% of all HE node-
negative patients, then at least 130 HE node-negative patients would need to be 
mapped in order to show statistical significance of SNM in upstaging of patients. 
Table 1 shows four studies with 34 or more HE node-negative patients. SNs in 
three of these studies were differently examined than the NSNs.10;27 Only the study 
by Wong et al.12 investigated SNs and NSNs in an identical fashion. They found a 
FN rate of 47% when considering the lymph node metastases found in HE stained 
sections. However, the FN rate was 28% when the SNs and NSNs from the HE node-
negative patients were examined with step sectioning and immunohistochemistry. 
Additionally, Wong et al.12 reported an overall presence of tumor cells in 4.7% of 
SNs and in 0.3% of NSNs (P < 0.001) confirming the SN concept. By examining 
SNs and NSNs from 34 CRC patients with immunohistochemistry, Turner et al.9 
showed that SNs are significantly more likely to contain tumor cells than NSNs 
(P < 0.001; odds ratio, 9.64; 95% confidence interval, 4.94 – 19.60). However, 
they did not examine the SNs and NSNs identically. The SNs were examined on 
four levels and the NSNs were examined on three levels and even though the SNs 
of all the patients were HE negative, six patients actually had HE positive NSNs.
In some studies FN rates were calculated considering the results obtained with 
HE staining of all lymph nodes and focused examination of only SNs.51 FN rates 
decreased when results from upstaging techniques of SNs were included in the 
calculation. This might relate to the fact that in most FN cases the real SNs could 
not take up the tracer because of occluded lymphatic vessels due to metastases. 
The likelihood of detecting OTC in false-negative SNs from such a specimen is 
increased because tumor cells had already started to metastasize to these nodes 
too.
We should bear in mind that the intended benefit of SNM in CRC is mainly to 
facilitate in OTC assessment. This suggests that the study of Wong et al.12, reporting 
that the SN concept is applicable to HE node-negative CRC, needs confirmation.
CONCLUSIONS
SNM in CRC is technically feasible. However, there is a large variation in 
identification rates and false-negative rates usually ascribed to the learning 
curve effect, differences in SNM technique and tumor T stage. Most studies show 
that SNM in CRC is usually unreliable in patients with lymph nodes containing 
macrometastases detected with HE staining. All studies regarding the first four blue 
nodes as the real SNs showed low false-negative rates. We should bear in mind 
that SNM in CRC is mainly intended to facilitate OTC assessment, suggesting that 
the few studies reporting that the SN concept is applicable to HE node-negative 
CRC need confirmation. A uniform protocol regarding the technical aspects of 
SNM is mandatory. Therefore, in the current situation, OTC assessment combined 
with SNM has to be considered merely an experimental diagnostic strategy. The 
formulation of transatlantic working parties may aid in tackling this problem by 
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ABSTRACT
Background: A number of patients with colorectal liver metastases who 
undergo locoregional treatment, show progressive disease after surgery. These 
patients might benefit from additional systemic chemotherapy. The aim of this 
study was to identify these high-risk patients by bone marrow analysis for the 
presence of disseminated tumor cells.
Patients and methods: Bone marrow was aspirated prior to surgery from 81 
colorectal cancer patients scheduled for liver tumor resection or isolated liver 
perfusion and 59 control patients who were operated on for benign diseases. 
Samples were analyzed with quantitative reverse transcriptase-polymerase 
chain reaction (RT-PCR) for the expression of cytokeratin 20 (CK20) and with 
immunocytochemistry (CK-ICC) combined with automated microscopy by use of 
anti-cytokeratin antibodies A45-B/B3. 
Results: Bone marrow samples in 7 of 43 control patients and 26 of 69 
colorectal liver metastases patients tested positive with the CK20 RT-PCR (Chi-
square test, 16% vs 38%, P = 0.016). The CK-ICC test was positive in 6 of 59 
control patients and in 15 of 69 colorectal liver metastases patients (Chi-square 
test, 10% vs 22%, P = 0.078). In a multivariate Cox regression analysis a 
positive CK20 RT-PCR test (hazard ratio 2.5, 95 per cent confidence interval 1.2 
to 5.2, P = 0.014) and a serum carcinoembryonic antigen level higher than 200 
micrograms per liter (hazard ratio 2.4, 95 per cent confidence interval 1.0 to 5.9, 
P = 0.045) were independent predictors for a reduced disease-related survival. 
No correlations between survival and a positive CK-ICC test were found. 
Conclusions: Disseminated tumor cells in bone marrow of patients with 
colorectal liver metastases detected by CK20 RT-PCR is associated with a worse 
clinical outcome. However, also numerous control patients had positive bone 
marrow both by RT-PCR and immunocytochemistry. Therefore research on more 
specific antibodies or molecular markers is required. Detection of disseminated 
tumor cells in bone marrow by CK20 RT-PCR may aid in improving individual 
patient’s treatment.
INTRODUCTION
Locoregional treatment of colorectal cancer metastases confined to the liver 
contributes to improved survival and can even lead to cure. Surgical resection 
is as yet the only effective curative treatment.1;2 Patients with unresectable liver 
metastases can be treated with isolated hepatic perfusion.3 The reported 3-year 
survival of patients treated with surgical liver resection ranges from 57% to 73%4;5 
and patients treated with isolated hepatic perfusion show a 3-year survival of 37%.6 
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A high percentage of patients who have undergone locoregional treatment for 
colorectal liver metastases show progressive disease, i.e. progression within the 
liver and/or extrahepatic relapse, within a relatively short period of time after 
locoregional treatment. These high-risk patients might benefit from additional 
systemic treatment.7 Although colorectal cancer usually does not metastasize to 
the bone, disseminated tumor cells found in bone marrow could predict disease 
outcome since their presence might represent the aggressive nature of the 
tumor.8;9 
The aim of this study was to assess whether the presence of disseminated tumor 
cells in bone marrow from patients who undergo locoregional treatment of colorectal 
liver metastases is associated with a worse outcome of disease. The presence of 
disseminated tumor cells in bone marrow was analyzed using quantitative reverse 
transcriptase-polymerase chain reaction (RT-PCR) for cytokeratin 20 (CK20) and 
immunocytochemistry (CK-ICC) combined with automated microscopy by using 
antibodies A45-B/B3 which recognize cytokeratins 8, 18 and 19.
PATIENTS AND METHODS
Patients
Between October 2001 and May 2005, a total of 81 consecutive patients with 
colorectal liver metastases scheduled for resection or isolated hepatic perfusion at 
the Department of Surgery at the Leiden University Medical Center were included. 
All patients had previously undergone a resection of their primary colorectal tumor 
and underwent preoperative chest and abdominal computed tomography (CT) to 
confirm metastatic disease confined to the liver. CT was performed using a helical 
scanner (SR7000 or AVE; Philips Medical System, Best, The Netherlands). Non-
enhanced and contrast-enhanced (150 ml non-ionic agent, 350 mg iodine per ml, 
using power injection at 3 ml/s via the antecubital vein, fixed delay 60 s) images 
of the liver were obtained. After scanning the liver, the remainder of the abdomen 
was scanned. Eligibility and exclusion criteria for the scheduled treatment and 
criteria for disease progression within the liver according to the WHO guidelines 
have been previously published.1;6;10 During follow-up, CT-scans were made 4, 8 
and 12 months after surgery and then after every 12 months until 3 years after 
surgery except for patients who underwent an isolated hepatic perfusion. These 
patients were permanently followed by CT-scans. Patients who did not undergo 
any intervention and patients who showed disease progression and could not be 
surgically treated, were referred to a medical oncologist for further treatment. 
Bone marrow samples from 59 control patients who were operated on for 
benign diseases such as inflammatory bowel diseases (n = 31), diverticulosis/-itis 
(n = 8), cholelithiasis or cholecystitis (n = 13), hernia inguinalis or cicatricalis 
(n = 6) or endometriosis externa (n = 1) were assessed. Approval from the Ethical 
Committee for this study was granted and informed written consent was obtained 
from all patients. No complications were seen after bone marrow aspiration. 
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Bone marrow aspiration 
Twenty to 30 ml of bone marrow was aspirated from the anterior iliac crest prior 
to surgery under general anesthesia. Prior to inserting the needle in the anterior 
iliac crest, an incision was made into the overlying skin to prevent contamination 
with skin epithelial cells. Mononuclear cells were isolated from bone marrow using 
ficoll gradient centrifugation and aliquoted to isolate RNA for the RT-PCR analysis 
or to make cytospin-slides to stain with ICC. 
Quantitative reverse transcriptase-polymerase chain reaction 
Total RNA was extracted from mononuclear cells by Trizol reagent (Invitrogen, 
Breda, The Netherlands) according to the manufacturer’s instructions. Random 
primed cDNA was synthesized from 1 µg of total RNA using the 1st strand cDNA 
synthesis kit for RT-PCR (AMV) (Roche, Indianapolis, USA). cDNA samples 
were five times diluted to 100 µl to diminish pipetting variation. Primers and 
probes for the marker CK20 were selected with Primer Express®v1.5 software 
(Applied Biosystems, Foster City, California, USA). The forward sequence of 
the CK20 primer was 5’-gagctgagacgcacctccc-3’ and the reverse sequence was 
5’-gggcctccagagagctcaac-3’ leading to a product with an amplicon length of 132 
base pairs. The sequence of the probe was 5’-TET-accaaggcccgttacagcagccagt-
TAMRA-3’. The low-copy housekeeping gene porphobilinogen deaminase was 
used as an internal control. The forward primer sequence for porphobilinogen 
deaminase was 5’-ggcaatgcggctgcaa-3’ and the reverse primer sequence was 
5’-gggtacccacgcgaatcac-3’ leading to a product with an amplicon length of 63 
base pairs. The probe sequence for porphobilinogen deaminase was 5’-TET-
ctcatctttgggctgttttcttccgcc-TAMRA-3’. For each patient two RNA samples resulting 
in cDNA samples were processed. Five microliters of cDNA (equivalent to 0.05 μg 
total RNA) were used per amplification. For all PCRs the following PCR conditions 
were used: after activation of the polymerase (10 min. at 95°C) 55 cycles of 
15 sec at 95°C, 30 sec at 65°C and data collection at an additional 30 sec at 
65°C were performed. Probe concentrations were 120 nM for porphobilinogen 
deaminase and 160 nM for all other markers, reporter dye is TET and quencher 
TAMRA for all probes. Per reaction 300nM of each primer was used. Magnesium 
concentrations were 4 mM for porphobilinogen deaminase and CK20. Quantitative 
PCR was performed on an ABI PRISM® 7700 Sequence Detector System (Applied 
Biosystems) using the qPCR™ Core Kit (Eurogentec, Seraing, Belgium) and 
analyzed using SDS v. 1.7 software package (Applied Biosystems). 
The sensitivity of these tests was determined by spiking tumor cells from the 
colon cancer cell line CCL-218 in bone marrow from a patient undergoing surgery 
for a benign disease. Serial five-fold dilutions were made with a total number of 
2x106 cells per sample. Each sample was amplified four times to determine the 
reproducibility of the detection. CK20 RT-PCR resulted in positive results for bone 
marrow samples with one CCL-218 cell.
Disseminated tumor cells in bone marrow 111
Cytospin-slides and immunocytochemistry
Mononuclear cells were washed twice with phosphate buffered saline (PBS), 
and diluted in PBS to a concentration of 0.5 x 106 cells per ml (containers from 
Greiner Bio-One). Four ml of this suspension were evenly spread onto Histobond® 
adhesion micro slides (Marienfeld, Lauda-Königshofen, Germany) through 
cytocentrifugation in centrifugation buckets (home made by the Department of 
Molecular Cell Biology, Leiden University Medical Center, Leiden, The Netherlands). 
Centrifugation was at 190g for 10 minutes in a swing-out rotor, with a controlled 
start and brake (Hettich, Tuttlingen, Germany) resulting in 2 million cells per 
glass slide. Slides were dried overnight at 37oC and stored at –70oC. The slides 
were stained with primary antibodies A45-B/B3 (diluted 1:100), directed against 
cytokeratins 8, 18 and 19 (Micromet AG, Munich, Germany) or with isotype control 
antibodies directed against an irrelevant antigen, MOPC21, as a negative control 
staining (diluted 1:200) (BD Pharmingen, Erembodegem, Belgium). A detailed 
protocol in a comparative immunostaining study of bone marrow specimens has 
been published before by Pantel et al.11 This staining resulted in a red precipitate 
in the cytoplasm of cytokeratin-positive cells. The slides were counterstained with 
hematoxylin (Mayer’s Hemalum; Merck, Darmstadt, Germany) to visualize nuclear 
morphology. The detection limit of CK-ICC was previously found to be up to one 
tumor cell among 1.87 x 106 hematopoietic cells.12
Automated microscopy
The stained slides were analyzed using the ARIOL SL-50 automated microscope® 
(Applied Imaging Corporation, San Jose, CA). One slide stained for cytokeratin 
and one negative control (MOPC21) slide were analyzed per patient. The features 
of this system have been previously published.13 
Data definition 
A PCR sample was considered positive if the threshold cycle was less than 55. The 
threshold cycle reflects the PCR cycle number at which the fluorescence generated 
within a reaction crosses the threshold (background noise). The threshold cycle is 
inversely proportional to the copy number of the target template i.e. the higher 
the template concentration, the lower the threshold cycle measured. Bone marrow 
from a patient was considered positive if at least one of the PCR samples was 
positive. In case of immunocytochemistry combined with automated microscopy, 
cytokeratin-positive cells were confirmed by a pathologist (AMvL) and categorized 
into tumor cells, candidate tumor cells, apoptotic cells or hematopoietic cells, 
based on morphological criteria according to the guidelines of the European 
ISHAGE Working Group for Standardization of Tumor Cell Detection.14;15 Candidate 
tumor cells and apoptotic cells were cells that did not meet all criteria for a positive 
cell but could not be unambiguously defined as normal. A patient was considered 
positive if at least one tumor cell, candidate tumor cell or apoptotic cell was found. 
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Statistical analysis
Statistical analysis was carried out using SPSS software, version 12.0.1 
(SPSS Inc, Chicago, Illinois, USA). Numerical data are presented as mean + 
standard deviation. Endpoint was disease-related survival. Correlation between 
clinicopathologic features and test results was assessed by a Chi-square test. 
Disease-related survival was considered from the day of surgery to the day of 
death due to disease or censored at most recent follow-up visit. Patients who 
did not undergo locoregional treatment, who showed extrahepatic disease at the 
time of surgery or who died after the operation due to complications or none 
disease-related causes were excluded from disease-related survival analyses. 
Cox regression analysis was used to calculate univariate and multivariate hazard 
ratio’s (HR) with corresponding 95 per cent confidence intervals (CI) and p-values 
(P). Differences in disease-related survival between the groups were presented as 
mean + standard error and were compared by the logrank test. A p-value of less 
than 0.05 was considered statistically significant. Factors with a (overall) p-value 
less than 0.10 in the univariate analysis were entered into the multivariate logistic 
or Cox regression model. 
RESULTS
Patient and treatment characteristics
Patient characteristics and the type of surgical intervention are shown in Table 
1. Twenty-two of 81 patients did not undergo the planned locoregional treatment 
because of the presence of extrahepatic disease (n = 14) or insufficient vital liver 
tissue (n = 5). Resection could not be performed in three patients because of the 
high number of metastases (n = 2) or the location of the metastasis to the portal 
vein (n = 1). In one patient who had undergone complete resection of two liver 
metastases, a resected suspicious lesion on the diaphragm was a metastasis. 
Four patients had undergone resection of lung metastases and 30 patients had 
received systemic chemotherapy for liver disease before locoregional treatment. 
The time interval between the end of the chemotherapy and surgery ranged from 
3 weeks to 13 months with a median of 10 weeks. Patients were successfully 
followed until October 2008. Sixty-five (80%) of 81 patients died during follow-up. 
The median follow-up from the date of diagnosis of the primary tumor of patients 
alive (n = 16) was 5.4 years with a range of 3.6 to 10.7 years. From the date of 
liver surgery of patients alive (n = 16), the median follow-up was 4.2 years with 
a range of 3.1 to 6.9 years.
Results of quantitative RT-PCR and CK-ICC (immunocytochemistry 
combined with automated microscopy)
Due to a sometimes low number of harvested mononuclear cells, bone marrow 
of not all 59 control patients and 81 colorectal liver metastases patients could 
be analyzed with both RT-PCR and CK-ICC. Bone marrow samples of 43 control 
patients were analyzed with RT-PCR and bone marrow samples of all 59 control 
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patients were analyzed with immunocytochemistry combined with automated 
microscopy. Samples of 81 colorectal liver metastases patients were analyzed 
with RT-PCR (n = 69) and or immunocytochemistry combined with automated 
microscopy (n = 69). 
Bone marrow samples in 7 of 43 control patients and 26 of 69 colorectal liver 
metastases patients tested positive with the CK20 RT-PCR (Chi-square test, 16% 
vs 38%, P = 0.016). CK20 expression was seen in 5 (25%) of 20 patients who 
underwent resection, 15 (56%) of 27 patients who underwent an isolated hepatic 
perfusion and 6 (27%) of 22 patients who underwent no intervention. 
By using CK-ICC, bone marrow samples tested positive in 6 of 59 control patients 
and in 15 of 69 colorectal liver metastases patients (Chi-square test, 10% vs 
22%, P = 0.078). Bone marrow from control patients was found positive due to 
the presence of tumor cells (n = 1), candidate tumor cells (n = 1) or apoptotic 
cells (n = 4). For patients with liver metastases, bone marrow analysis resulted 
in the presence of tumor cells (n = 4), candidate tumor cells (n = 7) or apoptotic 
cells (n = 7) (Figure 1). A positive CK-ICC test was seen in 5 (23%) of 22 patients 
who underwent a resection, 3 (10%) of 31 patients who underwent an isolated 
hepatic perfusion and 7 out of 16 (44%) patients who underwent no intervention. 
Bone marrow of 43 control patients and of 57 colorectal liver metastases patients 
Figure 1. Cytokeratin-positive cells in preoperatively aspirated bone marrow, 
considered as (A) a tumor cell (B) a candidate tumor cell (C) an apoptotic cell and (D) a 
hematopoietic cell according to the guidelines of the European ISHAGE Working Group for 
Standardization of Tumor Cell Detection.14 
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Mean age (yrs)a 58.6 + 8.9





Nodal status of primary tumor
Negative 27 33
Positive 54 67
Time span between PT and LM (months)
< 12 58 72








< 200 µg/l 64 79
> 200 µg/l 16 20
not assessed 1 1
Number of liver metastasesc
< 4 22 27
> 4 59 73
Maximal diameter of liver metastases (cm)c
< 5 59 73






Isolated liver perfusion 33 41
No intervention 22 27
PT, primary tumor; LM, liver metastases; CEA, carcinoembryonic antigen; a Presented as mean + standard 
deviation; b Lung metastases had been resected before locoregional treatment of liver metastases; c Serum 
CEA level was dichotomized according to Fong et al.4 and the number of metastases and maximal diameter 
were dichotomized according to Nordlinger et al.10
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were analyzed by both CK-ICC and CK20 RT-PCR. The data obtained from patients 
and controls that were analyzed using both tests, showed no significant correlation 
between the CK-ICC test and the CK20 RT-PCR test (Chi-square test, P = 0.948 
and P = 0.811, respectively), which may relate to the difference in techniques and 
markers used.
Correlation with clinicopathological parameters
With CK20 RT-PCR significantly more patients diagnosed with four or more liver 
metastases had bone marrow samples tested positive as compared to patients with 
less than four liver metastases (Chi-square test, 23 of 50 vs 3 of 19, P = 0.021).
With CK-ICC significantly more patients with extrahepatic metastases at time of 
surgery had a positive bone marrow as compared to patients without extrahepatic 
metastases (Chi-square test, 6 of 12 vs 9 of 57, P = 0.009). No significant 
difference in extrahepatic metastases at the time of surgery was seen between 
CK20 RT-PCR positive and negative patients (Chi-square test, 4 of 26 vs 11 of 43, 
P = 0.320). 
No significant difference in the CK-ICC test (Chi-square test, P = 0.067) or 
CK20 RT-PCR (Chi-square test, P = 0.683) was seen between the patient group 




We analyzed whether a positive CK-ICC or CK20 RT-PCR test could predict disease-
related survival. Twenty-two patients who did not undergo the planned locoregional 
treatment and four treated patients who died because of none disease-related 
causes were excluded for analysis leading to a total of 55 patients. 
An univariate analysis for disease-related survival showed a serum 
carcinoembryonic antigen (CEA) level higher than 200 micrograms per liter, four 
or more liver metastases, isolated liver perfusion and a positive CK20 RT-PCR test 
to be prognostic factors (Table 2). These variables were entered in the multivariate 
analysis. A positive CK20 RT-PCR test (HR 2.5, 95% CI 1.2 to 5.2, P = 0.014) 
and a serum CEA level higher than 200 micrograms per liter (HR 2.4, 95% CI 1.0 
to 5.9, P = 0.045) were demonstrated to be independent predictors for reduced 
disease-related survival in a multivariate analysis. From the diagnosis of the 
primary tumor, a median disease-related survival of 4.6 years (range 1.5 to 10.7 
years) was seen for patients with a negative CK20 RT-PCR test (n = 25) compared 
to 3.5 years (range 1.0 to 6.2 years) for patients with a positive CK20 RT-PCR test 
(n = 18) (Logrank test, P = 0.010). A serum CEA level of 200 micrograms or less 
per liter (n = 45) led to a median disease-related survival of 4.2 years (range 1.1 
to 10.7 years) compared to 2.1 years (range 1.0 to 4.6 years) if serum CEA higher 
than 200 micrograms (n = 10) (Logrank test, P = 0.001).
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DISCUSSION
This study shows that a positive CK20 RT-PCR test in bone marrow and a serum CEA 
level higher than 200 micrograms per liter were independent predictors of reduced 
disease-related survival. We found similar results as published by Koch et al.16 who 
examined bone marrow samples from 25 patients with colorectal liver metastases 
who underwent surgical resection. They found a positive CK20 RT-PCR test to be an 
independent prognostic factor for recurrence-free survival. Vlems et al.17 analyzed 
bone marrow from 22 patients undergoing hepatic resection for colorectal liver 
metastases. They showed that patients without treatment with chemotherapy 
before liver resection did not have CK20 RT-PCR positive bone marrow samples. 
Table 2. Univariate analysis for disease-related survival (n=55)a
Disease-related survival
Characteristics HR 95% CI P
TNM stage of primary tumor .680b
1 1
2 0.7 (0.2-3.0) .653
3 0.6 (0.2-2.3) .487
4 0.5 (0.2-1.7) .277
Nodal status of primary tumor
Positive vs negative 1.4 (0.7-2.8) .303
Time span between PT and LM (months)
< 12 vs > 12 1.3 (0.7-2.7) .429
Preoperative systemic chemotherapy
No vs yes 0.7 (0.4-1.3) .214
Serum CEA levelc
> 200 µg/l vs < 200 µg/l 3.2 (1.5-6.6) .002
No of liver metastasesc
> 4 vs < 4 2.1 (1.0-4.4) .038
Maximal diameter of liver metastases (cm)c
> 5 vs < 5 1.2 (0.6-2.3) .583
Surgical intervention
Resection 1
Isolated liver perfusion 2.1 (1.1-4.0) .025
CK20 RT-PCR test in bone marrow (n=43)
Positive vs negative 2.6 (1.3-5.5) .009
CK-ICC test in bone marrow (n=49)
Positive vs negative 0.9 (0.3-2.3) .800
PT, primary tumor; LM, liver metastases; CEA, carcinoembryonic antigen; CK20, cytokeratin 20; HR, hazard 
ratio; CI, confidence interval; The second category is used as the reference category; a Patients who did not 
undergo locoregional treatment (n=22) or patients with extrahepatic disease at the time of surgery (n=15) 
or patients who died due to none disease-related causes (n=6) were excluded from this analysis; b Overall 
P value; c Serum CEA level was dichotomized according to Fong et al.4 and the number of metastases and 
maximal diameter were dichotomized according to Nordlinger et al.10
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In contrast, in our study no difference in RT-PCR test results was observed 
between patients with and without preoperative chemotherapy. This finding 
may be explained by the use of quantitative RT-PCR in our study compared to 
conventional RT-PCR in their study. Another explanation might be the time interval 
between the end of the chemotherapy and surgery. In our study, a median of 3 
months was found compared to one month in the study by Vlems et al.17 The 
additional value of our study compared to the above-mentioned studies lies in the 
sensitive detection techniques we used i.e. quantitative RT-PCR and CK-ICC and in 
the number of patients studied. Although, our patient study group did not consist 
of patients treated with resection only but also with isolated hepatic perfusion, we 
found similar results in the patient group who underwent resection of colorectal 
liver metastases.
Previous studies have developed a prognostic clinical MSKCC score (Memorial 
Sloan-Kettering Cancer Center) to assist in colorectal cancer patient selection 
for liver tumor resection.4;10;16 This clinical score consists of the following 
clinicopathological parameters predicting a worse clinical outcome: a positive 
nodal status of the primary tumor, less than 12 months between the primary tumor 
and the liver metastases, 4 or more liver metastases, metastases diameter more 
than 5 cm and serum CEA level higher than 200 micrograms per liter. When our 
results are confirmed in a larger patient set, the analysis of bone marrow samples 
could be added to this clinical score. Moreover, in cases in which the preoperative 
evaluation concluded that resection was not feasible and isolated hepatic perfusion 
was the only option, results from bone marrow analysis might be useful in making 
treatment decisions. Since curation or significant improvement of survival by 
isolated hepatic perfusion has yet to be unequivocally proven one might consider 
a strategy without surgical locoregional treatment in those cases that have a high 
risk for a reduced survival or to combine it upfront or after surgery with systemic 
treatment. Recently was reported that perioperative additional treatment with 
oxaliplatin, leucovorin and 5-fluorouracil improved progression free survival over 
surgery alone in patients whose metastases were actually resected.18
No relation between a positive CK-ICC test and disease-related survival was seen 
in our study whereas a positive CK-ICC test did correlate with the presence of 
extrahepatic disease at the time of surgery. Also, no correlation was seen between 
the CK-ICC test and the CK20 RT-PCR test. Several facts must be taking into 
consideration in trying to explain the difference between CK-ICC and RT-PCR 
test results. First, different markers were used for the tests. Primers specific for 
CK20 for RT-PCR and antibodies recognizing CK8, 18 and 19 for CK-ICC were 
used. Second, RNA which more likely represents active production of cytokeratin 
might be produced by colon-cancer-initiating cells whereas CK-ICC may detect 
differentiated tumor cells with already intracellular produced cytokeratin.19 
Recently, it was shown that undifferentiated colon-cancer-initiating cells which did 
not show CK20 protein expression were responsible for the tumorigenic potential 
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whereas differentiated colon cancer cells immunohistochemically stained with 
anti-CK20 antibodies had lost their ability to form tumors in immunocompromised 
mice.20 For breast cancer, tumor cells detected with the CK-ICC test are found to be 
of major prognostic significance.21 The bone marrow of these cancer patients not 
just reflects the spread of metastases but is also a site for metastases outgrowth. 
This may relate to the possibility that the bone marrow compartment offers a 
more fertile microenvironment for breast cancer cells than for colorectal cancer 
cells.22 Nonetheless, we found the CK20 RT-PCR test in bone marrow of patients 
with colorectal liver metastases to be of prognostic value.
Curiously, bone marrow from a number of control patients also tested positive 
with both the CK-ICC and the CK20 RT-PCR tests. These control patients did not 
have a malignant disease. Other groups report false positive percentages as high 
as 22%-61%.15 Contamination or cross-reactivity of the monoclonal antibody with 
related epitopes present on hematopoietic cells or circulating normal epithelial 
cells can be responsible. For immunocytochemistry the morphological examination 
of immunostained cells is therefore essential and for this reason standardized by 
the International Society for Cellular Therapy Committee (ISHAGE).14;15 Several 
studies have shown that careful morphological examination is essential to identify 
the prognostic relevance of cytokeratin positive cells.21;23 In our study, we saw 
a correlation between a positive CK-ICC test and the presence of extrahepatic 
disease at the time of surgery but no prognostic significance was found of a 
CK-ICC test in the patient group who underwent locoregional treatment for their 
colorectal liver metastases.
In conclusion, the presence of disseminated tumor cells in bone marrow detected 
with CK20 RT-PCR, is associated with a worse clinical outcome. Disseminated 
tumor cells in bone marrow detected with the CK-ICC test failed to show prognostic 
significance. CK20 RT-PCR may therefore be a more valuable diagnostic tool than 
the CK-ICC test in patients with colorectal liver metastases. The fact, however, 
that numerous control patients had positive bone marrow both by RT-PCR and 
CK-ICC stresses the need for research on more specific molecular markers or 
antibodies. The analysis of preoperatively aspirated bone marrow from patients 
with colorectal liver metastases for the presence of disseminated tumor cells may 
have additional value to the current clinicopathological characteristics in identifying 
high-risk patients who may benefit from additional systemic treatment.
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ABSTRACT 
Background: Up to 30% of curatively resected colorectal cancer patients with 
tumor-negative lymph nodes, show disease recurrence. We assessed whether 
these high-risk patients can be identified by examining primary tumors for the 
following blood and lymphatic vasculature markers: A) sialyl Lewis X (sLeX), 
vascular endothelial growth factor (VEGF)-C and VEGF-D expression; B) blood 
and lymphatic microvessel density (BMVD/LMVD); and C) the presence of blood 
and lymphatic vessel invasion. 
Patients and methods: Thirty-six cases (disease recurrence within 5 years) 
and 72 controls (no disease recurrence for at least 5 years) were selected in a 
case-control design. Tumor sections were stained by antibodies CSLEX1 (sLeX), 
anti-VEGF-C, anti-VEGF-D, anti-CD31 (BMVD) or D2-40 (LMVD) to determine 
the parameters as mentioned above.
Results: A multivariate analysis showed sLeX expression and high LMVD (odds 
ratio 5.1, 95% confidence interval 1.3-20.0 and odds ratio 3.1, 95% confidence 
interval 1.0-10.0, respectively) to be independent factors predicting disease 
recurrence. Expression of sLeX correlated with liver metastases (P = 0.015). A 
high LMVD was related to regional intra-abdominal or intrapelvic metastases in 
lymph nodes and distant metastases other than in the liver and lungs such as 
peritoneum, bones, brain and adrenal glands (P = 0.004). A high BMVD in the 
invasive front correlated with lung metastases (P = 0.018). 
Conclusions: We show that high-risk node-negative colorectal cancer patients 
can be identified by primary tumor assessment for sLeX expression and LMVD. 
Our results are consistent with the notion that both lymphatic and hematogenous 
metastasis play a role in colorectal cancer. 
INTRODUCTION
In most countries, patients with curatively resected colorectal cancer (CRC) 
without nodal tumor involvement do not receive adjuvant systemic therapy since 
meaningful survival benefits have not been proven yet.1;2 However, 10 to 30 percent 
of these patients show disease recurrence.3;4 Although, a small survival benefit 
has been reported in stage II CRC patients who received 5-fluorouracil5, adjuvant 
systemic treatment of all node-negative CRC patients will lead to overtreatment 
and unnecessary complications due to adverse effects of the treatment. Providing 
only high-risk patients with adjuvant systemic therapy prevents unnecessary 
treatment and leads to an optimized cure rate. Lymph node-negative CRC patients 
at risk for disease recurrence may be identified by tumor features known to 
determine the process of invasion and metastasis which was the focus of this study. 
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Invasion and metastasis can be facilitated by proteins which stimulate tumor 
cell attachment to host cellular or extracellular matrix determinants, proteolysis 
of extracellular matrix host barriers such as the basement membrane, tumor 
cell migration and formation of distant metastases.6 Tumor cells are expected 
to express similar molecules as leucocytes to interact with blood and lymphatic 
microvessel endothelium. Normally, the blood group-related antigen sialyl Lewis 
X (sLeX) is located on the membrane of neutrophils and binds to the endothelial 
leukocyte adhesion molecule-1 also known as E-selectin which leads to neutrophil 
extravasation and migration into tissue.7 In cancer, the interaction of sLeX on 
tumor cells and E-selectin was shown to mediate adhesion of tumor cells to 
endothelial cells.8 Previous publications have reported high sLeX expression on 
tumor cells to be a prognostic factor in colorectal cancer.9;10 
The vascular endothelial growth factor (VEGF) family has been reported to be 
involved in the formation of blood and lymphatic microvessels11 through which 
tumor cells disseminate. The VEGF family includes five ligands: VEGF-A, VEGF-B, 
VEGF-C, VEGF-D, and placenta growth factor and three receptors: VEGFR-1, 
VEGFR-2, and VEGFR-3.12 Studies have shown that VEGF-C and VEGF-D, which 
are ligands for VEGFR-3, can induce tumor lymphangiogenesis and lymphatic 
metastasis.13;14 
Also, the number and tumor invasion of blood and lymphatic microvessels have 
been shown to play a role in the process of metastasis.15-17 
In this study, we examined whether disease recurrence in lymph node-negative 
CRC patients could be predicted by assessing their primary tumors for: A) the 
expression of angiogenic and lymphangiogenic factors, sLeX, VEGF-C, and 
VEGF-D; B) blood and lymphatic microvessel density; and C) the presence of 
blood and lymphatic vessel invasion. 
PATIENTS AND METHODS
Patients
Between January 1981 and December 2001, 1044 patients underwent surgery for 
a primary CRC at the Leiden University Medical Center. For the present study, a 
selection was made from the total group of patients with tumor-negative lymph 
nodes (N0) and without metastases (M0) at the time of surgery (n = 506). Patients 
who were operated on their first CRC in another hospital, or who were diagnosed with 
another invasive malignancy before or within five years after the date of diagnosis 
of the primary colorectal carcinoma, and patients who developed a local recurrence 
were excluded for the present study. Cases (n = 36) were defined as patients who 
suffered from regional or distant recurrent disease at least three months after but 
within five years after the date of diagnosis of primary CRC. Cases developed liver 
metastases (n = 23), and/or lung metastases (n = 8), and/or regional metastases 
which were considered intra-abdominal or intrapelvic metastases in lymph nodes 
or in connective tissue (n = 7), and/or peritoneal metastases (n = 5), and/or other 
distant metastases (n = 8). The latter consists of brain, bone or adrenal metastases. 
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Controls were patients who did not develop locoregional or distant disease within 
five years after diagnosis of primary CRC. For each case two controls were matched 
for TNM stage, date of incidence and date of birth, leading to a total number of 
72 controls. Of patients with rectal carcinoma, two had received preoperative and 
three had received postoperative radiotherapy. None of the patients had received 
adjuvant chemotherapy. 
A tumor was considered mucinous when more than 50% of its volume consisted of 
mucinous component. Tumor growth pattern at the invasive margin was classified 
as either expanding also known as pushing or infiltrative based on the predominant 
morphology as defined by Jass et al.18 Clinicopathologic characteristics of patients 
are shown in Table 1.
Immunohistochemistry
Four micron sections were cut from formalin-fixed paraffin-embedded tumors, 
transferred to aminopropylethoxysilane (APES) coated slides, and dried overnight 
at 37°C. One section of each tumor was stained by hematoxylin and eosin (HE). 
Five sections of each tumor were respectively stained with CSLEX1 also known as 
CD15s (Becton Dickinson Pharmingen, San Jose, California, 1:150), a monoclonal 
antibody that binds to sLeX, polyclonal anti-VEGF-C (Zymed, San Francisco, 
Figure 1. CSLEX1, VEGF-C and VEGF-D expression in colorectal tumors. A tumor 
negatively stained (A) and positively stained (B) for CSLEX1; this tumor showed both 
membrane and cytoplasmic brown staining. A tumor with negative (C) and positive 
cytoplasmic brown staining (D) for VEGF-C; similar faint cytoplasmic brown staining as 
shown in negatively stained tumors for VEGF-C was seen in phosphate buffered saline 
controles for the VEGF-C staining; this background staining could be clearly differentiated 
from positive cytoplasmic brown staining for VEGF-C. A tumor with negative (E) and positive 
cytoplasmic brown staining (F) for VEGF-D; a brown stromal background staining was seen.
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California, 1:100), monoclonal anti-VEGF-D (Research and Development Systems, 
Minneapolis, USA, 1:400), monoclonal antibody anti-CD31 (Dako, Glostrup, 
Denmark, 1:300), or monoclonal antibody D2-40 (Signet Laboratories, Dedham, 
MA, USA, 1:100). All primary antibodies were diluted in phosphate-buffered saline 
(PBS) with 1% bovine serum albumine (BSA). As negative control the sections 
were incubated with only PBS/1% BSA. For the immunohistochemical staining 
procedure, the sections were deparaffinized in xylene. Endogenous peroxidase 
was blocked in methanol containing 0.3% hydrogen peroxide at room temperature 
for 20 minutes. Subsequently the sections were rehydrated. After washing in PBS, 
antigen retrieval treatment for the antibodies CSLEX1, anti-VEGF-C and anti-
VEGF-D was done by boiling the sections in 1 mM EDTA (ethylene diamine tetra 
acetic acid, pH 8.0) solution during 10 minutes. Antigen retrieval for anti-CD31 
and D2-40 was done by boiling the sections in a 0.01 M sodium citrate solution (pH 
6.0) during 10 minutes. After applying the primary antibodies, the sections were 
incubated overnight at room temperature. Detection of the antigen was achieved 
by incubating the sections for 30 minutes with the biotinylated rabbit-anti-mouse 
conjugate (Dako, Glostrup, Denmark, 1:200) or with biotinylated swine-anti-
Figure 2. Visualization of lymphatic and blood vessels in colorectal tumors. 
Lymphatic vessels were stained brown when using immunohistochemistry by the antibodies 
D2-40 (A). These lymphatic vessels showed no staining by immunohistochemistry when 
using antibodies CD31 (B). Blood vessels were not recognized by D2-40 (C) but were brown 
stained by CD31 (D).
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rabbit conjugate (Dako, Glostrup, Denmark, 1:400) for VEGF-C and incubation 
for 30 minutes with a streptavidin-biotin-peroxidase conjugate (DAKO, Glostrup, 
Denmark, 1:100). For the staining with anti-CD31 and D2-40, detection of the 
antigen was achieved with Envision (Dako, Glostrup, Denmark). The sections 
were developed in 3,3-di-amino-benzidine tetrahydrochloride (DAB) substrate in a 
buffered 0.05 M Tris/HCl (pH 7.6) solution containing 0.002% hydrogen peroxide 
leading to brown-staining of the antigen. Counterstaining was done with Mayer’s 
Hematoxylin. For microscopic analysis the sections were dehydrated and mounted 
in pertex. Tumor cells positive for sLeX, VEGF-C or VEGF-D and vessels positive 
for CD31 or D2-40 stained brown.
Quantification 
Slides were evaluated by using a standard light microscope. At least two 
investigators (Doekhie, Morreau, Speetjens or Dekker) independently examined 
each staining and discordant cases were re-evaluated to reach consensus. Tissue 
sections which were too much damaged by the staining procedure were excluded 
from further analysis, leading to a variable number of examined slides (Table 2 
and 3).
Sialyl Lewis X staining with CSLEX1 showed immunoreactivity of apical cell 
membranes, cytoplasm of tumor cells and secretory material in luminal spaces 
as reported previously.9 For the sLeX expression the percentage of cytoplasmic 
stained tumor cells and apical membrane stained tumor cells were separately 
estimated at 100x magnification. VEGF-C and VEGF-D expression showed 
cytoplasmic localization. In these stainings, the percentage of cytoplasmic stained 
tumor cells was estimated, also at 100x magnification. 
Microvessel density was assessed in sections stained by anti-CD31 and D2-
40 antibodies, as described previously.15 Three fields with the highest vascular 
density (hot spots) were identified both within intratumoral stroma and the 
invasive front if present, using 50x and 100x magnification. Subsequently, the 
number of vessels was counted using 200x magnification after applying a 10x10 
grid on the hot spots corresponding to an area of 0.25 mm2. All vessels hitting 
two of the sides of the grid were included in the count, whereas vessels hitting 
the other two sides of the grid were excluded from the count, using the principles 
of Gundersen et al.19 Microvessels in the submucosa served as internal controls 
in assessing the quality of staining for CD31 and D2-40. Any immunoreactive 
endothelial cell or endothelial cell cluster that was clearly separated from the 
adjacent microvessels was considered as a single countable microvessel. The 
occasionally found immunoreactive lymphocytes, macrophages, and plasma cells 
were excluded on the basis of the staining pattern and cell morphology. Regions 
of necrosis were excluded from analysis. 
Blood and lymphatic vessel invasion was assessed in HE stained sections 
and in sections stained with antibodies directed against CD31 or D2-40. 
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In HE stained sections, the presence of tumor cells in luminal spaces lined by 
endothelial cells in peritumoral stroma was scored as blood or lymphatic vessel 
invasion. On immunohistochemically stained sections, the presence of tumor cells 
inside a CD31 or D2-40 stained vessel was considered as blood or lymphatic 
vessel invasion. 
Statistical analysis
Statistical analysis was carried out using SPSS software, version 12.0.1 (SPSS 
Inc, Chicago, IL). For both blood and lymphatic vessels, statistical analysis was 
performed using the maximum number of counted vessels in the hot spots as was 
also done in a recent study in which the same antibodies were used.20 Numerical 
data are presented as mean + standard deviation or as median and range in case 
of skewness. The clinicopathologic features of cases and controls were compared 
either by a Chi-square test, Student T-test or Mann-Whitney test. Univariate and 
multivariate odds ratio’s (OR), 95% confidence intervals (95% CI) and p-values 
(P) were calculated by applying logistic regression analysis with patient’s clinical 
outcome as dependent variable. Parameters with a (overall) p-value less than 0.10 
in the univariate analysis were entered into the multivariate logistic regression 
model.
RESULTS
Standard patient and histopathological characteristics
No significant difference in sex, T stage, tumor size, tumor location, tumor 
differentiation, mucinous tumors, number of harvested lymph nodes and serum 
CEA level was seen between the case and control group. We did see that patients 
from the case group were significantly more often identified with tumors showing 
an infiltrative growth pattern in comparison to patients from the control group 
(Chi-square test, 41% vs 21%, P = 0.031). Patient characteristics are shown in 
Table 1 and univariate analysis of clinicopathological characteristics is shown in 
Table 4.
Expression of sialyl Lewis X, VEGF-C and VEGF-D
Membrane and cytoplasmic staining for CSLEX1 were scored separately. 
Membrane and cytoplasmic staining respectively was seen in 91 and 74 of 99 
examined CSLEX1 stained sections. Significantly more cases than controls showed 
cytoplasmic staining for CSLEX1 (Chi-square test, 91% vs 67%, P = 0.012) (Table 
2). No difference in membrane staining was seen between the case and control 
group.
More cases than controls were identified with cytoplasmic positively stained tumor 
cells for VEGF-C (Chi-square test, 44% vs 27%, P = 0.093) and VEGF-D (Fisher’s 
exact test, 21% vs 6%, P = 0.039) (Table 2). Representative immunohistochemical 
stainings for CSLEX1, VEGF-C and VEGF-D are shown in Figure 1. Cytoplasmic 
background staining was seen in negative controles for the VEGF-C staining. 
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Tumors negative for VEGF-C showed similar background staining which could 
be clearly differentiated from positive staining for VEGF-C (Figure 1C, D). The 
univariate analysis of these angiogenesis and lymphangiogenesis-related tumor 
cell markers is shown in Table 2. 
Blood and lymphatic microvessel density
We choose to count blood and lymphatic microvessels in three hot spots (i.e. fields 
with the highest vascular density) located in intratumoral stroma and three hot 
spots at the invasive front. Blood microvessels stained by anti-CD31 antibodies 
were seen in tumor stroma or the invasive front in all of 96 analyzed primary 
tumors (100%) and lymphatic microvessels stained by D2-40 antibodies were 
seen in 78 of 96 (81%) analyzed primary tumors. As previously shown21;22, we 
found that anti-CD31 antibodies did not stain D2-40 positive lymphatic vessels 
and vice versa (Figure 2). We counted more blood microvessels (39 + 12; median 
37; range 12 to 80) than lymphatic microvessels (14 + 9; median 15; range 
Figure 3. Tumor cell invasion in lymphatic and blood vessels in colorectal tumors. 
Lymphatic vessel invasion seen on a hematoxylin and eosin stained section (A) and 
immunohistochemically stained section by the antibodies D2-40 (B); lymphatic vessels were 
brown stained by D2-40. Blood vessel invasion seen on a hematoxylin and eosin stained 
section (C) and immunohistochemically stained section by the antibodies CD31 (D); blood 
vessels were brown stained by CD31.
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Characteristics n % n % n % Pa
Sex
Female 53 49 16 44 37 51 .496
Male 55 51 20 56 35 49
Age (years)b 67  + 12 67  + 12 67  + 12 .911c
TNM staged
I 6 6 2 6 4 6 1.000e
II 102 94 34 94 68 94
T stagef
T2 6 6 2 6 4 6 .126
T3 88 82 26 72 62 86
T4 14 13 8 22 6 8
Tumor size (cm) (n=104)b, g 5.1  + 2.0 4.9 + 1.9 (n=34) 5.2 + 2.1 (=70) .539c
Tumor location
Colon (coecum – sigmoid) 89 82 30 83 59 82 .858
Rectum (rectosigmoid – 
rectum)
19 18 6 17 13 18
Differentiation
Good 27 25 9 25 18 25 .912
Moderate 68 63 22 61 46 64
Poor 13 12 5 14 8 11
Mucinous
No 98 91 32 89 66 92 .728e
Yes 10 9 4 11 6 8
Growth pattern (n=97)h
Expanding or pushing 70 72 20 60 50 79 .031
Infiltrating 27 28 14 41 13 21
Number of lymph nodesi 6 (1-26) 6 (1-18) 6 (1-26) .096j
Preoperative serum 
CEA level (n=43)k
< 6 µg/l 30 70 5 56 25 74 .417e
> 6 µg/l 13 30 4 44 9 26
CEA, carcinoembryonic antigen; a Chi-square test of cases vs controls, unless mentioned otherwise; 
b Presented as mean + standard deviation; c Student T-test; d According to the 6th edition of the TNM 
classification39; e Fisher’s exact test; f If T2 and T3 stage were combined, the P value was 0.043; this 
comparison was therefore used in the logistic regression; g Tumor size could not be found in pathology 
reports from four patients; h Patients were excluded from analysis if no invasive front was found in 
primary tumor sections; i Presented as median and range between brackets; j Mann-Whitney test; 
k Serum CEA had been determined in only 43 of 108 patients as it was not a standard procedure.
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0 to 42). Patients with more than 46 blood microvessels in the invasive front 
(high BMVD) were more often seen in the case than in the control group (Fisher’s 
exact test, 25% vs 10%, P = 0.077), but it did not reach signifance (Table 3). 
Significantly more patients with more than 20 lymphatic microvessels in tumor 
stroma or invasive front (high LMVD) were seen in the case group than in the 
control group (Chi-square test, 33% vs 14%, P = 0.027) (Table 3). 
Concluding, overall more blood microvessels than lymphatic microvessels were 
observed. In the case group, a higher number of blood and lymphatic microvessels 
was seen compared to the control group.  
Blood and lymphatic vessel invasion
Blood and lymphatic vessel invasion detected on HE stained sections will be 
referred to as morphological vaso-invasion. In 49 of 108 (45%) primary tumors, 
morphological vaso-invasion was found. 
Lymphatic vessel invasion was seen in 8 of 96 (8%) D2-40 stained tumor sections 
(Figure 3A, B) and blood vessel invasion was only seen in one of 96 (1%) sections 
stained with antibodies directed against CD31 (Figure 3C, D). Seven of the 8 
patients with lymphatic vessel invasion detected on the D2-40 stained sections 
had been recognized on the HE stained sections and the one tumor with blood 
vessel invasion was also seen on the HE stained section. These results show that 
morphological vaso-invasion scored on HE stained sections overestimated the 
actual blood and lymphatic vessel invasion as seen after immunohistochemical 
staining.
Table 2. Sialyl Lewis X and vascular endothelial growth factor C and D cytoplasmic staining 
in primary colorectal tumors (n=99)a
All patients Cases Controls Univariate analysis
n % n % n % Pb OR 95% CI P
CSLEX1
Negative 25 25 3 9 22 33 .012 1
Positive 74 75 29 91 45 67 4.7 (1.3-17.2) .019
VEGF-C
Negative 67 68 18 56 49 73 .093 1
Positive 32 32 14 44 18 27 2.1 (0.9-5.1) .096
VEGF-D
Negative 88 89 26 79 62 94 .039c 1
Positive 11 11 7 21 4 6 4.2 (1.1-15.5) .033
VEGF, vascular endothelial growth factor; OR, odds ratio; CI, confidence interval; a Primary tumors 
from three controls could not be retrieved from the archive and tissue sections which were destroyed 
after staining were excluded from analysis leading to a lower number of examined slides; b Chi-square 
test of cases vs controls, unless mentioned otherwise; c Fisher’s exact test.
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Relation between studied variables 
We assessed mutual correlation between the different markers that were 
investigated. We found that 10 of 11 tumors showing positive staining for VEGF-D 
were also positive for VEGF-C (Chi-square test, P < 0.001). 
Significantly more patients with positively stained tumor cells for VEGF-C showed 
a high LMVD compared to patients negative for VEGF-C (Chi-square test, 11 of 31 
vs 8 of 59, P = 0.015) indicating an association between VEGF-C expression and 
lymphangiogenesis. Sialyl Lewis X expression seemed to be related to an infiltrating 
type of tumor growth as significantly more of these tumors showed cytoplasmic 
positive staining with CSLEX1 (Chi-square test, 24 of 27 vs 46 of 68, P = 0.034) 
compared to tumors with an expanding growth pattern. Also significantly more 
infiltrating tumors showed morphological vaso-invasion compared to expanding 
tumors (Chi-square test, 19 of 27 vs 27 of 70, P = 0.005). This correlation suggests 
a role of infiltrating tumor growth in the overestimation of blood and lymphatic 
vessel invasion in the morphological vaso-invasion score. 
Table 3. Microvessel density and microvessel tumor invasion in primary colorectal tumorsa
All 
patients
Cases Controls Univariate analysis
n % n % n % Pb OR 95% CI P
BMVD invasive front 
(n=90)c, d
Low 76 84 24 75 52 90 .077e 1
High 14 16 8 25 6 10 2.9 (0.9-9.3) .074
LMVD tumor stroma 
or invasive front 
(n=91)c, f
Low 72 79 22 67 50 86 .027 1
High 19 21 11 33 8 14 3.1 (1.1-8.8) .032
Blood vessel 
invasion (n=96)
Absent 95 99 32 97 63 100 .344e NA
Present 1 1 1 3 0 0
Lymphatic vessel 
invasion (n=96)
Absent 88 92 28 85 60 95 .119e 1
Present 8 8 5 15 3 5 3.6 (0.8-16) .096
BMVD, blood microvessel density; LMVD, lymphatic microvessel density; OR, odds ratio; CI, confidence 
interval; NA, not assessable; a Primary tumors from three controls could not be retrieved from the 
archive and tissue sections which were destroyed after staining were excluded from analysis leading to 
a variable number of examined slides; blood microvessels were stained with anti-CD31 antibodies and 
lymphatic vessels were stained with D2-40 antibodies; b Chi-square test of cases vs controls, unless 
mentioned otherwise; c Maximum number of counted vessels from hot spots; invasive front was not 
present on all sections; d High: greater than 46; e Fisher’s exact test; f High: greater than 20.
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Logistic regression analysis
All variables with a P value lower than 0.10 in the univariate analysis (Tables 2, 
3 and 4) were entered in a forward step multivariate analysis. T stage, tumor 
growth pattern, CSLEX1-, VEGF-C- or VEGF-D-expression, high BMVD, high LMVD 
and lymphatic vessel invasion were entered in the multivariate analysis. The 
independent factors predicting disease recurrence that remained were sLeX tumor 
expression by CSLEX1 and a high LMVD (OR 5.1, 95% CI 1.3-20.0 and OR 3.1, 
95% CI 1.0-10.0, respectively). 
Table 4. Univariate analysis of clinicopathological characteristics
Univariate analysis
Characteristics OR 95% CI P
Sex
Female 1
Male 1.3 (0.6-3.0) .497
Age (years) 1.0 (0.97-1.03) .910
T stage
T2 and T3 1
T4 3.1 (1.0-9.9) .050
Tumor size (cm) (n=104) 0.9 (0.8-1.2) .536
Tumor location
Colon (coecum – sigmoid) 1
Rectum (rectosigmoid – rectum) 0.9 (0.3-2.6) .858
Differentiation .913a
Good 1
Moderate 1.0 (0.4-2.5) .927
Poor 1.3 (0.3-4.9) .750
Number of lymph nodes 0.9 (0.9-1.0) .132
Mucinous
No 1
Yes 1.4 (0.4-5.2) .640
Growth pattern
Expanding or pushing 1
Infiltrating 2.7 (1.1-6.7) .034
Preoperative serum CEA level 
(n=43)
< 6 µg/l 1
> 6 µg/l 2.2 (0.5-10.2) .303
OR, odds ratio; CI, confidence interval; CEA, carcinoembryonic antigen; a Overall P value.
Lymphangiogenic factors in colorectal cancer 133
Correlation with site of metastases
The site of the metastases was registered in our hospital, which enabled us to 
assess its correlation with the different variables tested. Primary tumors with 
CSLEX1 expression significantly more often led to disease recurrence in the liver 
compared to primary tumors negative for CSLEX1 (Chi-square test, 20 of 74 vs 
one of 25, P = 0.015). Liver metastases were also significantly more often seen in 
the patients with infiltrative tumors than in patients with expanding tumors (Chi-
square test, 11 of 27 vs 11 of 70, P = 0.008). 
Patients with a high BMVD in the invasive front developed lung metastases 
significantly more often than patients with a low BMVD in the invasive front 
(Fisher’s exact test, 4 of 14 vs 4 of 76, P = 0.018). 
The chance to develop regional, peritoneal or metastases to the brain, bones or 
adrenal glands was significantly higher in patients with high LMVD compared to 
patients with low LMVD (Fisher’s exact test, 8 of 19 vs 8 of 72, P = 0.004). This 
chance also significantly increased with the T stage (Fisher’s exact, T4 stage: 6 
of 14 vs T2 or T3 stage: 12 of 94, P = 0.012) and decreased with the number of 
harvested lymph nodes (Fisher’s exact test, 0 of 22 in patients with 12 or more 
examined lymph nodes vs 18 of 86 in patients with less than 12 lymph nodes, 
P = 0.021). Moreover, no correlation was seen between a high LMVD, T4 stage 
or 12 or more harvested lymph nodes. When entering these three variables in 
a multivariate analysis, a high LMVD remained as an independent predictor for 
regional, peritoneal or metastases to distant sites other than liver and lungs (OR 
7.3, 95% CI 2.0-27.4, P = 0.003).
DISCUSSION
In this study, we show sLeX expression and a high LMVD of the primary tumor 
to be independent risk factors for disease recurrence in curatively resected CRC 
patients with tumor-negative lymph nodes. Our results confirm data from Nakagoe 
et al.9 showing that lymph node-negative CRC patients with sLeX expression 
detected with CSLEX1 have a worse prognosis. Moreover, we showed a significant 
correlation between sLeX expression and liver metastases as previously reported 
by others.23;24 We saw a correlation between sLeX expression and infiltrative tumor 
growth pattern and showed the latter also to correlate with disease recurrence.18 
The reproducibility of tumor growth pattern assessment has been shown to 
be problematic25 which suggests growth pattern to be an unreliable prognostic 
marker in contrast with sLeX immunohistochemical detection. Our results suggest 
that sLeX expression plays a role in infiltrative tumor growth and in facilitating the 
hematogenous spread of tumor cells through blood microvessels via the portal 
vein to the liver.
The lymphatic system has also been believed to be one of the most important 
pathways for tumor cell dissemination as it is expected that tumor cells can 
enter lymphatic microvessels easier than blood microvessels because 
the former show a discontinuous or completely absent basement membrane and 
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are devoid of pericytes.26 Years of research have resulted in several lymphatic 
endothelial cell specific markers.26 In this study, we used D2-40 which was reported 
to be more sensitive in detecting lymphatic endothelium than Prox1, LYVE-1 and 
podoplanin.27 We found a high LMVD detected with D2-40 to be an independent 
risk factor for disease recurrence. Similar findings were seen by Matsumoto et al.28 
who used the anti-podoplanin antibody to detect lymphatic microvessels in primary 
tumors of 106 stage I to IV CRC patients. They showed a high LMVD and lymphatic 
vessel invasion to correlate with a poor outcome but only the former remained 
as an independent predictor in the multivariate analysis. Saad et al.20 examined 
BMVD and LMVD in 90 stage I to IV CRC patients by using anti-CD31 and D2-40 
antibodies, respectively. They observed a significant correlation between LMVD 
and liver metastases, but they did not analyze other types of distant metastases. 
In our study, a high LMVD was found not to correlate with liver metastases or lung 
metastases but with regional intra-abdominal or intrapelvic metastases in lymph 
nodes and other distant metastases such as peritoneum, bones, brain and adrenal 
glands. We suggest that a high LMVD leads to tumor cell dissemination through 
lymphatic microvessels into intra-abdominal or pelvic lymph nodes. The lymphatic 
system finally returns lymph to the systemic blood circulation via the thoracic duct 
leading to metastases in the bones, brain and other distant sites. 
Additionally, a high BMVD correlated with disease recurrence restricted to the 
lungs. This may explain the variability in published studies regarding the prognostic 
relevance of BMVD as it probably depends on the number of patients in those 
particular studies who suffered from disease recurrence in the lungs. Accordingly, 
a recent meta-analysis showed a high BMVD, detected by using antibodies directed 
against CD31 or CD34, to significantly predict poor clinical outcome.29 
We assessed tumor invasion in blood and lymphatic vessels on HE stained 
sections and referred to this as morphological vaso-invasion. By comparing 
morphological vaso-invasion and blood and lymphatic vessel invasion scored 
on immunohistochemically stained sections, we found the former to be 
overestimated as reported previously by others.30 Analysis suggested that scoring 
of morphological vaso-invasion does not distinguish between blood or lymphatic 
vessel invasion and an infiltrative tumor growth pattern. Previous studies have 
shown that artifactual tissue retraction around tumor islands complicate and 
overestimate true lymphovascular invasion.16;17 Immunohistochemical staining of 
blood and lymphatic vessels with specific antibodies resolves this problem and 
enables objective estimation of tumor invasion in vessels. 
To our knowledge, we are the first to identify a multiple set of tumor markers each 
correlating with a different preferential site of metastasis in CRC. Our results support 
two types of mechanisms involved in metastasis. First, there is the mechanical way 
of tumor cell dissemination through blood and lymphatic microvessels, resulting 
in tumor cell arrest in the narrow capillary network in different organs including 
lymph nodes. There they may proliferate and develop clinically evident metastases. 
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Hematogenous and lymphatic metastasis is expected to increase with the number 
of blood and lymphatic microvessels. This may explain the correlation between a 
high BMVD and lung metastases and the correlation between a high LMVD and 
regional intra-abdominal or intrapelvic metastases in lymph nodes with eventually 
distant metastases. 
In addition to this mechanical entrapment of tumor cells, also biological processes 
determine outgrow of metastases as explained by the “seed and soil” theory.31;32 
This theory suggests that a subpopulation of tumor cells with metastatic potential, 
recently identified as colon-cancer-initiating cells33, disseminate through the 
whole body. These cells proliferate and differentiate to form clinically evident 
metastases at preferential sites depending on local molecular interaction among 
which availability of local growth factors. In our study, the correlation between 
sLeX expression and liver metastases may be explained by this pathway. The 
interaction of the antigen sLeX on tumor cells and E-selectin on endothelial 
cells was shown to mediate adhesion of tumor cells to endothelial cells8 possibly 
facilitating tumor cell invasion in blood microvessels, extravasation and migration 
into tissue. Additionally, colorectal tumor cells showing sLeX expression might 
prefer the liver to grow out to form clinically evident metastases due to interaction 
with local E-selectin.34
It is important to realize that this study regards a small patient group but even in 
these small patient numbers we showed significant findings consistent with current 
thoughts in terms of hematogenous and lymphatic metastasis. Furthermore, only 
20% of our patient group had undergone an adequate lymph node harvest of 
at least 12 lymph nodes as recommended by the American Joint Committee on 
Cancer Staging35, which is a limitation of our study. Nevertheless, similar numbers 
were reported by Johnson et al.36 and Baxter et al.37 who showed adequate lymph 
node evaluation in 22% of 569 CRC specimens respectively 37% of 116995 CRC 
patients. They reported the effect of different pathology assistants, older age and 
rectal cancer to affect the number of lymph nodes retrieved.37;38   
In summary, our study shows that high-risk lymph node-negative CRC patients 
can be identified by assessing the primary tumor for sLeX expression with CSLEX1 
and LMVD. Our results have to be validated in prospective studies which should 
also evaluate whether these high-risk CRC patients may benefit from adjuvant 
systemic therapy. Moreover, our results are consistent with the notion that both a 
lymphatic and hematogenous route plays a role in CRC. 
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Cancer is a leading cause of death worldwide, accounting for 7.9 million cases in 
2007 which comprises around 13% of all deaths.1 The number of cancer-related 
deaths is expected to increase with an estimated 9 million in 2015. Overall cancer 
mortality is mainly caused by solid tumors arising from lung, stomach, liver, 
colorectum and breast tissue. In this thesis, we will focus on gastric and colorectal 
cancer with the emphasis on the latter.
Gastric cancer is the second most common cancer worldwide with a varying 
incidence, being higher in Japan and some parts of South America (> 40 per 
100,000) and lower in Western Europe and the United States (< 15 per 100,000).2 
Environmental exposure rather than genetic factors play a role in the predisposition 
to gastric cancer.3
Colorectal cancer (CRC) is the third most prevalent cancer worldwide with an 
estimation of 1.2 million new cases and 630,000 deaths in 2007.4 The incidence 
of CRC is higher in developed countries, making it the second most common 
cancer in Europe.5 The risk for developing CRC increases with age as a result of 
accumulation of (epi)genetic mutations, with more than 90% of new cases being 
diagnosed in patients older than 50 years. Most cases of CRC occur in sporadic 
forms of which about 20% have some component of familial risk.6 Approximately 
5 to 10% are hereditary. 
Surgery is the first choice of treatment in gastric cancer and CRC. After surgery, 
patients receive adjuvant systemic treatment depending on disease stage. Disease 
stage is based on the Tumor-Node-Metastasis (TNM) classification system which 
is one of the most well established prognostic factors in solid tumors.7;8 After the 
introduction in 1987, the TNM system has been revised every few years to allow 
the incorporation of new evidence. Unfortunately, this staging system does not 
provide prediction of prognosis for the individual patient leading to both over- and 
undertreatment.
This thesis assesses whether gastric cancer and CRC patients with minimal 
metastatic disease at the time of surgery who are at risk for disease recurrence, 
can be identified by detection of occult tumor cells (OTC) in lymph nodes or bone 
marrow, or by analyzing the primary tumor for angiogenic and lymphangiogenic 
markers. 
Chapter 1 presents a general introduction and describes the background and 
outline of this thesis. In short, the TNM staging classification represents the 
routes of tumor spread namely local invasion (T), lymphatic spread (N) and 
hematogenous dissemination (M). With the current TNM classification, mostly 
macroscopical tumor spread is determined by using conventional hematoxylin 
and eosin stainings and radiological techniques. Therefore, numerous patients 
who are at risk for disease recurrence after supposedly curative resection are 
not recognized. By exploring the presence of minimal disease in lymph nodes or 
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bone marrow or by applying biological markers in the primary tumor related to 
tumor cell spread, a more individualized portrait of patient’s prognosis might be 
achieved. The first adjustments have been made in the last revision of this staging 
system since micrometastases (MM; > 0.2 mm and < 2 mm) and isolated tumor 
cells (ITC; < 0.2 mm) in lymph nodes were incorporated. 
In chapter 2 we investigate whether the presence of OTC in originally considered 
tumor-negative lymph nodes from curatively resected gastric cancer patients can 
predict disease recurrence. Also, the value of automated microscopy is evaluated. 
Forty cases (disease recurrence) and 41 controls (no disease recurrence for at 
least 5 years) were selected from the previously published multicenter Dutch D1-
D2 Gastric Cancer trial.9 One tissue section was immunohistochemically stained by 
anticytokeratin antibodies CAM5.2 and examined by conventional and automated 
microscopy. There was no significant difference in the presence of OTC, MM or 
ITC between the case and control groups (P = 0.658; P = 0.691; P = 0.887, 
respectively). However, significantly more cases than controls presented with 
20% or more OTC-positive lymph nodes (Chi-square test, 9 (24%) vs one (3%), 
P = 0.015). A multivariate logistic regression analysis showed that examination 
of less than five lymph nodes (OR 13.8, 95% CI 1.6-120.6, P = 0.018) was 
the only significant independent risk factor for disease recurrence, especially 
for locoregional disease recurrence (OR 20.4, 95% CI 2.2-190.8, P = 0.008). 
A similar analysis for distant disease recurrence showed a percentage of 20% or 
more OTC-positive lymph nodes to be the only significant independent risk factor 
(OR 15.6, 95% CI 1.6-151.4, P = 0.018). The sensitivity of immunohistochemistry 
evaluated by microscopy to identify cases with 20% or more OTC-positive lymph 
nodes increased from 8% for conventional microscopy to 22% for automated 
microscopy (McNemar’s test, P = 0.063). Our results suggest that locoregional 
disease recurrence might be the result of lymph nodes that were not removed. 
In addition, when 20% or more of the lymph nodes are OTC-positive, tumor cells 
may already have travelled to other sites in the body, eventually leading to distant 
metastases. 
Additionally, this chapter presents an overview of previously published 
immunohistochemistry studies regarding the clinical relevance of OTC in lymph 
nodes of patients with gastric cancer. There was an extensive variation in the 
antibodies that were used and in the reported upstaging percentages. Ten of 16 
studies reported a negative impact of the presence of OTC in lymph nodes on the 
clinical outcome.10-12 Similar to our study, Siewert et al.13 also reported clinical 
significance of the percentage of OTC-positive lymph nodes. 
Chapter 3 presents an overview of studies regarding the detection methods and 
clinical relevance of OTC in lymph nodes in CRC. 
Three out of four studies using polymerase chain reaction (PCR) for OTC detection, 
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showed its prognostic relevance. Certain DNA regions that might have contained 
tumor-specific mutations in the genes p53 or K-ras were amplified by the PCR 
assay in these studies. Disadvantages such as a non-consistent occurrence of 
p53 and K-ras mutations in CRC and the large number of codons or even exons in 
which mutations can be detected, will prevent PCR from becoming a ubiquitously 
utilized application for OTC detection. 
All six studies using reverse-transcriptase polymerase chain reaction (RT-PCR) 
to detect OTC in lymph nodes showed a negative impact of OTC on patient’s 
prognosis.14-19 However, two realtime RT-PCR studies failed to show any significance 
of OTC in lymph nodes.20;21 We concluded that OTC in lymph nodes detected with 
RT-PCR show prognostic value provided that fresh or frozen lymph nodes, the 
markers CEA, CK20 and GCC and the optimal number of PCR cycles are used. 
Only 9 out of 28 immunohistochemistry studies showed a significantly worse 
clinical outcome in patients with lymph nodes containing OTC. Particular studies 
using anticytokeratin antibodies CAM5.2, reported OTC-positive lymph nodes as 
clinically relevant. 
We found upstaging percentages through OTC assessment and the prognostic 
relevance of OTC in lymph nodes to vary among studies, particularly in the 
immunohistochemistry studies, which was related to differences in techniques 
used to detect OTC. 
In chapter 4, we assess the value of multiple sectioning of lymph nodes combined 
with immunohistochemical staining in detecting prognostic relevant OTC in CRC 
patients. The slides were examined by automated microscopy. Although OTC in 
lymph nodes detected by RT-PCR, more often are of clinical value, the hospital 
infrastructure for this technique is more demanding due to the need for fresh 
frozen tissue. Additionally, morphologic assessment of tissue samples analyzed, 
is warranted. This study was performed on histologically tumor-negative paraffin-
embedded lymph nodes previously studied by Liefers et al.14 with RT-PCR for CEA 
for the detection of OTC. They found a five-year survival rate of 50% for the OTC-
positive group and 91% for the negative group (P = 0.02). 
Lymph node tissue blocks from 20 patients were sectioned (five consecutive 
sections of 10 levels at 200 µm interval or until no material was left) and 
immunohistochemically stained using antibodies against cytokeratin, AE1/AE3. 
The stained slides were analyzed using rapid high capacity flatbed scanning. OTC 
were detected in all of six (100%) patients with disease recurrence, compared to 
eight of 14 (57%) patients who did not develop a recurrence (Chi-square test, 
P = 0.055). Five of six (83%) patients who developed disease recurrence were 
OTC-positive detected by CEA RT-PCR and three of 14 (21%) who showed no 
recurrence were OTC-positive. 
These findings showed that multilevel sectioning combined with immuno-
histochemical staining followed by automated microscopy had a higher sensitivity 
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in predicting disease recurrence than RT-PCR (100% vs 83%) but was lower in 
specificity (43% vs 79%). In this study, no distinction was made between MM and 
ITC but groups of cells (> 2) were separately noted and these were seen in all six 
patients with disease recurrence and in five of 14 (36%) patients without disease 
recurrence. Additionally, all patients with disease recurrence were identified after 
analysis of four levels at 200 µm distance. 
Chapter 5 addresses whether detailed examination of lymph nodes by multilevel 
sectioning and immunohistochemical staining can improve prognostication. Thirty-
six cases (disease recurrence within 5 years) and 72 controls (no disease recurrence 
for at least 5 years) were selected. Tissue sections from paraffin-embedded lymph 
nodes from four levels at 200 µm interval were immunohistochemically stained 
with anticytokeratin antibodies, AE1/AE3. These slides were analyzed using 
conventional and automated microscopy for the presence of tumor cells.
Altogether, the case group showed more MM (n = 3) than the control group (n = 
1). There was no difference in the presence of ITC between the case and control 
group. Analysis of a second level had led to the additional detection of one case 
with MM (n = 1), one case with macrometastasis (n = 1) and two cases and 
seven controls with ITC (n = 9). Examining more than two levels only resulted 
in detection of additional ITC. All MM and macrometastasis were detected by 
conventional analysis and automated microscopy only led to detection of more ITC. 
In a multivariate logistic regression analysis, the presence of macrometastases or 
MM (OR 34.5, 95% CI 2.7-440, P = 0.006), T4 stage (OR 2.9, 95% CI 0.4-23.5, P 
= 0.040) and number of lymph nodes (OR 0.9, 95% CI 0.8-1.0, P = 0.025) were 
independent predictors for disease recurrence. Messerini et al.22 and Bilchik et 
al.23 who also distinguished between MM and ITC reported similar detection rates 
for MM (9.9% and 3%, respectively). Additionally, the first study also showed 
prognostic relevance of MM and none for ITC. 
Detailed examination of lymph nodes in CRC by multilevel sectioning combined 
with immunohistochemical staining or RT-PCR in search for OTC is expensive and 
laborious given the enormous number of lymph nodes that can be harvested. 
Identification of sentinel lymph nodes (SNs) and selective detailed analysis of 
only these nodes, is suggested as a possible approach to circumvent this extra 
workload. Sentinel nodes are the first lymph nodes to drain the primary tumor and 
therefore have the highest chance of harboring tumor cells (see introduction, Figure 
1). In chapter 6, twenty-five studies on the feasibility and reliability of sentinel 
node mapping (SNM) in CRC are reviewed with the emphasis on differences in 
the SNM techniques used. There was a large variation in identification rates and 
false-negative (FN) rates, ranging from 58% to 100% (average 89%) and 0 to 
60% (average 33%), respectively. Factors that might have contributed to failed 
SNM procedures were incomplete circumferential injection around the tumor, 
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insufficient volumes of tracer for large tumors, inclusion of advanced tumors 
and rectal tumors. A major component reported was the learning curve effect, 
leading to a much higher identification rate of almost 100% in some studies 
if results from the early phase of the learning curve were not included in the 
analysis. High FN rates may be explained by extensive nodal replacement and 
large tumors, which can occlude lymphatic vessels leading to lymph drainage 
through an alternative route or by a long identification time between injection of 
the tracer and identification of the SNs, as blue dye travels fast and might have 
already reached a second echelon lymph nodes. Also, a low FN rate of 20% or less 
was mostly seen in studies where the number of SNs was limited to the first four 
blue nodes or the four or five blue nodes closest to the tumor whereas studies 
reporting a FN rate higher than 20% had a higher number of SNs. The majority 
of the latter studies considered all blue nodes or radioactive nodes as SNs leading 
to a wider range of SN. In melanoma and breast cancer lower FN rates are seen. 
The difference might be in larger tumors found in the colon and rectum and also 
in the dissimilarity in lymphatic drainage pattern. 
Limitations in rectal cancer are the close vicinity of the primary tumor and the 
pararectal lymph nodes resulting in overlapping radioactivity. Moreover, incising 
mesorectal tissue during the operation is a contraindication for oncologic adequate 
removal of rectal cancer. Neoadjuvant radiotherapy and advanced tumors can also 
hamper the identification of SNs. These factors make SNM in rectal cancer more 
difficult and of low clinical value. 
Two colon cancer studies showed that SNs are significantly more likely to contain 
tumor cells than nonsentinel nodes24;25 whereas conflicting results were seen in a 
third study published in 2006 in which no difference between SNs and nonsentinel 
nodes in regard to the frequency of MM or ITC involvement was seen.26 One SNM 
study in colon cancer reported a higher rate of disease recurrence in patients 
with SNs containing macrometastases or MM detected by hematoxylin and eosin 
staining or RT-PCR.27 Nevertheless, the reliability of SNM in colon cancer has not 
been clarified yet.
In CRC, disseminated tumor cells (DTC) are found in bone marrow although usually 
no clinically evident metastases develop in bone.28;29 We suspect that the presence 
of DTC in bone marrow might represent the aggressive nature of the tumor and 
could therefore be used to predict disease recurrence. This is evaluated in chapter 
7 by assessing whether the presence of DTC in bone marrow from 81 patients with 
colorectal liver metastases who were scheduled for surgical resection or isolated 
hepatic perfusion, is associated with a worse outcome of disease. The presence of 
DTC in bone marrow was analyzed by using quantitative RT-PCR for the expression 
of cytokeratin 20 (CK20) and or immunocytochemistry (CK-ICC) combined with 
automated microscopy by use of A45-B/B3, anti-cytokeratin antibodies. Bone 
marrow samples in 26 of 69 (38%) patients tested positive with the CK20 RT-
PCR and samples in 15 of 69 (22%) patients tested positive with the CK-ICC test. 
Summary and general discussion 145
In a multivariate Cox regression analysis a positive CK20 RT-PCR test (HR 2.5, 
95% CI 1.2 - 5.2, P = 0.014) and a serum CEA level greater than 200 micrograms 
per liter (HR 2.4, 95% CI 1.0 - 5.9, P = 0.045) were independent predictors for a 
reduced disease-related survival. A positive CK-ICC test did not relate to a worse 
survival but correlated with the presence of extrahepatic disease at the time of 
surgery (Chi-square test, P = 0.009). No correlation was seen between the CK20 
RT-PCR test and the CK-ICC test. Factors that might explain this are the difference 
in markers used for these tests or RNA detected by RT-PCR may more likely 
represent active production of cytokeratin whereas CK-ICC may detect dormant 
or apoptotic cells.30 
We found similar results as published by Koch et al.31 who examined bone marrow 
samples from 25 patients with colorectal liver metastases who underwent surgical 
resection. They found a positive CK20 RT-PCR test to be an independent prognostic 
factor for recurrence-free survival. Previously, a prognostic clinical MSKCC score 
(Memorial Sloan-Kettering Cancer Center) was proposed by Nordlinger et al.32 and 
Fong et al.33 to select patients who will have optimal chances for cure after hepatic 
resection. This clinical score consists of the following clinical and pathological risk 
factors: a positive nodal status of the primary tumor, less than 12 months between 
the primary tumor and the liver metastases, four or more liver metastases, a 
maximum diameter of the metastases of more than 5 cm and serum CEA level 
higher than 200 micrograms per liter. Given our results and others, the CK20 RT-
PCR might be an interesting variable to be added to the MSKCC score.
In general, the spread of tumor cells occurs through local invasion and or 
hematogenous routes and or lymphatic routes. To reach lymph nodes or other 
tissue compartments in the body, the tumor cells have to overcome many 
bounderies at the site of the primary tumor. This occurs with the aid of various 
proteins. In chapter 8 the markers related to tumor cell spread through blood 
and lymphatic vessels are studied for their prognostic significance. Specifically, we 
examine whether disease recurrence in lymph node-negative CRC patients can be 
predicted by assessing their primary tumors for the expression of the angiogenic 
and lymphangiogenic factors sialyl Lewis X (sLeX), vascular endothelial growth 
factor (VEGF)-C, and VEGF-D, and for blood and lymphatic microvessel density 
(BMVD and LMVD), and for the presence of blood and lymphatic vessel invasion. 
This is performed in a case-control design studying the same patient group as in 
chapter 5. Thirty-six cases (disease recurrence within 5 years) and 72 controls 
(no disease recurrence for at least 5 years) were selected. Tumor sections were 
stained by antibodies CSLEX1 also known as CD15s (sLeX), anti-VEGF-C, anti-
VEGF-D, anti-CD31 (BMVD) or D2-40 (LMVD) to determine the parameters as 
mentioned above.
A multivariate analysis showed sLeX expression and high LMVD (OR 5.1, 95% CI 1.3-
20.0 and OR 3.1, 95% CI 1.0-10.0, respectively) to be independent factors predicting 
disease recurrence. Expression of sLeX correlated with liver metastases (P = 0.015). 
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A high LMVD was related to regional intra-abdominal or intrapelvic metastases 
in lymph nodes and distant metastases other than in the liver and lungs such as 
peritoneum, bones, brain and adrenal glands (P = 0.004). A high BMVD in the 
invasive front correlated with lung metastases (P = 0.018). 
When comparing the results in chapter 5 and 8, the following is noticed. There 
is a significant correlation between the presence of macrometastases or MM 
and lymphatic vessel invasion (Fisher’s exact test, P = 0.001 and P = 0.014, 
respectively) but none with a high number of LMVD (Fisher’s exact test, P = 
0.170) (data not published). Also, lymph node metastases are related to distant 
metastases (Fisher’s exact test, P = 0.001). 
This study is one of the first studies that combine a multiple set of tumor markers 
each correlating with a hematogenous or lymphatic tumor spread as previously 
described by Pantel and Brakenhoff (see introduction, Figure 3).34 Additionally, 
these results imply two types of mechanisms involved in metastasis (passive and 
active intravasation) as previously described by the group of Jain (see introduction, 
Figure 2).35 First, there is the mechanical way of tumor cell dissemination 
through blood and lymphatic microvessels, resulting in tumor cell arrest in the 
narrow capillary network in different organs including lymph nodes. There they 
might proliferate and develop clinically evident metastases. This may explain 
the correlation between a high BMVD and lung metastases and the correlation 
between a high LMVD and regional intra-abdominal or intrapelvic metastases in 
lymph nodes with eventually distant metastases. 
Moreover, also biological processes determine outgrow of metastases as reflected 
in the “seed and soil” theory.36;37 This theory suggests that a subpopulation 
of tumor cells with metastatic potential, recently identified as colon-cancer-
initiating cells30, disseminate through the whole body. These cells proliferate and 
differentiate to form clinically evident metastases at preferential sites depending 
on local molecular interaction among which availability of local growth factors. In 
our study, the interaction of sLeX on tumor cells and E-selectin on endothelial cells 
might have facilitated tumor cell invasion in blood microvessels, extravasation 
and migration into distant tissue. As blood microvessels drain to the portal vein, 
the tumor cells arrive in the liver where their sLeX expression might prefer the 
liver to grow out to form clinically evident metastases due to interaction with local 
E-selectin.38 
GENERAL DISCUSSION
Chapters 2 to 5 assess the detection of OTC in lymph nodes and its clinical 
relevance. OTC in lymph nodes from gastric cancer patients (chapter 2) are 
of clinical value if they are present in at least 20% of the lymph nodes whereas 
in CRC (chapter 5), MM and not ITC are found to be of clinical relevance. The 
difference between these studies in OTC relevance might be explained by the 
higher number of harvested lymph nodes in gastric cancer compared to CRC 
(median 15 with a range of one to 92 vs median 6 with a range of one to 26). 
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Besides being a staging tool, lymphadenectomy has also been reported to have 
therapeutic value.39-41 In CRC and bladder cancer, improved survival was shown 
in both node-negative and node-positive patients when an increased number of 
lymph nodes was examined.39;40 The results of our study in gastric cancer patients 
(chapter 2) support the therapeutic value of a higher number of dissected lymph 
nodes as a significantly higher number of harvested lymph nodes was seen in less 
than 20% OTC-positive group (n = 27) compared to the greater or equal than 
20% OTC-positive group (n = 10) (Mann-Whitney test, median 18 (range 6 to 
92) vs median 8.5 (range one to 35); P = 0.021). This again corresponds to the 
survival benefit of patients with N2 disease42 who underwent a D2 dissection as 
previously reported.43
We do not expect the number of levels examined to be a factor for the difference 
between chapter 2 and 5 as the percentage of OTC-positive lymph nodes after 
analysis of the first level in CRC also did not differ between cases and controls. 
Furthermore, the anticytokeratin antibodies CAM5.2 and AE1/AE3 had been 
compared and no difference in staining pattern was observed (data not published). 
In chapter 4, we do not differentiate between ITC and MM. More patients are seen 
with OTC detected by multilevel sectioning and immunohistochemical staining 
in patients who have developed disease recurrence than in patients without 
recurrence, but it does not reach significance (P = 0.055). When disregarding 
single tumor cells as relevant, the sensitivity of the test remaines 100% and the 
specificity rises from 43% to 64% in predicting disease recurrence. Nevertheless, 
the specificity of the RT-PCR test is still higher (79%). This may relate to the fact that 
RT-PCR detects RNA which represents active cells whereas immunohistochemistry 
detects proteins which might also be in apoptotic tumor cells. 
An additional finding in the study presented in chapter 5 are four macrometastases 
in the first sectioning level which had not been recognized as such on the 
conventional hematoxylin and eosin stained sections. They were reported as 
vascular invasion or tumor deposits without lymphoid tissue. These patients had 
been considered as node-negative and did not receive adjuvant chemotherapy. 
The combination of serial sectioning and immunohistochemical brown-staining of 
tumor cells might lead to a more clear differentiation from surrounding lymphoid 
tissue. A recent review by Nagtegaal et al.44 shows that various studies have 
tried to determine the importance of tumor deposits based on contour, size and 
origin but all fail to provide an evidence base to substantiate its use in the TNM 
system. Detailed analysis of lymph nodes may aid in examining tumor deposits in 
perirectal and pericolic fat.
To further elucidate the role of MM and ITC in lymph nodes, it would be 
advisable for further studies to follow the guidelines recently provided by 
Turner et al.45 These guidelines regard criteria for clusters of tumor cells, 
measurements of OTC and a more extensive definition of ITC and MM. 
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In their study, the variability of pathologists in their distinction between MM and ITC 
decreased after examining the set of clearly defined histologic criteria. Agreement 
improved from 76% to 97% leading to a reproducible nodal classification.
Given our results and others, MM are predictors of disease recurrence in CRC 
and therefore correctly used in the current TNM staging classification. There is 
no clarity on ITC as yet. Stroma analysis, staining for apoptosis, laser capture 
followed by single cell analysis46 or other techniques might clarify their relevance. 
Also, automated microscopy might be helpful in detection of OTC.
Both in chapter 2 and 5, the number of examined lymph nodes are of clinical 
relevance. In chapter 5 that regards archival material and includes rectal cancer 
patients, only 20% of the patients had undergone the recommended examination 
of at least 12 lymph nodes by the American Joint Committee on Cancer (AJCC).8 
Similar findings are seen in other studies investigating large archival material.47;48 
Higher numbers of lymph nodes have been found in prospective studies investigating 
OTC detection23 implying a more dedicated search for lymph nodes. Fat clearance 
techniques increases the number of harvested lymph nodes, especially small 
lymph nodes less than 5 mm.49;50 However, these methods are time consuming, 
expensive and impractical as they involve noxious volatile agents. Recently, the 
use of modified Davidson’s fixative instead of conventional formalin fixation, 
showed an increase in lymph node yield, especially of smaller lymph nodes.51 An 
alternative might be injection of blue dye which also leads to detection of small 
lymph nodes.23 Nevertheless, at best 50% of patients in the United States undergo 
adequate lymph node evaluation for colon cancer.47;52 Risk factors reported for 
< 12 lymph nodes examined are male sex, older age, earlier T stage tumor, 
low-volume hospitals and preoperative (chemo)radiotherapy.47;52;53 Studies have 
suggested a wide range for adequate nodal evaluation but guidelines from the 
National Comprehensive Cancer Network, the College of American Pathologists, 
the National Cancer Institute and the AJCC all recommend the examination of 12 
or more lymph nodes because this is a feasible and effective threshold.8;54-56 To 
improve the number of harvested lymph nodes, guidelines from the Santa Monica 
Conference in 2007, are recommended. If less than 12 lymph nodes are found 
on initial examination, the pathologist should reexamine the specimen, possibly 
including microscopic examination of extramural soft tissue. A harvest of less than 
12 lymph nodes, should be documented in the pathology report including the type 
and extent of reexamination undertaken. Also, the surgeon bears responsibility for 
submitting both sufficient tissue for examination and a meticulous description of 
the surgical resection. As Jass et al.57 claim “there is no unacceptably low number 
of lymph nodes for an individual dissection, but the mean number of lymph nodes 
in a series of colon cancer dissections should approximately be between 12 and 15. 
In the case of rectal cancer with the increasing use of neoadjuvant radiotherapy, 
the mean number may be lower than 12 despite intensive search.
Summary and general discussion 149
Summarizing, the number of examined lymph nodes is a prognostic factor proven 
in numerous studies. Accordingly, it might also be a factor to include in a revised 
TNM system to aid in the decision-making regarding adjuvant systemic treatment.
CLINICAL PERSPECTIVES
Although surgical resection is the cornerstone in the treatment of both gastric 
cancer and CRC, surgery alone is not able to cure patients with minimal metastatic 
disease. These patients at risk for disease recurrence might benefit from additional 
systemic treatment and therefore their identification is a major issue. Detection 
and treatment of minimal metastatic disease is of increasing importance given the 
expected rise in the incidence of early-stage gastric and colorectal cancer patients 
through the use of gastroscopy, fecal occult blood tests and coloscopy. Additionally, 
curative surgical resection of isolated colorectal liver or lung metastases is more 
often becoming an option for treatment. Also in these patients, determination 
of minimal metastatic disease may direct further treatment. This thesis shows 
prognostic significance of occult tumor cells in lymph nodes or bone marrow and 
of primary tumor markers related to lymphatic and hematogenous spreading in 
patients who had undergone a supposedly curative resection, and, therefore, may 
indicate the presence of minimal metastatic disease.
For years, chemotherapy failed to show survival benefit in gastric cancer.58 In 2001, 
the Intergroup 0116 trial showed adjuvant chemoradiotherapy (5-fluorouracil 
plus leucovorin and radiation) to improve overall survival in gastric cancer.59 
Also, a Japanese trial confirmed an increase in overall survival after adjuvant 
chemotherapy with an oral fluoropyridimine S-1.60 The MAGIC trial (Medical 
Research Council Adjuvant Gastric Infusional Chemotherapy) showed perioperative 
chemotherapy (pre- and postoperative epirubicin, cisplatin and 5-fluorouracil) to 
result in improved progression-free and overall survival.61 Therefore, the gastric 
cancer patient group with minimal metastatic disease at risk for disease recurrence 
might optimally benefit from adjuvant chemotherapy. Currently, patient’s 
prognosis after neo-adjuvant chemotherapy and curative surgery followed by 
postoperative chemoradiotherapy or chemotherapy is investigated in the CRITICS 
(ChemoRadiotherapy after Induction chemoTherapy In Cancer of the Stomach) 
study which is being performed in the Netherlands.
Until recently, adjuvant systemic therapy in colon cancer had consisted of 
5-fluorouracil and leucovorin.62 Now, results with capecitabine, an oral 
fluoropyrimidine, suggests that 5-fluorouracil can be replaced by capecitabine.63-66 
Also, the MOSAIC (Multi-center International Study of Oxaliplatin/5-fluorouracil/
Leucovorin in the Adjuvant Treatment of Colon Cancer) trial showed that 
addition of oxaliplatin improved disease-free survival of patients with stage 
III disease.67 The value of adjuvant chemotherapy for patients with stage II 
disease remains controversial because evidence is inconsistent that adjuvant 
5-fluorouracil-based chemotherapy is associated with a better overall survival 
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compared to surgery alone.68-70 However, subgroups of patients with stage II CRC at 
risk for disease recurrence including T4 stage, perforation, complete obstruction71 
and given the results of this thesis, the presence of minimal metastatic disease, 
might benefit from adjuvant chemotherapy to a similar extent as shown for stage 
III CRC patients. Nevertheless, future studies have to prove this. 
Results of other studies investigating the survival benefit in gastric cancer and 
CRC patients treated with biological agents attacking several pathways such as 
bevacizumab and cetuximab have to be awaited.72-74
Concluding, considerable numbers of patients who underwent curative surgical 
resection of their gastric or colorectal tumor are at risk for disease recurrence. In 
this thesis, we have shown that patients treated for gastric or colorectal cancer 
who are at risk for disease recurrence can be identified through occult tumor 
cell detection in lymph nodes, disseminated tumor cell detection in bone marrow 
and analysis of angiogenic and lymphangiogenic features of the primary tumor. 
These findings can be implemented in new strategies for identification of high risk 
patients, leading to individualized therapy preventing over- and undertreatment. 
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Wereldwijd overleden in 2007 7,9 miljoen mensen aan kanker, ongeveer 13 procent 
van het totaal aantal overledenen. De verwachting is dat dit aantal zal stijgen naar 
9 miljoen in 2015.1 Maagkanker en dikkedarmkanker zijn twee veelvoorkomende 
vormen van kanker met een hoge mortaliteit. Deze ziekten staan centraal in dit 
proefschrift. 
De incidentie van maagkanker varieert van hoog in Japan en bepaalde delen van 
Zuid-Amerika (> 40 per 100.000) tot laag in West-Europa en de Verenigde Staten 
(< 15 per 100.000).2 Omgevingsfactoren spelen bij het krijgen van maagkanker 
een grotere rol dan genetische factoren.3 
In 2007 werden naar schatting ongeveer 1,2 miljoen nieuwe patiënten met 
dikkedarmkanker gediagnosticeerd.4 Deze vorm van kanker komt vaker voor in 
ontwikkelde landen. De kans op het ontwikkelen van dikkedarmkanker stijgt met 
de leeftijd als gevolg van een cumulatie van (epi)genetische mutaties. Meer dan 
90 procent van de nieuwe gevallen werd gediagnosticeerd bij patiënten ouder dan 
50 jaar. De meeste gevallen van dikkedarmkanker komen voor als sporadische 
vorm waarvan ongeveer 20 procent een familiaircomponent (twee of meerdere 
eerste- of tweedegraads familieleden met dikkedarmkanker) heeft.5 Daarnaast is 
ongeveer 5 tot 10 procent autosomaal dominant erfelijk.  
Chirurgie staat bij de behandeling van maagkanker en dikkedarmkanker op 
de eerste plaats, aangezien dit de meeste kans op genezing biedt. Patiënten 
worden, afhankelijk van het ziektestadium waarin zij verkeren, aanvullend 
behandeld met chemotherapie. Het ziektestadium wordt bepaald met behulp 
van het classificatiesysteem voor tumor-regionale lymfekliermetastasen-
afstandsmetastasen (TNM) (zie inleiding, tabel 2 en 3). Dit is de best beschreven 
prognostische factor bij solide tumoren.6;7 Het TNM-classificatiesysteem is sinds 
de introductie in 1987 meerdere malen aangepast naar gelang actuele resultaten. 
Desondanks kan dit stadiëringssysteem de prognose van de individuele patiënt 
nog niet voorspellen, met als gevolg over- en onderbehandeling.
In dit proefschrift wordt onderzocht of het mogelijk is patiënten met maagkanker 
of dikkedarmkanker met minimale gemetastaseerde ziekte ten tijde van de 
operatie die risico lopen de ziekte terug te krijgen, te identificeren door detectie 
van occulte tumorcellen (OTC) in lymfeklieren of beenmerg of door analyse van 
angiogenese en lymfangiogenese eigenschappen van de primaire tumor.
Hoofdstuk 1 behandelt de achtergrond en inhoud van dit proefschrift. De TNM-
classificatie representeert de onderling gerelateerde routes van tumorverspreiding, 
namelijk locale invasie (T), verspreiding via lymfevaten (N) en metastasering op 
afstand via bloedvaten (M). Met de huidige TNM-classificatie wordt met name 
macroscopische tumorverspreiding gedetecteerd door conventionele hematoxyline 
-eosinekleuringen en radiologische technieken. Vandaar dat de patiënten die risico 
lopen de ziekte terug te krijgen, na zogenoemde curatieve resectie niet worden 
herkend. Door te zoeken naar minimale ziekte in lymfeklieren of beenmerg of door 
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biologische markers in de primaire tumor gerelateerd aan tumormetastasering te 
onderzoeken, kan een preciezer beeld verkregen worden van de prognose van de 
individuele patiënt. De eerste stappen hierin zijn al ondernomen in de laatste revisie 
van het TNM-classificatiesysteem, waarbij minimale ziekten zoals micrometastasen 
(MM; > 0,2 mm en < 2 mm) en geïsoleerde tumorcellen (ITC; < 0,2 mm) 
in lymfeklieren zijn toegevoegd aan macrometastasen (> 2 mm) die met 
conventionele hematoxyline-eosinekleuringen meestal wel worden gevonden. 
In hoofdstuk 2 is onderzocht of de aanwezigheid van OTC in oorspronkelijk 
als tumornegatief bestempelde lymfeklieren van curatief geopereerde 
maagkankerpatiënten de terugkeer van de ziekte kan voorspellen. Daarnaast is 
de aanvullende waarde van geautomatiseerde microscopie onderzocht. Veertig 
patiënten die de ziekte terugkregen (cases) en 41 patiënten die minimaal vijf jaar 
ziektevrij bleven (controlegroep), werden geselecteerd uit de eerder gepubliceerde 
multicenter Nederlandse D1-D2 maagkankertrial.8 Eén weefselcoupe werd 
immunohistochemisch gekleurd door anticytokeratine antilichamen CAM5.2 en 
daarna bekeken door conventionele en geautomatiseerde microscopie. 
Uit het onderzoek bleek geen significant verschil in de aanwezigheid van OTC, 
MM of ITC tussen de cases en de controlegroep (P = 0,658 respectievelijk P = 
0,691 respectievelijk P = 0,887). In significant meer cases zat echter 20 procent 
of meer OTC-positieve lymfeklieren (Chi-squaretest, negen (24 procent) versus 
één (3 procent), P = 0,015). Uit een multivariate regressieanalyse blijkt dat het 
onderzoeken van minder dan vijf lymfeklieren (OR 13,8; 95% CI 1,6 - 120,6; P 
= 0,018) de enige significante onafhankelijke risicofactor is voor het ontwikkelen 
van een recidief, met name voor een locoregionaal recidief (OR 20,4; 95% CI 
2,2 - 190,8; P = 0,008). Een soortgelijke analyse voor afstandsmetastasen toont 
een percentage van 20 procent of meer OTC-positieve lymfeklieren als enige 
significante risicofactor (OR 15,6; 95% CI 1,6 - 151,4; P = 0,018). De sensitiviteit 
van immunohistochemie gevolgd door microscopie ter identificatie van cases 
met 20 procent of meer OTC-positieve lymfeklieren nam toe van 8 procent bij 
conventionele microscopie naar 22 procent bij geautomatiseerde microscopie 
(McNemar’s test, P = 0,063). 
Deze resultaten suggereren dat locoregionale recidieven het gevolg zijn van 
tumorpositieve lymfeklieren die niet zijn verwijderd. Als 20 procent of meer van 
de lymfeklieren OTC-positief zijn, hebben de tumorcellen zich al verspreid naar 
andere delen van het lichaam, wat uiteindelijk resulteert in afstandsmetastasen. 
Dit hoofdstuk geeft ook een overzicht van eerder gepubliceerde soortgelijke studies 
bij patiënten met maagkanker. Er is een uitgebreide variatie in antilichamen en 
in de gerapporteerde percentages van OTC-positieve lymfeklieren. Tien van 
zestien studies rapporteren een slechtere prognose bij aanwezigheid van OTC 
in lymfeklieren.9-11 Siewert et al.12 vermeldt ook klinische relevantie van het 
percentage OTC-positieve lymfeklieren, wat in overeenstemming is met deze 
studie. 
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Hoofdstuk 3 geeft een overzicht van studies waarin detectiemethoden en 
klinische relevantie van OTC in lymfeklieren bij patiënten met dikkedarmkanker 
worden onderzocht. Drie van de vier studies waarbij polymerase chain reaction 
(PCR) wordt gebruikt voor detectie van OTC, laten de prognostische relevantie 
hiervan zien. Bepaalde DNA-gebieden die tumorspecifieke mutaties in de genen 
p53 en K-ras kunnen bevatten, werden geamplificeerd door de PCR-test in deze 
studies. Nadelen zoals het niet consistent voorkomen van p53- en K-ras-mutaties 
bij dikkedarmkanker en het enorme aantal codons of zelfs exonen waarin mutaties 
kunnen voorkomen, zijn de reden dat PCR geen alom gebruikte methode zal 
worden voor detectie van OTC. 
Alle zes studies die reverse-transcriptase polymerase chain reaction (RT-PCR) 
toepasten om OTC in lymfeklieren te detecteren, vermelden een slechtere 
prognose bij OTC-detectie.13-18 Wel hebben twee veel gevoeligere real-time RT-
PCR-studies geen klinisch belang aangetoond van OTC in lymfeklieren.19;20 Er kan 
geconcludeerd worden dat OTC in lymfeklieren gedetecteerd met RT-PCR van 
prognostische waarde zijn, als gebruikgemaakt wordt van verse of ingevroren 
lymfeklieren, de markers CEA, CK20 en GCC en een optimaal aantal PCR-cycli. 
Slechts negen van 28 immunohistochemiestudies rapporteren een significant 
slechtere prognose bij patiënten met OTC-positieve lymfeklieren. Met name 
studies die gebruikmaakten van anticytokeratine antilichamen CAM5.2, vermelden 
dat OTC-positieve lymfeklieren klinisch relevant zijn. Er is geconcludeerd dat 
percentages OTC-positieve lymfeklieren en de prognostische relevantie van OTC 
varieerden tussen de studies. Dit wordt met name gezien in de immunohistochemie 
studies, wat gerelateerd kan worden aan verschillen in detectietechnieken.
In hoofdstuk 4 is de waarde geëvalueerd van immunohistochemische kleuringen 
van multipele lymfekliercoupes voor OTC-detectie bij patiënten met 
dikkedarmkanker. De glaasjes werden gescreend met geautomatiseerde 
microscopie. Hoewel OTC in lymfeklieren gedetecteerd door RT-PCR vaker van 
prognostisch belang zijn, is de infrastructuur in de ziekenhuizen voor deze techniek 
niet geschikt, doordat verse of ingevroren lymfeklieren nodig zijn voor een 
optimaal resultaat. Verder is tot nog toe morfologisch onderzoek van lymfeklieren 
obligaat. Deze studie is verricht op histologisch als tumornegatief bestempelde in 
paraffine ingebedde lymfeklieren, die Liefers et al.13 al eerder hebben onderzocht 
op de aanwezigheid van OTC met RT-PCR, gebruikmakend van de marker CEA. Zij 
vonden een vijfjaarsoverleving van 50 procent voor de OTC-positieve groep en 91 
procent voor de negatieve groep (P = 0,02). 
Coupes van paraffineblokken van twintig patiënten werden gesneden (vijf 
opeenvolgende coupes van tien niveaus op een afstand van tweehonderd 
micrometer of tot het weefsel opgesneden was) en immunohistochemisch 
gekleurd met anticytokeratine antilichamen AE1/AE3. De gekleurde glaasjes 
werden met de flatbedscanner gescreend. OTC werden gevonden in alle zes (100 
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procent) patiënten die een recidief hadden ontwikkeld, vergeleken met acht van 
veertien (57 procent) patiënten die ziektevrij waren gebleven (Chi-squaretest, P = 
0,055). Volgens de OTC-detectie met CEA RT-PCR waren vijf van zes (83 procent) 
patiënten die een recidief hadden ontwikkeld, OTC-positief en drie van veertien 
(21 procent) die ziektevrij waren gebleven, testen OTC-positief. 
Deze resultaten tonen aan dat het onderzoeken van meerdere coupes van 
lymfeklieren op verschillende niveaus, gecombineerd met immunohistochemische 
kleuringen en gevolgd door geautomatiseerde microscopie, een hogere sensitiviteit 
in het voorspellen van recidieven heeft dan RT-PCR (100 versus 83 procent). 
Tegelijkertijd geeft het wel een lagere specificiteit (43 versus 79 procent). 
In deze studie is er niet gedifferentieerd tussen MM en ITC, maar er zijn wel 
groepjes met tumorcellen (> 2) separaat gescoord en gezien in alle zes patiënten 
met een recidief en in vijf van veertien (36 procent) patiënten die ziektevrij 
bleven. Bijkomend moet vermeld worden dat alle patiënten met een recidief 
werden geïdentificeerd na analyse van vier lymfeklierniveaus op een afstand van 
tweehonderd micrometer. 
In hoofdstuk 5 staat de vraag centraal of met gedetailleerd onderzoek van 
lymfeklieren door immunohistochemische kleuringen van coupes van meerdere 
niveaus de prognose van patiënten met dikkedarmkanker beter kan worden 
voorspeld. Hiervoor werden 36 cases (terugkeer van ziekte binnen vijf jaar) en 
72 controles (ten minste vijf jaar geen terugkeer van ziekte) geselecteerd. Er zijn 
paraffinecoupes van lymfeklieren gesneden op vier niveaus met een afstand van 
tweehonderd micrometer en immunohistochemisch gekleurd met anticytokeratine 
antilichamen AE1/AE3. Deze glaasjes werden geanalyseerd met conventionele en 
geautomatiseerde microscopie.
In totaal heeft de groep met cases meer MM (n = 3) dan de controlegroep (n = 1). 
Er is geen verschil in aanwezigheid van ITC tussen de case en de controlegroep. 
Analyse van een tweede lymfeklierniveau heeft geleid tot de additionele 
detectie van één case met MM (n = 1), één case met macrometastase (n = 
1) en twee cases en zeven controles met ITC (n = 9). Het onderzoeken van 
meer dan twee niveaus heeft alleen geresulteerd in detectie van additionele ITC. 
Alle MM en macrometastasen zijn gevonden door conventionele microscopie. 
Geautomatiseerde microscopie heeft alleen geleid tot de detectie van meer ITC. 
In een multivariate regressieanalyse zijn de aanwezigheid van macrometastasen 
of MM (OR 34,5; 95% CI 2,7 – 440; P = 0,006), T4 stadium (OR 2,9; 95% CI 0,4 - 
23,5; P = 0,040) en minder onderzochte lymfeklieren (OR 0,9; 95% CI 0,8 - 1,0; P 
= 0,025) onafhankelijke voorspellers voor terugkeer van ziekte. Messerini et al.21 
en Bilchik et al.22, die ook onderscheid maakten tussen MM en ITC, rapporteren 
soortgelijke lage detectiepercentages voor MM (9,9 respectievelijk 3 procent). 
Ook liet de eerste studie prognostische relevantie zien van MM en niet voor ITC. 
In de studie van Bilchik et al.22 is deze analyse niet gedaan.
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Gedetailleerd onderzoek van lymfeklieren bij patiënten met dikkedarmkanker met 
immunohistochemische kleuringen van coupes van meerdere niveaus of met RT-
PCR op zoek naar OTC is duur en arbeidsintensief, rekening houdend met het grote 
aantal lymfeklieren dat kan worden geïsoleerd. Identificatie van schildwachtklieren 
en selectieve analyse van alleen deze lymfeklieren zijn voorgesteld als een 
mogelijke wijze om deze werklast te vermijden. Schildwachtklieren (SWK’s) zijn 
de eerste lymfeklieren waar de primaire tumor naar draineert, daarom hebben zij 
de meeste kans op het bevatten van tumorcellen (zie inleiding, figuur 1). 
In hoofdstuk 6 wordt een overzicht gegeven van 25 studies die de haalbaarheid 
en de betrouwbaarheid van de SWK-procedure bij dikkedarmkanker hebben 
beschreven. Er bleek een grote variatie in identificatiepercentagesa en fout-
negatieve(FN-)percentagesb, variërend van 58 tot 100 procent (gemiddeld 
89 procent) respectievelijk 0 tot 60 procent (gemiddeld 33 procent). Factoren 
die hebben kunnen bijdragen tot mislukte SWK-procedures waren: incomplete 
injectie rondom de tumor, insufficiënte hoeveelheden tracerc voor grote tumoren, 
includeren van vergevorderde tumoren en rectale tumoren. Een belangrijke factor 
was het leercurve-effect, dat leidde tot een hoger identificatiepercentage van 
bijna honderd procent in sommige studies als de resultaten van de eerdere fase in 
de leercurveperiode niet werden geïncludeerd in de analyse. 
Hoge FN-percentages kunnen worden verklaard door uitgebreide tumoringroei in 
lymfeklieren en grote tumoren. Daardoor kunnen lymfevaten worden afgesloten, 
leidend tot lymfedrainage via een andere route. Ook een lange identificatietijd 
tussen injectie van de tracer en identificatie van de SWK’s kan een rol spelen. 
Blauwe kleurstof verspreidt zich namelijk snel en kan daardoor al een tweede 
echelon lymfeklieren hebben bereikt. Bovendien werd een laag FN-percentage van 
20 procent of minder meestal gezien in studies waar het aantal SWK’s beperkt 
bleef tot de eerste vier blauwe lymfeklieren of de vier of vijf blauwe klieren die 
het dichtst bij de tumor waren. Terwijl studies met een hoger FN-percentage 
(> 20 procent) een hoger aantal schildwachtklieren hadden gerapporteerd. Het 
overgrote deel van de laatstgenoemde studies had alle blauwe of radioactieve 
lymfeklieren beschouwd als SWK’s leidend tot een brede variatie in aantal SWK’s. 
Bij melanomen en borstkanker worden lagere FN-percentages gezien. Het verschil 
zou kunnen liggen in de grotere tumoren bij dikkedarmkanker en ook in het 
verschil in het lymfedrainagepatroon. 
Beperkingen bij endeldarmkanker zijn onder andere de korte afstand tussen 
a Identificatiepercentage is het aantal SWK-procedures waarmee ten minste één SWK (radioactief of 
blauw) is gevonden, gedeeld door het totaal aantal SWK-procedures.
b Fout-negatiefpercentage is het aantal gevallen waarbij de SWK’s tumornegatief zijn terwijl de niet-
SWK’s tumorpositief zijn, gedeeld door het aantal gevallen met tumorpositieve lymfeklieren.
c Tracer kan blauwe kleurstof zijn of radioactief materiaal dat rondom de tumor wordt ingespoten, 
waarna het naar de SWK’s wordt getransporteerd via de lymfebanen.
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primaire tumor en lymfeklieren resulterend in overlappende radioactiviteit 
van de tracer. Daarnaast mag het weefsel rondom de endeldarm tijdens de 
operatie niet worden ingesneden in verband met het adequaat verwijderen van 
endeldarmkanker. Bestraling voor de operatie en vergevorderde tumoren kunnen 
ook de identificatie van SWK’s verstoren. Deze factoren maken de SWK-procedure 
in endeldarmkanker ingewikkeld en klinisch van minder belang. 
Twee studies bij patienten met dikkedarmkanker hebben aangetoond dat SWK’s 
significant vaker tumorcellen bevatten dan niet-SWK’s.23;24 Een derde studie laat 
tegenstrijdige resultaten zien, waarbij er geen verschil in de aanwezigheid van MM 
of ITC werd gezien tussen SWK’s en niet-SWK’s.25 Eén SWK-studie bij patienten 
met dikkedarmkanker meldde een hoger percentage van terugkeer van de ziekte 
bij patiënten met SWK’s die macrometastasen of MM bevatten.26 Toch is de 
betrouwbaarheid van de SWK-procedure bij dikkedarmkanker nog niet eenduidig.
Hoewel er bij patiënten met dikkedarmkanker meestal geen botmetastasen 
optreden, worden er wel tumorcellen in het beenmerg gevonden.27;28 Mogelijk 
geven deze tumorcellen in het beenmerg de agressieve aard van de tumor 
weer en kan detectie van deze tumorcellen in beenmerg gebruikt worden om 
terugkeer van ziekte te voorspellen. In hoofdstuk 7 werd dit onderzocht door na 
te gaan of de aanwezigheid van tumorcellen in het beenmerg van 81 patiënten 
met levermetastasen, afkomstig uit de dikke darm, die gepland stonden voor 
resectie of leverperfusie, een slechte prognose kon voorspellen. De aanwezigheid 
van tumorcellen in beenmerg is onderzocht met kwantitatieve RT-PCR, waarbij 
gebruik werd gemaakt van cytokeratine 20 (CK20), en of immunocytochemie (CK-
ICC) gecombineerd met geautomatiseerde microscopie. Hierbij werden A45-B/B3 
anticytokeratine antilichamen gebruikt. 26 beenmergmonsters van 69 (38 procent) 
patiënten zijn positief met de CK20-RT-PCR-test en monsters van 15 van 69 (22 
procent) patiënten testen positief met de CK-ICC-test. Uit een multivariate Cox-
regressieanalyse blijkt dat een positieve CK20-RT-PCR-test (HR 2,5; 95% CI 1,2 
- 5,2; P = 0,014) en een serum-CEA-niveau hoger dan tweehonderd microgram 
per liter (HR 2,4; 95% CI 1,0 - 5,9; P = 0,045) onafhankelijke voorspellers 
zijn voor een kortere ziektegerelateerde overleving. Een positieve CK-ICC-test 
correleert niet met een slechtere overleving, maar wel met de aanwezigheid 
van extrahepatische ziekte tijdens de operatie (Chi-squaretest, P = 0,009). Er is 
geen correlatie tussen de CK20-RT-PCR-test en de CK-ICC-test. Factoren die dit 
kunnen verklaren, zijn het verschil in gebruikte markers voor deze testen of de 
mogelijkheid dat de RT-PCR actief delende cellen detecteert, terwijl CK-ICC cellen 
in rust of in afbraak detecteert.29 
Deze resultaten corresponderen met die van Koch et al.30 Zij onderzochten 
beenmerg van 25 patiënten met levermetastasen afkomstig uit de dikke darm, 
die chirurgische resectie ondergingen. In deze studie was een positieve CK20-
RT-PCR ook een onafhankelijke prognostische factor voor recidiefvrije overleving. 
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Eerder is een prognostische klinische MSKCC-score (Memorial Sloan-Kettering 
Cancer Center) samengesteld door Nordlinger et al.31 en Fong et al.32 om patiënten 
te selecteren die optimaal baat hebben bij een leverresectie. Deze klinische 
score bestaat uit de volgende klinische en pathologische eigenschappen: een 
positieve lymfeklierstatus van de primaire tumor, minder dan twaalf maanden 
tussen de primaire tumor en het ontstaan van levermetastasen, vier of meer 
levermetastasen, maximale diameter van metastasen groter dan vijf centimeter 
en een serum-CEA-niveau groter dan tweehonderd microgram per liter. Elke 
eigenschap is één punt en hoe hoger het aantal punten hoe slechter de prognose 
voor de patiënten. Gezien deze resultaten en die van anderen zou de CK20-RT-
PCR een aanvullende variabele kunnen zijn voor de MSKCC-score.
Tumorcellen verspreiden zich in het algemeen door locale invasie en/of hematogene 
en/of lymfogene routes. Om lymfeklieren of andere weefselcompartimenten in 
het lichaam te bereiken, moeten de tumorcellen verscheidene obstakels rondom 
de primaire tumor overwinnen. Dit gebeurt met behulp van verschillende 
eiwitten. In hoofdstuk 8 is de prognostische relevantie onderzocht van markers 
gerelateerd aan tumorverspreiding via bloed- en lymfevaten. Er is met name 
bekeken of ziekteterugkeer bij dikkedarmkankerpatiënten met tumornegatieve 
lymfeklieren voorspeld kon worden door de primaire tumor te onderzoeken op 
expressie van angiogenese en lymfangiogenese factoren sialyl-Lewis-X (sLeX), 
vasculaire endotheliale groeifactor (VEGF)-C en VEGF-D, en op bloedvat- en 
lymfevatdichtheid (BVD en LVD), en op de aanwezigheid van tumorcelinvasie 
van bloed- en lymfevaten. Dit is onderzocht met een case-controlestudieopzet, 
waarbij dezelfde patiëntengroep als in hoofdstuk 5 werd bestudeerd. 36 cases 
(ziekteterugkeer binnen vijf jaar) en 72 controles (ten minste vijf jaar ziektevrij) 
werden geselecteerd. Coupes van de tumor werden gekleurd met de antilichamen 
CSLEX1 oftewel CD15s (sLeX), anti-VEGF-C, anti-VEGF-D, anti-CD31 (BVD) of 
D2-40 (LVD) om de parameters te bepalen zoals hierboven vermeld.
Een multivariate analyse toont aan dat sLeX-expressie en een hoog LVD (OR 
5,1; 95% CI 1,3 - 20 respectievelijk OR 3,1; 95% CI 1 - 10) onafhankelijke 
voorspellers zijn voor terugkeer van ziekte. Expressie van sLeX correlateert met 
levermetastasen (P = 0,015). Een hoog LVD is gerelateerd aan regionale intra-
abdominale of intrapelviene lymfekliermetastasen en afstandsmetastasen op 
andere locaties dan de lever en longen zoals peritoneum, skelet, hersenen en 
bijnieren (P = 0,004). Een hoog BVD in het invasieve front van de tumor correleert 
met longmetastasen (P = 0,018). 
Bij vergelijking van de resultaten in hoofdstuk 5 en 8 valt op dat er een 
significante correlatie is tussen de aanwezigheid van macrometastasen of MM en 
lymfevatinvasie door tumorcellen (Fisher’s exacttest, P = 0,001 respectievelijk 
P = 0,014), maar geen correlatie met een hoge LVD (data niet gepubliceerd). 
Daarnaast zijn de lymfekliermetastasen gerelateerd aan afstandsmetastasen 
(Fisher’s exacttest, P = 0,001). 
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Deze studie is een van de eerste waarbij meerdere tumormarkers worden 
bestudeerd die elk correleren met hematogene of lymfogene tumoruitzaaiing 
zoals eerder beschreven door Pantel en Brakenhoff (zie inleiding, figuur 3).33 
Bovendien suggereren de resultaten dat er twee mechanismen betrokken zijn 
bij invasie (passieve en actieve intravasatie), die uiteindelijk resulteren in 
afstandsmetastasen, zoals eerder beschreven door de groep van Jain (zie inleiding, 
figuur 2).34 
Deze resultaten zijn als volgt te verklaren. Ten eerste is er de mechanische wijze 
van tumorcelverspreiding door bloed- en lymfevaten, waarbij de tumorcellen 
vastlopen in het smalle capillairennetwerk in verschillende organen inclusief die 
van de lymfeklieren. Hier kunnen de tumorcellen prolifereren en klinisch evidente 
metastasen vormen. Dit kan de correlatie tussen een hoge BVD en longmetastasen 
verklaren én de correlatie tussen een hoog LVD en regionale intra-abdominale of 
intrapelviene lymfekliermetastasen met uiteindelijk afstandsmetastasen. 
Ten tweede is er ook een biologisch proces dat de invadering en metastasering 
bepaalt en ten grondslag ligt aan de ‘seed-en-soil’ theorie.35;36 Deze theorie 
suggereert dat een subpopulatie van tumorcellen met het vermogen tot 
metastasering, recent geïdentificeerd als ‘colon-cancer-initiating’ cellen29, zich 
door het hele lichaam verspreidt. Deze cellen prolifereren en differentiëren om 
klinisch evidente metastasen te vormen op voorkeursplaatsen afhankelijk van de 
locale interactie met beschikbare groeifactoren. In deze studie heeft de interactie 
tussen sLeX op de tumorcellen en E-selectine op de endotheelcellen faciliterend 
gewerkt op de invasie van de tumorcellen in de bloedvaten, extravasatie en 
migratie in de lever met locaal uitgroei door interactie met E-selectine ter plekke.37 
CONCLUSIE
Chirurgie is feitelijk de eerste keuze van behandeling bij maagkanker en 
dikkedarmkanker. Afhankelijk van het TNM-stadium worden patiënten aanvullend 
behandeld met chemotherapie. Een beduidend aantal patiënten dat curatief 
geopereerd is aan maagkanker of dikkedarmkanker en volgens het TNM-
stadiëringssysteem geen aanvullende therapie behoeft, krijgt echter de ziekte 
terug. De resultaten uit dit proefschrift tonen aan dat deze hoogrisicopatiënten 
kunnen worden geïdentificeerd door OTC-detectie in lymfeklieren en beenmerg 
en door analyse van de bloed- en lymfevateigenschappen van de primaire tumor. 
Deze methoden om hoogrisicopatiënten te identificeren kunnen bijdragen aan 
een meer persoonsgebonden behandeling, waardoor over- en onderbehandeling 
van individuele patiënten met maagkanker en dikkedarmkanker kunnen worden 
voorkomen.
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APC  adenomatous polyposis coli
BMVD  blood microvessel density
BRCA  breast cancer gene
CD  cluster of differentiation
CEA  carcinoembryonic antigen
CI  confidence interval
CIN  chromosomal instability
DCC  deleted in colon cancer
CK  cytokeratin
CK-ICC  cytokeratin-immunocytochemistry
CK20  cytokeratin 20
CRC  colorectal cancer
CT  computed tomography
CTC  circulating tumor cells 
DCC  deleted in colorectal cancer
DNA  desoxy-ribonucleic acid
DTC  disseminated tumor cells
EGFR  epidermal growth factor receptor
5-FU  5-Fluorouracil
FAP  familial adenomatous polyposis
FN rate  false-negative rate 
GCC  guanylyl cyclase C
HE  hematoxylin and eosin
HR  hazard ratio
ICC  immunocytochemistry
IHC  immunohistochemistry
ITC  isolated tumor cells
LMVD  lymphatic microvessel density
MCC  missing in colon cancer
MM  micrometastasis
MSI  microsatellite instability
OR  odds ratio 
OTC  occult tumor cells
PBGD  porphobilinogen deaminase
PBS  phosphate-buffered saline
PCR  polymerase chain reaction
RNA  ribonucleic acid
RT-PCR  reverse-transcriptase polymerase chain reaction
SD  standard deviation
sLeX  sialyl Lewis X
SN  sentinel node
SNM  sentinel node mapping
SPSS  statistical package for social sciences
TNM  tumor node metastasis
VEGF  vascular endothelial growth factor
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